**Massachusetts HIV Epidemiologic Profile**

**Detailed Data Tables – Data as of 1/1/2024**

**Suggested citation:**

Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences. Massachusetts HIV Epidemiologic Profile, Detailed Data Tables – Data as of 1/1/2024

<https://www.mass.gov/lists/hivaids-epidemiologic-profiles> Published May 2024. Accessed [date].

**Bureau of Infectious Disease and Laboratory Sciences**  
**Massachusetts Department of Public Health**

**Jamaica Plain Campus/State Public Health Laboratory**

305 South Street  
Jamaica Plain, MA 02130

**Questions about this report**

Tel: (617) 983-6560

**To reach the Reporting and Partner Services Line[[1]](#footnote-1)**

Tel: (617) 983-6999

**To speak to the on-call epidemiologist**

Tel: (617) 983-6800

**Questions about infectious disease reporting**

Tel: (617) 983-6801

**HIV Data Dashboard**

<https://www.mass.gov/info-details/hiv-data-dashboard>

**Requests for additional data**

<https://www.mass.gov/lists/infectious-disease-data-reports-and-requests>

**Slide sets for Epidemiologic Profile Reports**

<https://www.mass.gov/lists/hivaids-epidemiologic-profiles>

**Massachusetts HIV Epidemiologic Profile: Detailed Data Tables – Data as of 1/1/2024[[2]](#footnote-2)**

**Table of Contents**

[**List of Commonly Used Acronyms**](#list_acronyms)

**Total**

[Table 1: Massachusetts Overall](#Massachusetts_Overall)

**By Sex Assigned at Birth**

[Table 2.1: Assigned Male at Birth](#Sex_at_Birth_Men) (AMAB)

[Table 2.2: Assigned Female at Birth](#Sex_at_Birth_Women) (AFAB)

**By Place of Birth**

[Table 3.1: United States](#place_of_birth_us)

[Table 3.2: Puerto Rico/US Dependency](#place_of_birth_pr_us_depen)

[Table 3.3: Non-US](#place_of_birth_non_us)

**By Race/Ethnicity**

[Table 4.1: White, non-Hispanic](#race_white)

[Table 4.2: Black, non-Hispanic](#race_black)

[Table 4.3: Hispanic/Latinx](#race_hispanic)

[Table 4.4: Asian/Pacific Islander](#race_api)

**By Age Group**

[Table 5.1: 0-12](#age_0_12)

[Table 5.2: 13-19](#age_13_19)

[Table 5.3: 20-29](#age_20_29)

[Table 5.4: 30-39](#age_30_39)

[Table 5.5: 40-49](#age_40_49)

[Table 5.6: 50-59](#age_50_59)

[Table 5.7: 60-69](#age_60_69)

[Table 5.8: 70+](#age_70plus)

**By Primary Exposure Mode**

[Table 6.1: Male-to-male sex (MSM)](#exposure_msm)

[Table 6.2: Injection drug use (IDU)](#exposure_idu)

[Table 6.3: MSM/IDU](#exposure_msm_idu)

[Table 6.4: Heterosexual sex](#exposure_htsx)

[Table 6.5: Presumed heterosexual sex](#exposure_pres_htsx)

[Table 6.6: No identified risk (NIR)](#exposure_nir)

**By Health Service Region (HSR) of Residence**

[Table 7.1: Boston HSR](#hsr_boston)

[Table 7.2: Central HSR](#hsr_central)

[Table 7.3: Metro West HSR](#hsr_metrowest)

[Table 7.4: Northeast HSR](#hsr_northeast)

[Table 7.5: Southeast HSR](#hsr_southeast)

[Table 7.6: Western HSR](#hsr_western)

**By County of Residence**

[Table 8.1: Barnstable, Dukes, and Nantucket Counties](#county_barnstable)

[Table 8.2: Berkshire County](#county_berkshire)

[Table 8.3: Bristol County](#county_bristol)

[Table 8.4: Essex County](#county_essex)

[Table 8.5: Franklin County](#county_franklin)

[Table 8.6: Hampden County](#county_hampden)

[Table 8.7: Hampshire County](#county_hampshire)

[Table 8.8: Middlesex County](#county_middlesex)

[Table 8.9: Norfolk County](#county_norfolk)

[Table 8.10: Plymouth County](#county_plymouth)

[Table 8.11: Suffolk County](#county_suffolk)

[Table 8.12: Worcester County](#county_worcester)

**By City of Residence (Select Cities in Massachusetts)**

[Table 9.1 Boston](#city_boston)

[Table 9.2 Brockton](#city_brockton)

[Table 9.3 Everett](#city_everett)

[Table 9.4 Lawrence](#city_lawrence)

[Table 9.5 Lowell](#city_lowell)

[Table 9.6 Lynn](#city_lynn)

[Table 9.7 Malden](#city_malden)

[Table 9.8 New Bedford](#city_newbedford)

[Table 9.9 Springfield](#city_springfield)

[Table 9.10 Worcester](#city_worcester)

**Trends**

[Table 10.1: Trends in HIV Diagnoses, 2013-2022](#hiv_trends_ma_overall)

[Table 10.2: Trends in HIV Diagnoses, 2013-2022: AMAB](#hiv_trends_men)

[Table 10.3: Trends in HIV Diagnoses, 2013-2022: AFAB](#hiv_trends_women)

[Table 10.4a: Trends in AIDS Diagnoses, 2013-2022](#aids_trends_ma_overall)

[Table 10.4b: Trends in Progression to AIDS, 2013-2022](#aids_progression_trends)

[Table 10.5a: Trends in Individuals Living with HIV Infection, 2013-2017](#prevalence_trends_2008_2012)

[Table 10.5b: Trends in Individuals Living with HIV Infection, Continued, 2018-2022](#prevalence_trends_2013_2017)

[Table 10.6: Trends in Deaths among Individuals with HIV, 2013-2022](#death_trends_ma_overall)

**Crude and Age-Adjusted Rates**

[Table 11.1: Crude and Age-Adjusted Rates by Demographic Characteristics](#rates_demographics)

[Table 11.2: Crude and Age-Adjusted Rates by Health Service Region, County and Select Cities](#rates_county_city)

**Care Continuum**

[Table 12.1: Stages of HIV care among individuals newly diagnosed with HIV infection, 2021](#continuum_dx)

[Table 12.2: Viral suppression among individuals newly diagnosed with HIV infection by stage of care, 2021](#viral_supp_dx)

[Table 12.3: Stages of HIV care among persons living with HIV infection, 2021](#continuum_plwh)

[Table 12.4: Viral suppression among persons living with HIV infection by stage of care, 2022](#viral_supp_plwh)

[Table 12.5: Viral suppression among persons living with HIV infection and engaged in care, 2022](#viral_supp_plwh_engaged)

[**Technical Notes**](#technical_notes)

**LIST OF COMMONLY USED ACRONYMS**

**AFAB** Assigned Female at Birth

**AI/AN** American Indian/Alaska Native

**AIDS** Acquired Immunodeficiency Syndrome

**AIDS DX** AIDS Diagnoses

**AMAB** Assigned Male at Birth

**API** Asian/Pacific Islander

**BIDLS** Bureau of Infectious Disease and Laboratory Sciences

**HIV** Human Immunodeficiency Virus

**HIV DX** HIV Infection Diagnoses

**HSR** Health Service Region

**HTSX** Heterosexual Sex

**IDU** Injection Drug Use

**MDPH** Massachusetts Department of Public Health

**MSM** Male-to-Male Sex

**N** Number

**N/A** Not Applicable

**NH** Non-Hispanic

**NIR** No Identified Risk

**PLWH** Persons Living with HIV infection

**Pres. HTSX** Presumed Heterosexual Sex

**PR** Puerto Rico

**PR/USD** Puerto Rico/US Dependency

**PWID** Persons who Inject Drugs

|  |
| --- |
| **MASSACHUSETTS OVERALL** |

**TABLE 1.1** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **1,329** | **100%** | **23,643** | **100%** | **1,024** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 952 | 72% | 16,791 | 71% | 756 | 74% |
| AFAB | 377 | 28% | 6,852 | 29% | 268 | 26% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 1,315 | 99% | 23,521 | 99% | 1,019 | 100% |
| Transgender | 14 | 1% | 122 | 1% | 5 | <1% |
| **Place of birth** |  |  |  |  |  |  |
| US | 735 | 55% | 14,007 | 59% | 769 | 75% |
| PR/USD | 44 | 3% | 2,189 | 9% | 133 | 13% |
| Non-US | 550 | 41% | 7,447 | 31% | 122 | 12% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 459 | 35% | 9,066 | 38% | 468 | 46% |
| Black NH | 440 | 33% | 7,172 | 30% | 297 | 29% |
| Hispanic/Latinx | 376 | 28% | 6,507 | 28% | 240 | 23% |
| API | 32 | 2% | 572 | 2% | 5 | <1% |
| Other/Unknown | 22 | 2% | 326 | 1% | 14 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 493 | 37% | 9,436 | 40% | 298 | 29% |
| IDU | 202 | 15% | 3,448 | 15% | 348 | 34% |
| MSM/IDU | 51 | 4% | 902 | 4% | 54 | 5% |
| HTSX | 104 | 8% | 3,229 | 14% | 120 | 12% |
| Other | 2 | <1% | 471 | 2% | 7 | 1% |
| Presumed HTSX | 138 | 10% | 2,158 | 9% | 49 | 5% |
| NIR | 339 | 26% | 3,999 | 17% | 148 | 14% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 2 | <1% | 23 | <1% | 0 | 0% |
| 13–19 | 22 | 2% | 45 | <1% | 0 | 0% |
| 20–29 | 326 | 25% | 1,041 | 4% | 18 | 2% |
| 30–39 | 468 | 35% | 3,328 | 14% | 62 | 6% |
| 40–49 | 230 | 17% | 4,051 | 17% | 111 | 11% |
| 50–59 | 170 | 13% | 7,135 | 30% | 318 | 31% |
| 60–69 | 95 | 7% | 6,020 | 25% | 349 | 34% |
| 70+ | 16 | 1% | 2,000 | 8% | 166 | 16% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 375 | 28% | 6,299 | 27% | 260 | 25% |
| Central HSR | 116 | 9% | 2,446 | 10% | 128 | 13% |
| Metro West HSR | 197 | 15% | 3,791 | 16% | 134 | 13% |
| Northeast HSR | 264 | 20% | 4,330 | 18% | 180 | 18% |
| Southeast HSR | 230 | 17% | 3,975 | 17% | 161 | 16% |
| Western HSR | 116 | 9% | 2,799 | 12% | 160 | 16% |
| Prison | 30 | 2% | N/A | N/A | N/A | N/A |
| Unknown | 1 | <1% | 3 | <1% | 1 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY SEX ASSIGNED AT BIRTH: ASSIGNED MALE AT BIRTH** |

**TABLE 2.1** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals assigned male at birth by current gender, place of birth, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **952** | **100%** | **16,791** | **100%** | **756** | **100%** |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 939 | 99% | 16,678 | 99% | ≥5 | N/A |
| Transgender | 13 | 1% | 113 | 1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 577 | 61% | 10,883 | 65% | 577 | 76% |
| PR/USD | 34 | 4% | 1,415 | 8% | 105 | 14% |
| Non-US | 341 | 36% | 4,493 | 27% | 74 | 10% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 358 | 38% | 7,572 | 45% | 373 | 49% |
| Black NH | 239 | 25% | 3,906 | 23% | 187 | 25% |
| Hispanic/Latinx | 306 | 32% | 4,606 | 27% | 181 | 24% |
| API | 30 | 3% | 464 | 3% | 4 | 1% |
| Other/Unknown | 19 | 2% | 243 | 1% | 11 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 493 | 52% | 9,436 | 56% | 298 | 39% |
| IDU | 136 | 14% | 2,219 | 13% | 236 | 31% |
| MSM/IDU | 51 | 5% | 902 | 5% | 54 | 7% |
| HTSX | 36 | 4% | 910 | 5% | 47 | 6% |
| Other | 1 | <1% | 254 | 2% | 3 | <1% |
| NIR | 235 | 25% | 3,070 | 18% | 118 | 16% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 11 | <1% | 0 | 0% |
| 13–19 | 19 | 2% | 25 | <1% | 0 | 0% |
| 20–29 | 269 | 28% | 800 | 5% | 14 | 2% |
| 30–39 | 347 | 36% | 2,540 | 15% | 41 | 5% |
| 40–49 | 152 | 16% | 2,660 | 16% | 78 | 10% |
| 50–59 | 104 | 11% | 4,937 | 29% | 222 | 29% |
| 60–69 | 51 | 5% | 4,371 | 26% | 268 | 35% |
| 70+ | 9 | 1% | 1,447 | 9% | 133 | 18% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 274 | 29% | 4,835 | 29% | 198 | 26% |
| Central HSR | 76 | 8% | 1,617 | 10% | 87 | 12% |
| Metro West HSR | 142 | 15% | 2,701 | 16% | 94 | 12% |
| Northeast HSR | 192 | 20% | 2,927 | 17% | 137 | 18% |
| Southeast HSR | 148 | 16% | 2,831 | 17% | 116 | 15% |
| Western HSR | 92 | 10% | 1,877 | 11% | 123 | 16% |
| Prison | 27 | 3% | N/A | N/A | N/A | N/A |
| Unknown | 1 | <1% | 3 | <1% | 1 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY SEX ASSIGNED AT BIRTH: ASSIGNED FEMALE AT BIRTH** |

**TABLE 2.2** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals assigned female at birth by current gender, place of birth, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **377** | **100%** | **6,852** | **100%** | **268** | **100%** |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 6,843 | 100% | ≥5 | N/A |
| Transgender | <5 | N/A | 9 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 158 | 42% | 3,124 | 46% | 192 | 72% |
| PR/USD | 10 | 3% | 774 | 11% | 28 | 10% |
| Non-US | 209 | 55% | 2,954 | 43% | 48 | 18% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 101 | 27% | 1,494 | 22% | 95 | 35% |
| Black NH | 201 | 53% | 3,266 | 48% | 110 | 41% |
| Hispanic/Latinx | 70 | 19% | 1,901 | 28% | 59 | 22% |
| API | 2 | 1% | 108 | 2% | 1 | <1% |
| Other/Unknown | 3 | 1% | 83 | 1% | 3 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| IDU | 66 | 18% | 1,229 | 18% | 112 | 42% |
| HTSX | 68 | 18% | 2,319 | 34% | 73 | 27% |
| Other | 1 | <1% | 217 | 3% | 4 | 1% |
| Presumed HTSX | 138 | 37% | 2,158 | 31% | 49 | 18% |
| NIR | 104 | 28% | 929 | 14% | 30 | 11% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 12 | <1% | 0 | 0% |
| 13–19 | 3 | 1% | 20 | <1% | 0 | 0% |
| 20–29 | 57 | 15% | 241 | 4% | 4 | 1% |
| 30–39 | 121 | 32% | 788 | 12% | 21 | 8% |
| 40–49 | 78 | 21% | 1,391 | 20% | 33 | 12% |
| 50–59 | 66 | 18% | 2,198 | 32% | 96 | 36% |
| 60–69 | 44 | 12% | 1,649 | 24% | 81 | 30% |
| 70+ | 7 | 2% | 553 | 8% | 33 | 12% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 101 | 27% | 1,464 | 21% | 62 | 23% |
| Central HSR | 40 | 11% | 829 | 12% | 41 | 15% |
| Metro West HSR | 55 | 15% | 1,090 | 16% | 40 | 15% |
| Northeast HSR | 72 | 19% | 1,403 | 20% | 43 | 16% |
| Southeast HSR | 82 | 22% | 1,144 | 17% | 45 | 17% |
| Western HSR | 24 | 6% | 922 | 13% | 37 | 14% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PLACE OF BIRTH: UNITED STATES** |

**TABLE 3.1** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals born in the US by sex assigned at birth, current gender, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **735** | **100%** | **14,007** | **100%** | **769** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 577 | 79% | 10,883 | 78% | 577 | 75% |
| AFAB | 158 | 21% | 3,124 | 22% | 192 | 25% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 728 | 99% | 13,932 | 99% | 764 | 99% |
| Transgender | 7 | 1% | 75 | 1% | 5 | 1% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 416 | 57% | 8,254 | 59% | 459 | 60% |
| Black NH | 161 | 22% | 3,327 | 24% | 212 | 28% |
| Hispanic/Latinx | 141 | 19% | 2,052 | 15% | 83 | 11% |
| API | 6 | 1% | 132 | 1% | <5 | N/A |
| Other/Unknown | 11 | 1% | 242 | 2% | ≥5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 296 | 40% | 6,948 | 50% | 265 | 34% |
| IDU | 191 | 26% | 2,383 | 17% | 261 | 34% |
| MSM/IDU | 48 | 7% | 725 | 5% | 47 | 6% |
| HTSX | 38 | 5% | 1,349 | 10% | 73 | 9% |
| Other | 0 | 0% | 339 | 2% | 5 | 1% |
| Presumed HTSX | 34 | 5% | 602 | 4% | 27 | 4% |
| NIR | 128 | 17% | 1,661 | 12% | 91 | 12% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 11 | <1% | 0 | 0% |
| 13–19 | 16 | 2% | 22 | <1% | 0 | 0% |
| 20–29 | 205 | 28% | 625 | 4% | 15 | 2% |
| 30–39 | 269 | 37% | 1,987 | 14% | 51 | 7% |
| 40–49 | 108 | 15% | 2,000 | 14% | 80 | 10% |
| 50–59 | 85 | 12% | 4,198 | 30% | 227 | 30% |
| 60–69 | 43 | 6% | 3,910 | 28% | 278 | 36% |
| 70+ | 9 | 1% | 1,254 | 9% | 118 | 15% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 219 | 30% | 3,781 | 27% | 193 | 25% |
| Central HSR | 70 | 10% | 1,355 | 10% | 91 | 12% |
| Metro West HSR | 99 | 13% | 2,127 | 15% | 102 | 13% |
| Northeast HSR | 102 | 14% | 2,216 | 16% | 133 | 17% |
| Southeast HSR | 134 | 18% | 2,697 | 19% | 131 | 17% |
| Western HSR | 85 | 12% | 1,828 | 13% | 118 | 15% |
| Prison | 25 | 3% | N/A | N/A | N/A | N/A |
| Unknown | 1 | <1% | 3 | <1% | 1 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PLACE OF BIRTH: PUERTO RICO/US DEPENDENCY** |

**TABLE 3.2** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals born in Puerto Rico/US Dependency by sex assigned at birth, current gender, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **44** | **100%** | **2,189** | **100%** | **133** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 34 | 77% | 1,415 | 65% | 105 | 79% |
| AFAB | 10 | 23% | 774 | 35% | 28 | 21% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 2,171 | 99% | 133 | 100% |
| Transgender | <5 | N/A | 18 | 1% | 0 | 0% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | <5 | N/A | 20 | 1% | 0 | 0% |
| Black NH | <5 | N/A | 13 | 1% | 0 | 0% |
| Hispanic/Latinx | 42 | 95% | 2,156 | 98% | 133 | 100% |
| API | 0 | 0% | 0 | 0% | 0 | 0% |
| Other/Unknown | 0 | 0% | 0 | 0% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 18 | 41% | 349 | 16% | 16 | 12% |
| IDU | 6 | 14% | 874 | 40% | 78 | 59% |
| MSM/IDU | <5 | N/A | 101 | 5% | 6 | 5% |
| HTSX | 5 | 11% | 497 | 23% | 19 | 14% |
| Other | 0 | 0% | 34 | 2% | 1 | 1% |
| Presumed HTSX | <5 | N/A | 127 | 6% | 5 | 4% |
| NIR | 13 | 30% | 207 | 9% | 8 | 6% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 14 | 32% | 40 | 2% | <5 | N/A |
| 30–39 | 13 | 30% | 179 | 8% | 6 | 5% |
| 40–49 | 8 | 18% | 372 | 17% | 15 | 11% |
| 50–59 | <5 | N/A | 754 | 34% | 55 | 41% |
| 60–69 | <5 | N/A | 637 | 29% | 41 | 31% |
| 70+ | 0 | 0% | 205 | 9% | ≥5 | N/A |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 8 | 18% | 376 | 17% | 26 | 20% |
| Central HSR | 6 | 14% | 376 | 17% | 25 | 19% |
| Metro West HSR | <5 | N/A | 106 | 5% | 8 | 6% |
| Northeast HSR | 7 | 16% | 421 | 19% | 26 | 20% |
| Southeast HSR | 12 | 27% | 229 | 10% | 9 | 7% |
| Western HSR | 8 | 18% | 681 | 31% | 39 | 29% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PLACE OF BIRTH: NON-US** |

**TABLE 3.3** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals born outside the US by sex assigned at birth, current gender, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **550** | **100%** | **7,447** | **100%** | **122** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 341 | 62% | 4,493 | 60% | 74 | 61% |
| AFAB | 209 | 38% | 2,954 | 40% | 48 | 39% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 7,418 | 100% | 122 | 100% |
| Transgender | <5 | N/A | 29 | <1% | 0 | 0% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 43 | 8% | 792 | 11% | 9 | 7% |
| Black NH | 277 | 50% | 3,832 | 51% | 85 | 70% |
| Hispanic/Latinx | 193 | 35% | 2,299 | 31% | 24 | 20% |
| API | 26 | 5% | 440 | 6% | <5 | N/A |
| Other/Unknown | 11 | 2% | 84 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 179 | 33% | 2,139 | 29% | 17 | 14% |
| IDU | 5 | 1% | 191 | 3% | 9 | 7% |
| MSM/IDU | <5 | N/A | 76 | 1% | <5 | N/A |
| HTSX | 61 | 11% | 1,383 | 19% | 28 | 23% |
| Other | <5 | N/A | 98 | 1% | <5 | N/A |
| Presumed HTSX | 103 | 19% | 1,429 | 19% | 17 | 14% |
| NIR | 198 | 36% | 2,131 | 29% | 49 | 40% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | <5 | N/A | 12 | <1% | 0 | 0% |
| 13–19 | <5 | N/A | 21 | <1% | 0 | 0% |
| 20–29 | 107 | 19% | 376 | 5% | <5 | N/A |
| 30–39 | 186 | 34% | 1,162 | 16% | 5 | 4% |
| 40–49 | 114 | 21% | 1,679 | 23% | 16 | 13% |
| 50–59 | 81 | 15% | 2,183 | 29% | 36 | 30% |
| 60–69 | 49 | 9% | 1,473 | 20% | 30 | 25% |
| 70+ | 7 | 1% | 541 | 7% | ≥5 | N/A |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 148 | 27% | 2,142 | 29% | 41 | 34% |
| Central HSR | 40 | 7% | 715 | 10% | 12 | 10% |
| Metro West HSR | 96 | 17% | 1,558 | 21% | 24 | 20% |
| Northeast HSR | 155 | 28% | 1,693 | 23% | 21 | 17% |
| Southeast HSR | 84 | 15% | 1,049 | 14% | 21 | 17% |
| Western HSR | 23 | 4% | 290 | 4% | <5 | N/A |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 0 | 0% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY RACE/ETHNICITY: WHITE (NON-HISPANIC)** |

**TABLE 4.1** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among white (non-Hispanic) individuals by sex assigned at birth, current gender, place of birth, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **459** | **100%** | **9,066** | **100%** | **468** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 358 | 78% | 7,572 | 84% | 373 | 80% |
| AFAB | 101 | 22% | 1,494 | 16% | 95 | 20% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 9,048 | 100% | ≥5 | N/A |
| Transgender | <5 | N/A | 18 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 416 | 91% | 8,254 | 91% | 459 | 98% |
| PR/USD | 0 | 0% | 20 | <1% | 0 | 0% |
| Non-US | 43 | 9% | 792 | 9% | 9 | 2% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 165 | 36% | 5,454 | 60% | 205 | 44% |
| IDU | 150 | 33% | 1,273 | 14% | 147 | 31% |
| MSM/IDU | 34 | 7% | 517 | 6% | 26 | 6% |
| HTSX | 27 | 6% | 592 | 7% | 30 | 6% |
| Other | 1 | <1% | 114 | 1% | 3 | 1% |
| Presumed HTSX | 12 | 3% | 263 | 3% | 5 | 1% |
| NIR | 70 | 15% | 853 | 9% | 52 | 11% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 3 | <1% | 0 | 0% |
| 13–19 | 4 | 1% | 4 | <1% | 0 | 0% |
| 20–29 | 105 | 23% | 242 | 3% | 9 | 2% |
| 30–39 | 171 | 37% | 1,064 | 12% | 34 | 7% |
| 40–49 | 73 | 16% | 1,253 | 14% | 53 | 11% |
| 50–59 | 67 | 15% | 2,865 | 32% | 134 | 29% |
| 60–69 | 31 | 7% | 2,734 | 30% | 154 | 33% |
| 70+ | 7 | 2% | 901 | 10% | 84 | 18% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 106 | 23% | 2,003 | 22% | 81 | 17% |
| Central HSR | 50 | 11% | 879 | 10% | 61 | 13% |
| Metro West HSR | 70 | 15% | 1,561 | 17% | 71 | 15% |
| Northeast HSR | 84 | 18% | 1,626 | 18% | 98 | 21% |
| Southeast HSR | 92 | 20% | 2,110 | 23% | 104 | 22% |
| Western HSR | 41 | 9% | 886 | 10% | 53 | 11% |
| Prison | 15 | 3% | N/A | N/A | N/A | N/A |
| Unknown | 1 | <1% | 1 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY RACE/ETHNICITY: BLACK (NON-HISPANIC)** |

**TABLE 4.2** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among black (non-Hispanic) individuals by sex assigned at birth, current gender, place of birth, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **440** | **100%** | **7,172** | **100%** | **297** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 239 | 54% | 3,906 | 54% | 187 | 63% |
| AFAB | 201 | 46% | 3,266 | 46% | 110 | 37% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 435 | 99% | 7,141 | 100% | ≥5 | N/A |
| Transgender | 5 | 1% | 31 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 3,327 | 46% | 212 | 71% |
| PR/USD | <5 | N/A | 13 | <1% | 0 | 0% |
| Non-US | 277 | 63% | 3,832 | 53% | 85 | 29% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 100 | 23% | 1,338 | 19% | 45 | 15% |
| IDU | 17 | 4% | 709 | 10% | 81 | 27% |
| MSM/IDU | 8 | 2% | 134 | 2% | 15 | 5% |
| HTSX | 53 | 12% | 1,469 | 20% | 47 | 16% |
| Other | 1 | 0% | 206 | 3% | 2 | 1% |
| Presumed HTSX | 92 | 21% | 1,369 | 19% | 35 | 12% |
| NIR | 169 | 38% | 1,947 | 27% | 72 | 24% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 15 | <1% | 0 | 0% |
| 13–19 | 7 | 2% | 25 | <1% | 0 | 0% |
| 20–29 | 85 | 19% | 317 | 4% | 4 | 1% |
| 30–39 | 133 | 30% | 946 | 13% | 15 | 5% |
| 40–49 | 95 | 22% | 1,272 | 18% | 22 | 7% |
| 50–59 | 60 | 14% | 2,107 | 29% | 79 | 27% |
| 60–69 | 51 | 12% | 1,842 | 26% | 120 | 40% |
| 70+ | 8 | 2% | 648 | 9% | 57 | 19% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 151 | 34% | 2,351 | 33% | 129 | 43% |
| Central HSR | 32 | 7% | 713 | 10% | 28 | 9% |
| Metro West HSR | 69 | 16% | 1,370 | 19% | 45 | 15% |
| Northeast HSR | 64 | 15% | 1,115 | 16% | 26 | 9% |
| Southeast HSR | 88 | 20% | 1,100 | 15% | 34 | 11% |
| Western HSR | 34 | 8% | 521 | 7% | 35 | 12% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 2 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY RACE/ETHNICITY: HISPANIC/LATINX** |

**TABLE 4.3** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among Hispanic/Latinx individuals by sex assigned at birth, current gender, place of birth, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **376** | **100%** | **6,507** | **100%** | **240** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 306 | 81% | 4,606 | 71% | 181 | 75% |
| AFAB | 70 | 19% | 1,901 | 29% | 59 | 25% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 369 | 98% | 6,449 | 99% | 240 | 100% |
| Transgender | 7 | 2% | 58 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 141 | 38% | 2,052 | 32% | 83 | 35% |
| PR/USD | 42 | 11% | 2,156 | 33% | 133 | 55% |
| Non-US | 193 | 51% | 2,299 | 35% | 24 | 10% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 201 | 53% | 2,176 | 33% | 39 | 16% |
| IDU | 33 | 9% | 1,418 | 22% | 117 | 49% |
| MSM/IDU | 8 | 2% | 214 | 3% | 11 | 5% |
| HTSX | 22 | 6% | 1,080 | 17% | 42 | 18% |
| Other | 0 | 0% | 132 | 2% | 2 | 1% |
| Presumed HTSX | 32 | 9% | 475 | 7% | 9 | 4% |
| NIR | 80 | 21% | 1,012 | 16% | 20 | 8% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 3 | <1% | 0 | 0% |
| 13–19 | 9 | 2% | 11 | <1% | 0 | 0% |
| 20–29 | 124 | 33% | 407 | 6% | 5 | 2% |
| 30–39 | 140 | 37% | 1,107 | 17% | 11 | 5% |
| 40–49 | 55 | 15% | 1,329 | 20% | 33 | 14% |
| 50–59 | 38 | 10% | 1,930 | 30% | 98 | 41% |
| 60–69 | 10 | 3% | 1,323 | 20% | 70 | 29% |
| 70+ | 0 | 0% | 397 | 6% | 23 | 10% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 102 | 27% | 1,700 | 26% | 46 | 19% |
| Central HSR | 32 | 9% | 782 | 12% | 36 | 15% |
| Metro West HSR | 52 | 14% | 663 | 10% | 14 | 6% |
| Northeast HSR | 97 | 26% | 1,368 | 21% | 54 | 23% |
| Southeast HSR | 44 | 12% | 665 | 10% | 22 | 9% |
| Western HSR | 37 | 10% | 1,329 | 20% | 67 | 28% |
| Prison | 12 | 3% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 1 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY RACE/ETHNICITY: ASIAN/PACIFIC ISLANDER** |

**TABLE 4.4** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among Asian/Pacific Islander individuals by sex assigned at birth, current gender, place of birth, primary exposure mode, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **32** | **100%** | **572** | **100%** | **5** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 30 | 94% | 464 | 81% | 4 | 80% |
| AFAB | 2 | 6% | 108 | 19% | 1 | 20% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 32 | 100% | 563 | 98% | 5 | 100% |
| Transgender | 0 | 0% | 9 | 2% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 6 | 19% | 132 | 23% | <5 | N/A |
| PR/USD | 0 | 0% | 0 | 0% | 0 | 0% |
| Non-US | 26 | 81% | 440 | 77% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 17 | 53% | 298 | 52% | <5 | N/A |
| IDU | 0 | 0% | 19 | 3% | <5 | N/A |
| MSM/IDU | 0 | 0% | 13 | 2% | 0 | 0% |
| HTSX | 0 | 0% | 50 | 9% | 0 | 0% |
| Other | <5 | N/A | 11 | 2% | 0 | 0% |
| Presumed HTSX | <5 | N/A | 35 | 6% | 0 | 0% |
| NIR | 14 | 44% | 146 | 26% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 8 | 25% | 45 | 8% | 0 | 0% |
| 30–39 | 14 | 44% | 129 | 23% | 0 | 0% |
| 40–49 | 3 | 9% | 133 | 23% | 1 | 20% |
| 50–59 | 4 | 13% | 157 | 27% | 1 | 20% |
| 60–69 | <5 | N/A | 68 | 12% | <5 | N/A |
| 70+ | 0 | 0% | 34 | 6% | <5 | N/A |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 12 | 38% | 154 | 27% | 1 | 20% |
| Central HSR | 0 | 0% | 43 | 8% | 0 | 0% |
| Metro West HSR | 5 | 16% | 140 | 24% | 2 | 40% |
| Northeast HSR | 11 | 34% | 163 | 28% | 1 | 20% |
| Southeast HSR | <5 | N/A | 39 | 7% | <5 | N/A |
| Western HSR | <5 | N/A | 33 | 6% | <5 | N/A |
| Prison | 0 | 0% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 0–12 YEARS\*** |

**TABLE 5.1** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 0–12 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **2** | **100%** | **23** | **100%** | **0** | **0%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 1 | 50% | 11 | 48% | 0 | 0% |
| AFAB | 1 | 50% | 12 | 52% | 0 | 0% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | <5 | N/A | 23 | 100% | 0 | 0% |
| Transgender | <5 | N/A | 0 | 0% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 0 | 0% | 11 | 48% | 0 | 0% |
| PR/USD | <5 | N/A | 0 | 0% | 0 | 0% |
| Non-US | <5 | N/A | 12 | 52% | 0 | 0% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 1 | 50% | 3 | 13% | 0 | 0% |
| Black NH | 1 | 50% | 15 | 65% | 0 | 0% |
| Hispanic/Latinx | 0 | 0% | 3 | 13% | 0 | 0% |
| API | 0 | 0% | 2 | 9% | 0 | 0% |
| Other/Unknown | 0 | 0% | 0 | 0% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 0 | 0% | 0 | 0% | 0 | 0% |
| IDU | 0 | 0% | 0 | 0% | 0 | 0% |
| MSM/IDU | 0 | 0% | 0 | 0% | 0 | 0% |
| HTSX | 0 | 0% | 0 | 0% | 0 | 0% |
| Other | 2 | 100% | 23 | 100% | 0 | 0% |
| Presumed HTSX | 0 | 0% | 0 | 0% | 0 | 0% |
| NIR | 0 | 0% | 0 | 0% | 0 | 0% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 0 | 0% | 4 | 17% | 0 | 0% |
| Central HSR | 0 | 0% | 4 | 17% | 0 | 0% |
| Metro West HSR | 0 | 0% | 4 | 17% | 0 | 0% |
| Northeast HSR | 1 | 50% | 5 | 22% | 0 | 0% |
| Southeast HSR | 0 | 0% | 4 | 17% | 0 | 0% |
| Western HSR | 1 | 50% | 2 | 9% | 0 | 0% |
| Prison | 0 | 0% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 13–19 YEARS\*** |

**TABLE 5.2** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 13–19 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **22** | **100%** | **45** | **100%** | **0** | **0%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 19 | 86% | 25 | 56% | 0 | 0% |
| AFAB | 3 | 14% | 20 | 44% | 0 | 0% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 45 | 100% | 0 | 0% |
| Transgender | <5 | N/A | 0 | 0% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 16 | 73% | 22 | 49% | 0 | 0% |
| PR/USD | <5 | N/A | <5 | N/A | 0 | 0% |
| Non-US | <5 | N/A | ≥5 | N/A | 0 | 0% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 4 | 18% | 4 | 9% | 0 | 0% |
| Black NH | 7 | 32% | 25 | 56% | 0 | 0% |
| Hispanic/Latinx | 9 | 41% | 11 | 24% | 0 | 0% |
| API | <5 | N/A | <5 | N/A | 0 | 0% |
| Other/Unknown | <5 | N/A | <5 | N/A | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 17 | 77% | 9 | 20% | 0 | 0% |
| IDU | 0 | 0% | 0 | 0% | 0 | 0% |
| MSM/IDU | 0 | 0% | 0 | 0% | 0 | 0% |
| HTSX | <5 | N/A | <5 | N/A | 0 | 0% |
| Other | 0 | 0% | 32 | 71% | 0 | 0% |
| Presumed HTSX | 0 | 0% | <5 | N/A | 0 | 0% |
| NIR | <5 | N/A | <5 | N/A | 0 | 0% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 7 | 32% | 7 | 16% | 0 | 0% |
| Central HSR | 2 | 9% | 10 | 22% | 0 | 0% |
| Metro West HSR | 2 | 9% | 8 | 18% | 0 | 0% |
| Northeast HSR | 3 | 14% | 9 | 20% | 0 | 0% |
| Southeast HSR | 4 | 18% | 7 | 16% | 0 | 0% |
| Western HSR | 3 | 14% | 4 | 9% | 0 | 0% |
| Prison | 1 | 5% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### \*Please note that this age group does not include any minors under the age of consent (16 years); all individuals included were aged 16 – 19 years.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 20–29 YEARS** |

**TABLE 5.3** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 20–29 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **326** | **100%** | **1,041** | **100%** | **18** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 269 | 83% | 800 | 77% | 14 | 78% |
| AFAB | 57 | 17% | 241 | 23% | 4 | 22% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 315 | 97% | 1,021 | 98% | 18 | 100% |
| Transgender | 11 | 3% | 20 | 2% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 205 | 63% | 625 | 60% | 15 | 83% |
| PR/USD | 14 | 4% | 40 | 4% | <5 | N/A |
| Non-US | 107 | 33% | 376 | 36% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 105 | 32% | 242 | 23% | 9 | 50% |
| Black NH | 85 | 26% | 317 | 30% | 4 | 22% |
| Hispanic/Latinx | 124 | 38% | 407 | 39% | 5 | 28% |
| API | 8 | 2% | 45 | 4% | 0 | 0% |
| Other/Unknown | 4 | 1% | 30 | 3% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 193 | 59% | 572 | 55% | 7 | 39% |
| IDU | 33 | 10% | 55 | 5% | <5 | N/A |
| MSM/IDU | 17 | 5% | 23 | 2% | <5 | N/A |
| HTSX | 15 | 5% | 44 | 4% | <5 | N/A |
| Other | 0 | 0% | 157 | 15% | 1 | 6% |
| Presumed HTSX | 23 | 7% | 55 | 5% | 0 | 0% |
| NIR | 45 | 14% | 135 | 13% | <5 | N/A |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 93 | 29% | 268 | 26% | 6 | 33% |
| Central HSR | 29 | 9% | 128 | 12% | 3 | 17% |
| Metro West HSR | 46 | 14% | 157 | 15% | 2 | 11% |
| Northeast HSR | 71 | 22% | 219 | 21% | 2 | 11% |
| Southeast HSR | 53 | 16% | 149 | 14% | 4 | 22% |
| Western HSR | 27 | 8% | 120 | 12% | 1 | 6% |
| Prison | 7 | 2% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 30–39 YEARS** |

**TABLE 5.4** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 30–39 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **468** | **100%** | **3,328** | **100%** | **62** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 347 | 74% | 2,540 | 76% | 41 | 66% |
| AFAB | 121 | 26% | 788 | 24% | 21 | 34% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 3,283 | 99% | ≥5 | N/A |
| Transgender | <5 | N/A | 45 | 1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 269 | 57% | 1,987 | 60% | 51 | 82% |
| PR/USD | 13 | 3% | 179 | 5% | 6 | 10% |
| Non-US | 186 | 40% | 1,162 | 35% | 5 | 8% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 171 | 37% | 1,064 | 32% | 34 | 55% |
| Black NH | 133 | 28% | 946 | 28% | 15 | 24% |
| Hispanic/Latinx | 140 | 30% | 1,107 | 33% | 11 | 18% |
| API | 14 | 3% | 129 | 4% | 0 | 0% |
| Other/Unknown | 10 | 2% | 82 | 2% | 2 | 3% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 165 | 35% | 1,746 | 52% | 16 | 26% |
| IDU | 104 | 22% | 282 | 8% | 24 | 39% |
| MSM/IDU | 24 | 5% | 137 | 4% | 7 | 11% |
| HTSX | 28 | 6% | 233 | 7% | 5 | 8% |
| Other | 0 | 0% | 191 | 6% | <5 | N/A |
| Presumed HTSX | 33 | 7% | 248 | 7% | <5 | N/A |
| NIR | 114 | 24% | 491 | 15% | 7 | 11% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 152 | 32% | 956 | 29% | 14 | 23% |
| Central HSR | 33 | 7% | 326 | 10% | 11 | 18% |
| Metro West HSR | 69 | 15% | 557 | 17% | 10 | 16% |
| Northeast HSR | 83 | 18% | 697 | 21% | 12 | 19% |
| Southeast HSR | 81 | 17% | 466 | 14% | 8 | 13% |
| Western HSR | 34 | 7% | 324 | 10% | 7 | 11% |
| Prison | 15 | 3% | N/A | N/A | N/A | N/A |
| Unknown | 1 | <1% | 2 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 40–49 YEARS** |

**TABLE 5.5** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 40–49 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **230** | **100%** | **4,051** | **100%** | **111** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 152 | 66% | 2,660 | 66% | 78 | 70% |
| AFAB | 78 | 34% | 1,391 | 34% | 33 | 30% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 4,023 | 99% | 111 | 100% |
| Transgender | <5 | N/A | 28 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 108 | 47% | 2,000 | 49% | 80 | 72% |
| PR/USD | 8 | 3% | 372 | 9% | 15 | 14% |
| Non-US | 114 | 50% | 1,679 | 41% | 16 | 14% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 73 | 32% | 1,253 | 31% | 53 | 48% |
| Black NH | 95 | 41% | 1,272 | 31% | 22 | 20% |
| Hispanic/Latinx | 55 | 24% | 1,329 | 33% | 33 | 30% |
| API | 3 | 1% | 133 | 3% | 1 | 1% |
| Other/Unknown | 4 | 2% | 64 | 2% | 2 | 2% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 62 | 27% | 1,566 | 39% | 40 | 36% |
| IDU | 36 | 16% | 396 | 10% | 34 | 31% |
| MSM/IDU | <5 | N/A | 200 | 5% | 6 | 5% |
| HTSX | 26 | 11% | 605 | 15% | 9 | 8% |
| Other | <5 | N/A | 14 | <1% | 0 | 0% |
| Presumed HTSX | 32 | 14% | 538 | 13% | 7 | 6% |
| NIR | 71 | 31% | 732 | 18% | 15 | 14% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 61 | 27% | 1,080 | 27% | 24 | 22% |
| Central HSR | 23 | 10% | 471 | 12% | 19 | 17% |
| Metro West HSR | 39 | 17% | 667 | 16% | 14 | 13% |
| Northeast HSR | 50 | 22% | 736 | 18% | 26 | 23% |
| Southeast HSR | 35 | 15% | 640 | 16% | 16 | 14% |
| Western HSR | 16 | 7% | 457 | 11% | 12 | 11% |
| Prison | 6 | 3% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 50–59 YEARS** |

**TABLE 5.6** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 50–59 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **170** | **100%** | **7,135** | **100%** | **318** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 104 | 61% | 4,937 | 69% | 222 | 70% |
| AFAB | 66 | 39% | 2,198 | 31% | 96 | 30% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 170 | 100% | 7,111 | 100% | ≥5 | N/A |
| Transgender | 0 | 0% | 24 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 85 | 50% | 4,198 | 59% | 227 | 71% |
| PR/USD | <5 | N/A | 754 | 11% | 55 | 17% |
| Non-US | ≥5 | N/A | 2,183 | 31% | 36 | 11% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 67 | 39% | 2,865 | 40% | 134 | 42% |
| Black NH | 60 | 35% | 2,107 | 30% | 79 | 25% |
| Hispanic/Latinx | 38 | 22% | 1,930 | 27% | 98 | 31% |
| API | 4 | 2% | 157 | 2% | 1 | <1% |
| Other/Unknown | 1 | 1% | 76 | 1% | 6 | 2% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 35 | 21% | 2,717 | 38% | 88 | 28% |
| IDU | 19 | 11% | 1,067 | 15% | 114 | 36% |
| MSM/IDU | <5 | N/A | 282 | 4% | 17 | 5% |
| HTSX | 24 | 14% | 1,140 | 16% | 45 | 14% |
| Other | <5 | N/A | 21 | <1% | 2 | 1% |
| Presumed HTSX | 25 | 15% | 700 | 10% | 16 | 5% |
| NIR | 63 | 37% | 1,208 | 17% | 36 | 11% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 41 | 24% | 1,884 | 26% | 71 | 22% |
| Central HSR | 19 | 11% | 708 | 10% | 41 | 13% |
| Metro West HSR | 20 | 12% | 1,134 | 16% | 32 | 10% |
| Northeast HSR | 30 | 18% | 1,300 | 18% | 61 | 19% |
| Southeast HSR | 36 | 21% | 1,184 | 17% | 57 | 18% |
| Western HSR | 23 | 14% | 924 | 13% | 55 | 17% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 1 | <1% | 1 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 60–69 YEARS** |

**TABLE 5.7** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 60–69 years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **95** | **100%** | **6,020** | **100%** | **349** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 51 | 54% | 4,371 | 73% | 268 | 77% |
| AFAB | 44 | 46% | 1,649 | 27% | 81 | 23% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 95 | 100% | ≥5 | N/A | 349 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 3,910 | 65% | 278 | 80% |
| PR/USD | <5 | N/A | 637 | 11% | 41 | 12% |
| Non-US | 49 | 52% | 1,473 | 24% | 30 | 9% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 31 | 33% | 2,734 | 45% | 154 | 44% |
| Black NH | 51 | 54% | 1,842 | 31% | 120 | 34% |
| Hispanic/Latinx | 10 | 11% | 1,323 | 22% | 70 | 20% |
| API | <5 | N/A | 68 | 1% | <5 | N/A |
| Other/Unknown | <5 | N/A | 53 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 18 | 19% | 2,091 | 35% | 90 | 26% |
| IDU | 9 | 9% | 1,326 | 22% | 142 | 41% |
| MSM/IDU | <5 | N/A | 214 | 4% | 21 | 6% |
| HTSX | 10 | 11% | 900 | 15% | 36 | 10% |
| Other | <5 | N/A | 22 | <1% | 2 | 1% |
| Presumed HTSX | 22 | 23% | 425 | 7% | 15 | 4% |
| NIR | 33 | 35% | 1,042 | 17% | 43 | 12% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 17 | 18% | 1,568 | 26% | 99 | 28% |
| Central HSR | 10 | 11% | 608 | 10% | 41 | 12% |
| Metro West HSR | 14 | 15% | 931 | 15% | 46 | 13% |
| Northeast HSR | 23 | 24% | 1,015 | 17% | 57 | 16% |
| Southeast HSR | 21 | 22% | 1,166 | 19% | 48 | 14% |
| Western HSR | 10 | 11% | 732 | 12% | 58 | 17% |
| Prison | 0 | 0% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY AGE GROUP: 70+ YEARS** |

**TABLE 5.8** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals aged 70+ years by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **16** | **100%** | **2,000** | **100%** | **166** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 9 | 56% | 1,447 | 72% | 133 | 80% |
| AFAB | 7 | 44% | 553 | 28% | 33 | 20% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 16 | 100% | ≥5 | N/A | 166 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 9 | 56% | 1,254 | 63% | 118 | 71% |
| PR/USD | 0 | 0% | 205 | 10% | 15 | 9% |
| Non-US | 7 | 44% | 541 | 27% | 33 | 20% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 7 | 44% | 901 | 45% | 84 | 51% |
| Black NH | 8 | 50% | 648 | 32% | 57 | 34% |
| Hispanic/Latinx | 0 | 0% | 397 | 20% | 23 | 14% |
| API | 0 | 0% | 34 | 2% | <5 | N/A |
| Other/Unknown | 1 | 6% | 20 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | <5 | N/A | 735 | 37% | 57 | 34% |
| IDU | <5 | N/A | 322 | 16% | 31 | 19% |
| MSM/IDU | 0 | 0% | 46 | 2% | <5 | N/A |
| HTSX | 0 | 0% | 306 | 15% | 24 | 14% |
| Other | 0 | 0% | 11 | 1% | <5 | N/A |
| Presumed HTSX | <5 | N/A | 191 | 10% | 10 | 6% |
| NIR | 9 | 56% | 389 | 19% | 43 | 26% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 4 | 25% | 532 | 27% | 46 | 28% |
| Central HSR | 0 | 0% | 191 | 10% | 13 | 8% |
| Metro West HSR | 7 | 44% | 333 | 17% | 30 | 18% |
| Northeast HSR | 3 | 19% | 349 | 17% | 22 | 13% |
| Southeast HSR | 0 | 0% | 359 | 18% | 28 | 17% |
| Western HSR | 2 | 13% | 236 | 12% | 27 | 16% |
| Prison | 0 | 0% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PRIMARY EXPOSURE MODE: MALE-TO-MALE SEX (MSM)** |

**TABLE 6.1** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals with MSM primary exposure mode by current gender, place of birth, race/ethnicity, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **493** | **100%** | **9,436** | **100%** | **298** | **100%** |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 482 | 98% | 9,344 | 99% | ≥5 | N/A |
| Transgender | 11 | 2% | 92 | 1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 296 | 60% | 6,948 | 74% | 265 | 89% |
| PR/USD | 18 | 4% | 349 | 4% | 16 | 5% |
| Non-US | 179 | 36% | 2,139 | 23% | 17 | 6% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 165 | 33% | 5,454 | 58% | 205 | 69% |
| Black NH | 100 | 20% | 1,338 | 14% | 45 | 15% |
| Hispanic/Latinx | 201 | 41% | 2,176 | 23% | 39 | 13% |
| API | 17 | 3% | 298 | 3% | <5 | N/A |
| Other/Unknown | 10 | 2% | 170 | 2% | ≥5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | <5 | N/A | 0 | 0% | 0 | 0% |
| 13–19 | 17 | 3% | 9 | <1% | 0 | 0% |
| 20–29 | 193 | 39% | 572 | 6% | 7 | 2% |
| 30–39 | 165 | 33% | 1,746 | 19% | 16 | 5% |
| 40–49 | 62 | 13% | 1,566 | 17% | 40 | 13% |
| 50–59 | 35 | 7% | 2,717 | 29% | 88 | 30% |
| 60–69 | 18 | 4% | 2,091 | 22% | 90 | 30% |
| 70+ | <5 | N/A | 735 | 8% | 57 | 19% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 135 | 27% | 2,996 | 32% | 83 | 28% |
| Central HSR | 44 | 9% | 753 | 8% | 30 | 10% |
| Metro West HSR | 78 | 16% | 1,592 | 17% | 37 | 12% |
| Northeast HSR | 104 | 21% | 1,534 | 16% | 52 | 17% |
| Southeast HSR | 75 | 15% | 1,641 | 17% | 55 | 18% |
| Western HSR | 54 | 11% | 917 | 10% | 41 | 14% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 3 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PRIMARY EXPOSURE MODE: INJECTION DRUG USE (IDU)** |

**TABLE 6.2** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals with IDU primary exposure mode by sex assigned at birth, current gender, place of birth, race/ethnicity, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **202** | **100%** | **3,448** | **100%** | **348** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 136 | 67% | 2,219 | 64% | 236 | 68% |
| AFAB | 66 | 33% | 1,229 | 36% | 112 | 32% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 202 | 100% | ≥5 | N/A | ≥5 | N/A |
| Transgender | 0 | 0% | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 191 | 95% | 2,383 | 69% | 261 | 75% |
| PR/USD | 6 | 3% | 874 | 25% | 78 | 22% |
| Non-US | 5 | 2% | 191 | 6% | 9 | 3% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 150 | 74% | 1,273 | 37% | 147 | 42% |
| Black NH | 17 | 8% | 709 | 21% | 81 | 23% |
| Hispanic/Latinx | 33 | 16% | 1,418 | 41% | 117 | 34% |
| API | 0 | 0% | 19 | 1% | <5 | N/A |
| Other/Unknown | 2 | 1% | 29 | 1% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 0 | 0% | 0 | 0% |
| 13–19 | <5 | N/A | 0 | 0% | 0 | 0% |
| 20–29 | 33 | 16% | 55 | 2% | <5 | N/A |
| 30–39 | 104 | 51% | 282 | 8% | 24 | 7% |
| 40–49 | 36 | 18% | 396 | 11% | 34 | 10% |
| 50–59 | 19 | 9% | 1,067 | 31% | 114 | 33% |
| 60–69 | 9 | 4% | 1,326 | 38% | 142 | 41% |
| 70+ | <5 | N/A | 322 | 9% | ≥5 | N/A |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 91 | 45% | 780 | 23% | 74 | 21% |
| Central HSR | 21 | 10% | 504 | 15% | 52 | 15% |
| Metro West HSR | 15 | 7% | 398 | 12% | 37 | 11% |
| Northeast HSR | 23 | 11% | 601 | 17% | 67 | 19% |
| Southeast HSR | 26 | 13% | 548 | 16% | 53 | 15% |
| Western HSR | 6 | 3% | 617 | 18% | 65 | 19% |
| Prison | 19 | 9% | N/A | N/A | N/A | N/A |
| Unknown | 1 | <1% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PRIMARY EXPOSURE MODE: MALE-TO-MALE SEX/INJECTION DRUG USE (MSM/IDU)** |

**TABLE 6.3** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals with MSM/IDU primary exposure mode by current gender, place of birth, race/ethnicity, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **51** | **100%** | **902** | **100%** | **54** | **100%** |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 887 | 98% | ≥5 | N/A |
| Transgender | <5 | N/A | 15 | 2% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 48 | 94% | 725 | 80% | 47 | 87% |
| PR/USD | <5 | N/A | 101 | 11% | ≥5 | N/A |
| Non-US | <5 | N/A | 76 | 8% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 34 | 67% | 517 | 57% | 26 | 48% |
| Black NH | 8 | 16% | 134 | 15% | 15 | 28% |
| Hispanic/Latinx | 8 | 16% | 214 | 24% | 11 | 20% |
| API | 0 | 0% | 13 | 1% | 0 | 0% |
| Other/Unknown | 1 | 2% | 24 | 3% | 2 | 4% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 0 | 0% | 0 | 0% |
| 13–19 | 0 | 0% | 0 | 0% | 0 | 0% |
| 20–29 | 17 | 33% | 23 | 3% | <5 | N/A |
| 30–39 | 24 | 47% | 137 | 15% | 7 | 13% |
| 40–49 | <5 | N/A | 200 | 22% | 6 | 11% |
| 50–59 | <5 | N/A | 282 | 31% | 17 | 31% |
| 60–69 | <5 | N/A | 214 | 24% | 21 | 39% |
| 70+ | 0 | 0% | 46 | 5% | <5 | N/A |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 12 | 24% | 268 | 30% | 12 | 22% |
| Central HSR | <5 | N/A | 91 | 10% | 10 | 19% |
| Metro West HSR | 12 | 24% | 140 | 16% | 5 | 9% |
| Northeast HSR | <5 | N/A | 125 | 14% | 12 | 22% |
| Southeast HSR | 14 | 27% | 161 | 18% | <5 | N/A |
| Western HSR | <5 | N/A | 117 | 13% | 11 | 20% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PRIMARY EXPOSURE MODE: HETEROSEXUAL SEX (HTSX)** |

**TABLE 6.4** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals with HTSX primary exposure mode by sex assigned at birth, current gender, place of birth, race/ethnicity, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **104** | **100%** | **3,229** | **100%** | **120** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 36 | 35% | 910 | 28% | 47 | 39% |
| AFAB | 68 | 65% | 2,319 | 72% | 73 | 61% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 104 | 100% | ≥5 | N/A | 120 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 38 | 37% | 1,349 | 42% | 73 | 61% |
| PR/USD | 5 | 5% | 497 | 15% | 19 | 16% |
| Non-US | 61 | 59% | 1,383 | 43% | 28 | 23% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 27 | 26% | 592 | 18% | 30 | 25% |
| Black NH | 53 | 51% | 1,469 | 45% | 47 | 39% |
| Hispanic/Latinx | 22 | 21% | 1,080 | 33% | 42 | 35% |
| API | 0 | 0% | 50 | 2% | 0 | 0% |
| Other/Unknown | 2 | 2% | 38 | 1% | 1 | 1% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 15 | 14% | 44 | 1% | <5 | N/A |
| 30–39 | 28 | 27% | 233 | 7% | ≥5 | N/A |
| 40–49 | 26 | 25% | 605 | 19% | 9 | 8% |
| 50–59 | 24 | 23% | 1,140 | 35% | 45 | 38% |
| 60–69 | 10 | 10% | 900 | 28% | 36 | 30% |
| 70+ | <5 | N/A | 306 | 9% | 24 | 20% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 24 | 23% | 671 | 21% | 32 | 27% |
| Central HSR | 14 | 13% | 418 | 13% | 14 | 12% |
| Metro West HSR | 14 | 13% | 489 | 15% | 20 | 17% |
| Northeast HSR | 21 | 20% | 609 | 19% | 13 | 11% |
| Southeast HSR | 18 | 17% | 560 | 17% | 22 | 18% |
| Western HSR | 12 | 12% | 482 | 15% | 19 | 16% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PRIMARY EXPOSURE MODE: PRESUMED HETEROSEXUAL SEX (PRESUMED HTSX)** |

**TABLE 6.5** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals with Presumed HTSX primary exposure mode by place of birth, race/ethnicity, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **138** | **100%** | **2,158** | **100%** | **49** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | N/A\* | N/A | N/A | N/A | N/A | N/A |
| AFAB | 138 | 100% | 2,158 | 100% | 49 | 100% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 138 | 100% | ≥5 | N/A | 49 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 602 | 28% | 27 | 55% |
| PR/USD | <5 | N/A | 127 | 6% | 5 | 10% |
| Non-US | 103 | 75% | 1,429 | 66% | 17 | 35% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 12 | 9% | 263 | 12% | 5 | 10% |
| Black NH | 92 | 67% | 1,369 | 63% | 35 | 71% |
| Hispanic/Latinx | 32 | 23% | 475 | 22% | 9 | 18% |
| API | <5 | N/A | 35 | 2% | 0 | 0% |
| Other/Unknown | <5 | N/A | 16 | 1% | 0 | 0% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 23 | 17% | 55 | 3% | <5 | N/A |
| 30–39 | 33 | 24% | 248 | 11% | <5 | N/A |
| 40–49 | 32 | 23% | 538 | 25% | 7 | 14% |
| 50–59 | 25 | 18% | 700 | 32% | 16 | 33% |
| 60–69 | 22 | 16% | 425 | 20% | 15 | 31% |
| 70+ | <5 | N/A | 191 | 9% | 10 | 20% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 30 | 22% | 507 | 23% | 11 | 22% |
| Central HSR | 15 | 11% | 261 | 12% | 7 | 14% |
| Metro West HSR | 25 | 18% | 384 | 18% | 6 | 12% |
| Northeast HSR | 29 | 21% | 477 | 22% | 11 | 22% |
| Southeast HSR | 32 | 23% | 334 | 15% | 7 | 14% |
| Western HSR | 7 | 5% | 195 | 9% | 7 | 14% |
| Prison | 0 | 0% | N/A | N/A | N/A | N/A |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \*N/A=not applicable, presumed heterosexual exposure mode includes individuals assigned female at birth only with a negative history of injection drug use who report having sex with an individual that identifies as male of unknown HIV status and risk.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY PRIMARY EXPOSURE MODE: NO IDENTIFIED RISK (NIR)** |

**TABLE 6.6** HIV infectiondiagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV among individuals with no identified risk for HIV exposure mode by sex assigned at birth, current gender, place of birth, race/ethnicity, age, and Health Service Region (HSR)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **339** | **100%** | **3,999** | **100%** | **148** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 235 | 69% | 3,070 | 77% | 118 | 80% |
| AFAB | 104 | 31% | 929 | 23% | 30 | 20% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 3,991 | 100% | 148 | 100% |
| Transgender | <5 | N/A | 8 | <1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 128 | 38% | 1,661 | 42% | 91 | 61% |
| PR/USD | 13 | 4% | 207 | 5% | 8 | 5% |
| Non-US | 198 | 58% | 2,131 | 53% | 49 | 33% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 70 | 21% | 853 | 21% | 52 | 35% |
| Black NH | 169 | 50% | 1,947 | 49% | 72 | 49% |
| Hispanic/Latinx | 80 | 24% | 1,012 | 25% | 20 | 14% |
| API | 14 | 4% | 146 | 4% | <5 | N/A |
| Other/Unknown | 6 | 2% | 41 | 1% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12\* | <5 | N/A | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 45 | 13% | 135 | 3% | <5 | N/A |
| 30–39 | 114 | 34% | 491 | 12% | ≥5 | N/A |
| 40–49 | 71 | 21% | 732 | 18% | 15 | 10% |
| 50–59 | 63 | 19% | 1,208 | 30% | 36 | 24% |
| 60–69 | 33 | 10% | 1,042 | 26% | 43 | 29% |
| 70+ | 9 | 3% | 389 | 10% | 43 | 29% |
| **Health Service Region** |  |  |  |  |  |  |
| Boston HSR | 83 | 24% | 989 | 25% | 46 | 31% |
| Central HSR | 18 | 5% | 352 | 9% | 12 | 8% |
| Metro West HSR | 53 | 16% | 708 | 18% | 28 | 19% |
| Northeast HSR | 83 | 24% | 891 | 22% | 24 | 16% |
| Southeast HSR | 65 | 19% | 654 | 16% | 20 | 14% |
| Western HSR | 34 | 10% | 405 | 10% | 17 | 11% |
| Prison | <5 | N/A | N/A | N/A | N/A | N/A |
| Unknown | <5 | N/A | 0 | 0% | 1 | 1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY HEALTH SERVICE REGION (HSR) OF RESIDENCE: BOSTON HSR** |

**TABLE 7.1** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Boston HSR, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **375** | **100%** | **6,299** | **100%** | **260** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 274 | 73% | 4,835 | 77% | 198 | 76% |
| AFAB | 101 | 27% | 1,464 | 23% | 62 | 24% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 370 | 99% | 6,247 | 99% | ≥5 | N/A |
| Transgender | 5 | 1% | 52 | 1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 219 | 58% | 3,781 | 60% | 193 | 74% |
| PR/USD | 8 | 2% | 376 | 6% | 26 | 10% |
| Non-US | 148 | 39% | 2,142 | 34% | 41 | 16% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 106 | 28% | 2,003 | 32% | 81 | 31% |
| Black NH | 151 | 40% | 2,351 | 37% | 129 | 50% |
| Hispanic/Latinx | 102 | 27% | 1,700 | 27% | 46 | 18% |
| API | 12 | 3% | 154 | 2% | 1 | <1% |
| Other/Unknown | 4 | 1% | 91 | 1% | 3 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 135 | 36% | 2,996 | 48% | 83 | 32% |
| IDU | 91 | 24% | 780 | 12% | 74 | 28% |
| MSM/IDU | 12 | 3% | 268 | 4% | 12 | 5% |
| HTSX | 24 | 6% | 671 | 11% | 32 | 12% |
| Other | 0 | 0% | 88 | 1% | 2 | 1% |
| Presumed HTSX | 30 | 8% | 507 | 8% | 11 | 4% |
| NIR | 83 | 22% | 989 | 16% | 46 | 18% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 7 | 2% | 7 | <1% | 0 | 0% |
| 20–29 | 93 | 25% | 268 | 4% | 6 | 2% |
| 30–39 | 152 | 41% | 956 | 15% | 14 | 5% |
| 40–49 | 61 | 16% | 1,080 | 17% | 24 | 9% |
| 50–59 | 41 | 11% | 1,884 | 30% | 71 | 27% |
| 60–69 | 17 | 5% | 1,568 | 25% | 99 | 38% |
| 70+ | 4 | 1% | 532 | 8% | 46 | 18% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY HEALTH SERVICE REGION (HSR) OF RESIDENCE: CENTRAL HSR** |

**TABLE 7.2** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Central HSR, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **116** | **100%** | **2,446** | **100%** | **128** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 76 | 66% | 1,617 | 66% | 87 | 68% |
| AFAB | 40 | 34% | 829 | 34% | 41 | 32% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 116 | 100% | 2,435 | 100% | 128 | 100% |
| Transgender | 0 | 0% | 11 | <1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 70 | 60% | 1,355 | 55% | 91 | 71% |
| PR/USD | 6 | 5% | 376 | 15% | 25 | 20% |
| Non-US | 40 | 34% | 715 | 29% | 12 | 9% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 50 | 43% | 879 | 36% | 61 | 48% |
| Black NH | 32 | 28% | 713 | 29% | 28 | 22% |
| Hispanic/Latinx | 32 | 28% | 782 | 32% | 36 | 28% |
| API | 0 | 0% | 43 | 2% | 0 | 0% |
| Other/Unknown | 2 | 2% | 29 | 1% | 3 | 2% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 44 | 38% | 753 | 31% | 30 | 23% |
| IDU | 21 | 18% | 504 | 21% | 52 | 41% |
| MSM/IDU | <5 | N/A | 91 | 4% | 10 | 8% |
| HTSX | 14 | 12% | 418 | 17% | 14 | 11% |
| Other | <5 | N/A | 67 | 3% | 3 | 2% |
| Presumed HTSX | 15 | 13% | 261 | 11% | 7 | 5% |
| NIR | 18 | 16% | 352 | 14% | 12 | 9% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 2 | 2% | 10 | <1% | 0 | 0% |
| 20–29 | 29 | 25% | 128 | 5% | 3 | 2% |
| 30–39 | 33 | 28% | 326 | 13% | 11 | 9% |
| 40–49 | 23 | 20% | 471 | 19% | 19 | 15% |
| 50–59 | 19 | 16% | 708 | 29% | 41 | 32% |
| 60–69 | 10 | 9% | 608 | 25% | 41 | 32% |
| 70+ | 0 | 0% | 191 | 8% | 13 | 10% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY HEALTH SERVICE REGION (HSR) OF RESIDENCE: METRO WEST HSR** |

**TABLE 7.3** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Metro West HSR, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **197** | **100%** | **3,791** | **100%** | **134** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 142 | 72% | 2,701 | 71% | 94 | 70% |
| AFAB | 55 | 28% | 1,090 | 29% | 40 | 30% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 3,779 | 100% | ≥5 | N/A |
| Transgender | <5 | N/A | 12 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 99 | 50% | 2,127 | 56% | 102 | 76% |
| PR/USD | <5 | N/A | 106 | 3% | 8 | 6% |
| Non-US | ≥5 | N/A | 1,558 | 41% | 24 | 18% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 70 | 36% | 1,561 | 41% | 71 | 53% |
| Black NH | 69 | 35% | 1,370 | 36% | 45 | 34% |
| Hispanic/Latinx | 52 | 26% | 663 | 17% | 14 | 10% |
| API | 5 | 3% | 140 | 4% | 2 | 1% |
| Other/Unknown | 1 | 1% | 57 | 2% | 2 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 78 | 40% | 1,592 | 42% | 37 | 28% |
| IDU | 15 | 8% | 398 | 10% | 37 | 28% |
| MSM/IDU | 12 | 6% | 140 | 4% | 5 | 4% |
| HTSX | 14 | 7% | 489 | 13% | 20 | 15% |
| Other | 0 | 0% | 80 | 2% | 1 | 1% |
| Presumed HTSX | 25 | 13% | 384 | 10% | 6 | 4% |
| NIR | 53 | 27% | 708 | 19% | 28 | 21% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 2 | 1% | 8 | <1% | 0 | 0% |
| 20–29 | 46 | 23% | 157 | 4% | 2 | 1% |
| 30–39 | 69 | 35% | 557 | 15% | 10 | 7% |
| 40–49 | 39 | 20% | 667 | 18% | 14 | 10% |
| 50–59 | 20 | 10% | 1,134 | 30% | 32 | 24% |
| 60–69 | 14 | 7% | 931 | 25% | 46 | 34% |
| 70+ | 7 | 4% | 333 | 9% | 30 | 22% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY HEALTH SERVICE REGION (HSR) OF RESIDENCE: NORTHEAST HSR** |

**TABLE 7.4** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Northeast HSR, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **264** | **100%** | **4,330** | **100%** | **180** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 192 | 73% | 2,927 | 68% | 137 | 76% |
| AFAB | 72 | 27% | 1,403 | 32% | 43 | 24% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 4,316 | 100% | ≥5 | N/A |
| Transgender | <5 | N/A | 14 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 102 | 39% | 2,216 | 51% | 133 | 74% |
| PR/USD | 7 | 3% | 421 | 10% | 26 | 14% |
| Non-US | 155 | 59% | 1,693 | 39% | 21 | 12% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 84 | 32% | 1,626 | 38% | 98 | 54% |
| Black NH | 64 | 24% | 1,115 | 26% | 26 | 14% |
| Hispanic/Latinx | 97 | 37% | 1,368 | 32% | 54 | 30% |
| API | 11 | 4% | 163 | 4% | 1 | 1% |
| Other/Unknown | 8 | 3% | 58 | 1% | 1 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 104 | 39% | 1,534 | 35% | 52 | 29% |
| IDU | 23 | 9% | 601 | 14% | 67 | 37% |
| MSM/IDU | <5 | N/A | 125 | 3% | 12 | 7% |
| HTSX | 21 | 8% | 609 | 14% | 13 | 7% |
| Other | <5 | N/A | 93 | 2% | 1 | 1% |
| Presumed HTSX | 29 | 11% | 477 | 11% | 11 | 6% |
| NIR | 83 | 31% | 891 | 21% | 24 | 13% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 5 | <1% | 0 | 0% |
| 13–19 | 3 | 1% | 9 | <1% | 0 | 0% |
| 20–29 | 71 | 27% | 219 | 5% | 2 | 1% |
| 30–39 | 83 | 31% | 697 | 16% | 12 | 7% |
| 40–49 | 50 | 19% | 736 | 17% | 26 | 14% |
| 50–59 | 30 | 11% | 1,300 | 30% | 61 | 34% |
| 60–69 | 23 | 9% | 1,015 | 23% | 57 | 32% |
| 70+ | 3 | 1% | 349 | 8% | 22 | 12% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY HEALTH SERVICE REGION (HSR) OF RESIDENCE: SOUTHEAST HSR** |

**TABLE 7.5** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Southeast HSR, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **230** | **100%** | **3,975** | **100%** | **161** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 148 | 64% | 2,831 | 71% | 116 | 72% |
| AFAB | 82 | 36% | 1,144 | 29% | 45 | 28% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 3,961 | 100% | 161 | 100% |
| Transgender | <5 | N/A | 14 | <1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 134 | 58% | 2,697 | 68% | 131 | 81% |
| PR/USD | 12 | 5% | 229 | 6% | 9 | 6% |
| Non-US | 84 | 37% | 1,049 | 26% | 21 | 13% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 92 | 40% | 2,110 | 53% | 104 | 65% |
| Black NH | 88 | 38% | 1,100 | 28% | 34 | 21% |
| Hispanic/Latinx | 44 | 19% | 665 | 17% | 22 | 14% |
| API | <5 | N/A | 39 | 1% | 0 | 0% |
| Other/Unknown | <5 | N/A | 61 | 2% | 1 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 75 | 33% | 1,641 | 41% | 55 | 34% |
| IDU | 26 | 11% | 548 | 14% | 53 | 33% |
| MSM/IDU | 14 | 6% | 161 | 4% | <5 | N/A |
| HTSX | 18 | 8% | 560 | 14% | 22 | 14% |
| Other | 0 | 0% | 77 | 2% | <5 | N/A |
| Presumed HTSX | 32 | 14% | 334 | 8% | 7 | 4% |
| NIR | 65 | 28% | 654 | 16% | 20 | 12% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 4 | 2% | 7 | <1% | 0 | 0% |
| 20–29 | 53 | 23% | 149 | 4% | 4 | 2% |
| 30–39 | 81 | 35% | 466 | 12% | 8 | 5% |
| 40–49 | 35 | 15% | 640 | 16% | 16 | 10% |
| 50–59 | 36 | 16% | 1,184 | 30% | 57 | 35% |
| 60–69 | 21 | 9% | 1,166 | 29% | 48 | 30% |
| 70+ | 0 | 0% | 359 | 9% | 28 | 17% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY HEALTH SERVICE REGION (HSR) OF RESIDENCE: WESTERN HSR** |

**TABLE 7.6** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Western HSR, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **116** | **100%** | **2,799** | **100%** | **160** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 92 | 79% | 1,877 | 67% | 123 | 77% |
| AFAB | 24 | 21% | 922 | 33% | 37 | 23% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 2,781 | 99% | 160 | 100% |
| Transgender | <5 | N/A | 18 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 85 | 73% | 1,828 | 65% | 118 | 74% |
| PR/USD | 8 | 7% | 681 | 24% | ≥5 | N/A |
| Non-US | 23 | 20% | 290 | 10% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 41 | 35% | 886 | 32% | 53 | 33% |
| Black NH | 34 | 29% | 521 | 19% | 35 | 22% |
| Hispanic/Latinx | 37 | 32% | 1,329 | 47% | 67 | 42% |
| API | <5 | N/A | 33 | 1% | <5 | N/A |
| Other/Unknown | <5 | N/A | 30 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 54 | 47% | 917 | 33% | 41 | 26% |
| IDU | 6 | 5% | 617 | 22% | 65 | 41% |
| MSM/IDU | <5 | N/A | 117 | 4% | 11 | 7% |
| HTSX | 12 | 10% | 482 | 17% | 19 | 12% |
| Other | <5 | N/A | 66 | 2% | 0 | 0% |
| Presumed HTSX | 7 | 6% | 195 | 7% | 7 | 4% |
| NIR | 34 | 29% | 405 | 14% | 17 | 11% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | 1% | 2 | <1% | 0 | 0% |
| 13–19 | 3 | 3% | 4 | <1% | 0 | 0% |
| 20–29 | 27 | 23% | 120 | 4% | 1 | 1% |
| 30–39 | 34 | 29% | 324 | 12% | 7 | 4% |
| 40–49 | 16 | 14% | 457 | 16% | 12 | 8% |
| 50–59 | 23 | 20% | 924 | 33% | 55 | 34% |
| 60–69 | 10 | 9% | 732 | 26% | 58 | 36% |
| 70+ | 2 | 2% | 236 | 8% | 27 | 17% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: BARNSTABLE, DUKES, AND NANTUCKET COUNTIES** |

**TABLE 8.1** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Barnstable, Dukes, and Nantucket Counties, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **31** | **100%** | **1,060** | **100%** | **26** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 24 | 77% | 936 | 88% | 24 | 92% |
| AFAB | 7 | 23% | 124 | 12% | 2 | 8% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 31 | 100% | ≥5 | N/A | 26 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 19 | 61% | 833 | 79% | 23 | 88% |
| PR/USD | 0 | 0% | 11 | 1% | <5 | N/A |
| Non-US | 12 | 39% | 216 | 20% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 15 | 48% | 808 | 76% | 24 | 92% |
| Black NH | 5 | 16% | 92 | 9% | <5 | N/A |
| Hispanic/Latinx | 10 | 32% | 128 | 12% | <5 | N/A |
| API | <5 | N/A | 8 | 1% | 0 | 0% |
| Other/Unknown | <5 | N/A | 24 | 2% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 18 | 58% | 780 | 74% | 22 | 85% |
| IDU | <5 | N/A | 49 | 5% | <5 | N/A |
| MSM/IDU | <5 | N/A | 42 | 4% | <5 | N/A |
| HTSX | 0 | 0% | 57 | 5% | <5 | N/A |
| Other | 0 | 0% | 6 | 1% | 0 | 0% |
| Presumed HTSX | <5 | N/A | 39 | 4% | <5 | N/A |
| NIR | 5 | 16% | 87 | 8% | 0 | 0% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 7 | 23% | 25 | 2% | 0 | 0% |
| 30–39 | 11 | 35% | 94 | 9% | <5 | N/A |
| 40–49 | 5 | 16% | 148 | 14% | <5 | N/A |
| 50–59 | 7 | 23% | 321 | 30% | 9 | 35% |
| 60–69 | <5 | N/A | 350 | 33% | 7 | 27% |
| 70+ | 0 | 0% | 121 | 11% | 5 | 19% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: BERKSHIRE COUNTY** |

**TABLE 8.2** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Berkshire County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **9** | **100%** | **238** | **100%** | **12** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 7 | 78% | 175 | 74% | 11 | 92% |
| AFAB | 2 | 22% | 63 | 26% | 1 | 8% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 9 | 100% | 238 | 100% | 12 | 100% |
| Transgender | 0 | 0% | 0 | 0% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 6 | 67% | 200 | 84% | 12 | 100% |
| PR/USD | <5 | N/A | <5 | N/A | 0 | 0% |
| Non-US | <5 | N/A | ≥5 | N/A | 0 | 0% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 4 | 44% | 150 | 63% | 9 | 75% |
| Black NH | <5 | N/A | 49 | 21% | <5 | N/A |
| Hispanic/Latinx | <5 | N/A | 32 | 13% | <5 | N/A |
| API | 0 | 0% | <5 | N/A | 0 | 0% |
| Other/Unknown | 0 | 0% | <5 | N/A | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | <5 | N/A | 118 | 50% | 9 | 75% |
| IDU | <5 | N/A | 27 | 11% | <5 | N/A |
| MSM/IDU | 0 | 0% | 10 | 4% | <5 | N/A |
| HTSX | <5 | N/A | 35 | 15% | 0 | 0% |
| Other | 0 | 0% | 4 | 2% | 0 | 0% |
| Presumed HTSX | 0 | 0% | 14 | 6% | 0 | 0% |
| NIR | <5 | N/A | 30 | 13% | 0 | 0% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 0 | 0% | 0 | 0% |
| 13–19 | 0 | 0% | 0 | 0% | 0 | 0% |
| 20–29 | <5 | N/A | 10 | 4% | 0 | 0% |
| 30–39 | <5 | N/A | 22 | 9% | <5 | N/A |
| 40–49 | <5 | N/A | 49 | 21% | 0 | 0% |
| 50–59 | <5 | N/A | 76 | 32% | <5 | N/A |
| 60–69 | 0 | 0% | 56 | 24% | 6 | 50% |
| 70+ | 0 | 0% | 25 | 11% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: BRISTOL COUNTY** |

**TABLE 8.3** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Bristol County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **86** | **100%** | **1,552** | **100%** | **78** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 62 | 72% | 1,050 | 68% | 49 | 63% |
| AFAB | 24 | 28% | 502 | 32% | 29 | 37% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 1,543 | 99% | 78 | 100% |
| Transgender | <5 | N/A | 9 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 67 | 78% | 1,115 | 72% | 64 | 82% |
| PR/USD | 6 | 7% | 171 | 11% | 6 | 8% |
| Non-US | 13 | 15% | 266 | 17% | 8 | 10% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 45 | 52% | 827 | 53% | 48 | 62% |
| Black NH | 20 | 23% | 335 | 22% | 16 | 21% |
| Hispanic/Latinx | 20 | 23% | 358 | 23% | 14 | 18% |
| API | 0 | 0% | 13 | 1% | 0 | 0% |
| Other/Unknown | 1 | 1% | 19 | 1% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 34 | 40% | 504 | 32% | 18 | 23% |
| IDU | 14 | 16% | 338 | 22% | 35 | 45% |
| MSM/IDU | 7 | 8% | 75 | 5% | <5 | N/A |
| HTSX | 7 | 8% | 255 | 16% | 14 | 18% |
| Other | 0 | 0% | 38 | 2% | 0 | 0% |
| Presumed HTSX | 10 | 12% | 110 | 7% | <5 | N/A |
| NIR | 14 | 16% | 232 | 15% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 26 | 30% | 65 | 4% | 3 | 4% |
| 30–39 | 32 | 37% | 194 | 13% | 3 | 4% |
| 40–49 | 10 | 12% | 265 | 17% | 7 | 9% |
| 50–59 | 11 | 13% | 473 | 30% | 27 | 35% |
| 60–69 | 5 | 6% | 431 | 28% | 28 | 36% |
| 70+ | <5 | N/A | 118 | 8% | 10 | 13% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: ESSEX COUNTY** |

**TABLE 8.4** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Essex County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **135** | **100%** | **2,235** | **100%** | **100** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 101 | 75% | 1,514 | 68% | 76 | 76% |
| AFAB | 34 | 25% | 721 | 32% | 24 | 24% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 2,227 | 100% | 100 | 100% |
| Transgender | <5 | N/A | 8 | <1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 60 | 44% | 1,222 | 55% | 75 | 75% |
| PR/USD | 6 | 4% | 264 | 12% | 14 | 14% |
| Non-US | 69 | 51% | 749 | 34% | 11 | 11% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 44 | 33% | 870 | 39% | 57 | 57% |
| Black NH | 20 | 15% | 440 | 20% | 9 | 9% |
| Hispanic/Latinx | 69 | 51% | 865 | 39% | 32 | 32% |
| API | <5 | N/A | 37 | 2% | <5 | N/A |
| Other/Unknown | <5 | N/A | 23 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 48 | 36% | 766 | 34% | 29 | 29% |
| IDU | 12 | 9% | 331 | 15% | 41 | 41% |
| MSM/IDU | <5 | N/A | 72 | 3% | 7 | 7% |
| HTSX | 13 | 10% | 332 | 15% | 7 | 7% |
| Other | <5 | N/A | 50 | 2% | <5 | N/A |
| Presumed HTSX | 14 | 10% | 238 | 11% | <5 | N/A |
| NIR | 46 | 34% | 446 | 20% | 13 | 13% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 2 | <1% | 0 | 0% |
| 13–19 | 1 | 1% | 7 | <1% | 0 | 0% |
| 20–29 | 37 | 27% | 101 | 5% | 1 | 1% |
| 30–39 | 40 | 30% | 347 | 16% | 7 | 7% |
| 40–49 | 27 | 20% | 365 | 16% | 12 | 12% |
| 50–59 | 18 | 13% | 688 | 31% | 35 | 35% |
| 60–69 | 12 | 9% | 544 | 24% | 33 | 33% |
| 70+ | 0 | 0% | 181 | 8% | 12 | 12% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: FRANKLIN COUNTY** |

**TABLE 8.5** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Franklin County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **4** | **100%** | **109** | **100%** | **5** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | <5 | N/A | 82 | 75% | <5 | N/A |
| AFAB | <5 | N/A | 27 | 25% | <5 | N/A |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | <5 | N/A | ≥5 | N/A | 5 | 100% |
| Transgender | <5 | N/A | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | <5 | N/A | 97 | 89% | 5 | 100% |
| PR/USD | <5 | N/A | <5 | N/A | 0 | 0% |
| Non-US | 0 | 0% | ≥5 | N/A | 0 | 0% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 3 | 75% | 83 | 76% | 5 | 100% |
| Black NH | <5 | N/A | 8 | 7% | 0 | 0% |
| Hispanic/Latinx | <5 | N/A | 15 | 14% | 0 | 0% |
| API | 0 | 0% | 0 | 0% | 0 | 0% |
| Other/Unknown | 0 | 0% | 3 | 3% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | <5 | N/A | 53 | 49% | <5 | N/A |
| IDU | 0 | 0% | 16 | 15% | <5 | N/A |
| MSM/IDU | 0 | 0% | 9 | 8% | <5 | N/A |
| HTSX | 0 | 0% | 14 | 13% | 0 | 0% |
| Other | 0 | 0% | <5 | N/A | 0 | 0% |
| Presumed HTSX | <5 | N/A | <5 | N/A | 0 | 0% |
| NIR | <5 | N/A | 9 | 8% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 0 | 0% | 0 | 0% |
| 13–19 | 0 | 0% | <5 | N/A | 0 | 0% |
| 20–29 | 0 | 0% | <5 | N/A | 0 | 0% |
| 30–39 | <5 | N/A | 8 | 7% | 0 | 0% |
| 40–49 | 0 | 0% | 12 | 11% | <5 | N/A |
| 50–59 | <5 | N/A | 42 | 39% | <5 | N/A |
| 60–69 | 0 | 0% | 30 | 28% | <5 | N/A |
| 70+ | 0 | 0% | 16 | 15% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: HAMPDEN COUNTY** |

**TABLE 8.6** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Hampden County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **90** | **100%** | **2,192** | **100%** | **132** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 70 | 78% | 1,413 | 64% | 98 | 74% |
| AFAB | 20 | 22% | 779 | 36% | 34 | 26% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 2,175 | 99% | 132 | 100% |
| Transgender | <5 | N/A | 17 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 64 | 71% | 1,328 | 61% | 92 | 70% |
| PR/USD | 8 | 9% | 646 | 29% | ≥5 | N/A |
| Non-US | 18 | 20% | 218 | 10% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 26 | 29% | 504 | 23% | 34 | 26% |
| Black NH | 30 | 33% | 431 | 20% | 32 | 24% |
| Hispanic/Latinx | 33 | 37% | 1,215 | 55% | 61 | 46% |
| API | 0 | 0% | 22 | 1% | <5 | N/A |
| Other/Unknown | 1 | 1% | 20 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 40 | 44% | 596 | 27% | 26 | 20% |
| IDU | <5 | N/A | 545 | 25% | 59 | 45% |
| MSM/IDU | <5 | N/A | 89 | 4% | 6 | 5% |
| HTSX | 10 | 11% | 403 | 18% | 18 | 14% |
| Other | 1 | 1% | 50 | 2% | 0 | 0% |
| Presumed HTSX | 6 | 7% | 166 | 8% | 7 | 5% |
| NIR | 27 | 30% | 343 | 16% | 16 | 12% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | 1% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 24 | 27% | 100 | 5% | 1 | 1% |
| 30–39 | 25 | 28% | 264 | 12% | 5 | 4% |
| 40–49 | 12 | 13% | 354 | 16% | 10 | 8% |
| 50–59 | 18 | 20% | 733 | 33% | 48 | 36% |
| 60–69 | 7 | 8% | 561 | 26% | 45 | 34% |
| 70+ | <5 | N/A | 176 | 8% | 23 | 17% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: HAMPSHIRE COUNTY** |

**TABLE 8.7** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Hampshire County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **10** | **100%** | **250** | **100%** | **13** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 9 | 90% | 200 | 80% | 13 | 100% |
| AFAB | 1 | 10% | 50 | 20% | 0 | 0% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 10 | 100% | 250 | 100% | 13 | 100% |
| Transgender | 0 | 0% | 0 | 0% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 8 | 80% | 195 | 78% | 11 | 85% |
| PR/USD | <5 | N/A | 28 | 11% | <5 | N/A |
| Non-US | <5 | N/A | 27 | 11% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 6 | 60% | 145 | 58% | 7 | 54% |
| Black NH | <5 | N/A | 31 | 12% | <5 | N/A |
| Hispanic/Latinx | 0 | 0% | 64 | 26% | <5 | N/A |
| API | <5 | N/A | 6 | 2% | 0 | 0% |
| Other/Unknown | 1 | 10% | 4 | 2% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 8 | 80% | 146 | 58% | 6 | 46% |
| IDU | 0 | 0% | 28 | 11% | <5 | N/A |
| MSM/IDU | 0 | 0% | 9 | 4% | <5 | N/A |
| HTSX | 0 | 0% | 29 | 12% | <5 | N/A |
| Other | 0 | 0% | 8 | 3% | 0 | 0% |
| Presumed HTSX | <5 | N/A | 9 | 4% | 0 | 0% |
| NIR | <5 | N/A | 21 | 8% | 0 | 0% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | <5 | N/A | 9 | 4% | 0 | 0% |
| 30–39 | <5 | N/A | 28 | 11% | <5 | N/A |
| 40–49 | <5 | N/A | 40 | 16% | 0 | 0% |
| 50–59 | <5 | N/A | 74 | 30% | <5 | N/A |
| 60–69 | <5 | N/A | 77 | 31% | 5 | 38% |
| 70+ | <5 | N/A | 20 | 8% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: MIDDLESEX COUNTY** |

**TABLE 8.8** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Middlesex County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **240** | **100%** | **4,524** | **100%** | **150** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 169 | 70% | 3,158 | 70% | 109 | 73% |
| AFAB | 71 | 30% | 1,366 | 30% | 41 | 27% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 4,508 | 100% | ≥5 | N/A |
| Transgender | <5 | N/A | 16 | <1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 2,244 | 50% | 108 | 72% |
| PR/USD | <5 | N/A | 237 | 5% | 18 | 12% |
| Non-US | 145 | 60% | 2,043 | 45% | 24 | 16% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 81 | 34% | 1,691 | 37% | 78 | 52% |
| Black NH | 76 | 32% | 1,571 | 35% | 38 | 25% |
| Hispanic/Latinx | 64 | 27% | 988 | 22% | 32 | 21% |
| API | 11 | 5% | 201 | 4% | 1 | 1% |
| Other/Unknown | 8 | 3% | 73 | 2% | 1 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 103 | 43% | 1,784 | 39% | 39 | 26% |
| IDU | 19 | 8% | 521 | 12% | 48 | 32% |
| MSM/IDU | 6 | 3% | 137 | 3% | 7 | 5% |
| HTSX | 16 | 7% | 559 | 12% | 16 | 11% |
| Other | 1 | <1% | 99 | 2% | 1 | 1% |
| Presumed HTSX | 33 | 14% | 499 | 11% | 11 | 7% |
| NIR | 62 | 26% | 925 | 20% | 28 | 19% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 6 | <1% | 0 | 0% |
| 13–19 | 4 | 2% | 9 | <1% | 0 | 0% |
| 20–29 | 62 | 26% | 228 | 5% | 2 | 1% |
| 30–39 | 82 | 34% | 695 | 15% | 10 | 7% |
| 40–49 | 47 | 20% | 851 | 19% | 24 | 16% |
| 50–59 | 20 | 8% | 1,329 | 29% | 43 | 29% |
| 60–69 | 18 | 8% | 1,017 | 22% | 45 | 30% |
| 70+ | 6 | 3% | 389 | 9% | 26 | 17% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: NORFOLK COUNTY** |

**TABLE 8.9** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Norfolk County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **94** | **100%** | **1,561** | **100%** | **69** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 69 | 73% | 1,096 | 70% | 49 | 71% |
| AFAB | 25 | 27% | 465 | 30% | 20 | 29% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 94 | 100% | ≥5 | N/A | ≥5 | N/A |
| Transgender | 0 | 0% | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 52 | 55% | 995 | 64% | 57 | 83% |
| PR/USD | <5 | N/A | 41 | 3% | <5 | N/A |
| Non-US | ≥5 | N/A | 525 | 34% | ≥5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 31 | 33% | 654 | 42% | 38 | 55% |
| Black NH | 45 | 48% | 609 | 39% | 24 | 35% |
| Hispanic/Latinx | 15 | 16% | 215 | 14% | <5 | N/A |
| API | 3 | 3% | 62 | 4% | <5 | N/A |
| Other/Unknown | 0 | 0% | 21 | 1% | 2 | 3% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 31 | 33% | 616 | 39% | 22 | 32% |
| IDU | 7 | 7% | 198 | 13% | 18 | 26% |
| MSM/IDU | 8 | 9% | 50 | 3% | <5 | N/A |
| HTSX | 5 | 5% | 232 | 15% | 10 | 14% |
| Other | 0 | 0% | 38 | 2% | 1 | 1% |
| Presumed HTSX | 7 | 7% | 146 | 9% | <5 | N/A |
| NIR | 36 | 38% | 281 | 18% | 12 | 17% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 1 | 1% | 2 | <1% | 0 | 0% |
| 20–29 | 20 | 21% | 61 | 4% | 1 | 1% |
| 30–39 | 32 | 34% | 243 | 16% | 6 | 9% |
| 40–49 | 17 | 18% | 216 | 14% | 5 | 7% |
| 50–59 | 11 | 12% | 475 | 30% | 19 | 28% |
| 60–69 | 9 | 10% | 438 | 28% | 23 | 33% |
| 70+ | 4 | 4% | 122 | 8% | 15 | 22% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: PLYMOUTH COUNTY** |

**TABLE 8.10** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Plymouth County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **102** | **100%** | **1,291** | **100%** | **55** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 57 | 56% | 822 | 64% | 43 | 78% |
| AFAB | 45 | 44% | 469 | 36% | 12 | 22% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | ≥5 | N/A | 55 | 100% |
| Transgender | <5 | N/A | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 44 | 43% | 738 | 57% | 42 | 76% |
| PR/USD | 5 | 5% | 46 | 4% | <5 | N/A |
| Non-US | 53 | 52% | 507 | 39% | ≥5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 30 | 29% | 489 | 38% | 30 | 55% |
| Black NH | 55 | 54% | 592 | 46% | 16 | 29% |
| Hispanic/Latinx | 13 | 13% | 175 | 14% | 8 | 15% |
| API | <5 | N/A | 18 | 1% | 0 | 0% |
| Other/Unknown | <5 | N/A | 17 | 1% | 1 | 2% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 23 | 23% | 359 | 28% | 15 | 27% |
| IDU | 9 | 9% | 150 | 12% | 16 | 29% |
| MSM/IDU | 5 | 5% | 50 | 4% | 0 | 0% |
| HTSX | 11 | 11% | 231 | 18% | 6 | 11% |
| Other | 0 | 0% | 26 | 2% | <5 | N/A |
| Presumed HTSX | 16 | 16% | 164 | 13% | <5 | N/A |
| NIR | 38 | 37% | 311 | 24% | 16 | 29% |
| **Age** |  |  |  |  |  |  |
| 0–12\* | <5 | N/A | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 18 | 18% | 51 | 4% | 1 | 2% |
| 30–39 | 36 | 35% | 162 | 13% | 4 | 7% |
| 40–49 | 18 | 18% | 216 | 17% | 5 | 9% |
| 50–59 | 16 | 16% | 374 | 29% | 19 | 35% |
| 60–69 | 13 | 13% | 367 | 28% | 14 | 25% |
| 70+ | 0 | 0% | 118 | 9% | 12 | 22% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: SUFFOLK COUNTY** |

**TABLE 8.11** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Suffolk County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **375** | **100%** | **6,307** | **100%** | **260** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 274 | 73% | 4,842 | 77% | 198 | 76% |
| AFAB | 101 | 27% | 1,465 | 23% | 62 | 24% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 370 | 99% | 6,255 | 99% | ≥5 | N/A |
| Transgender | 5 | 1% | 52 | 1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 219 | 58% | 3,785 | 60% | 193 | 74% |
| PR/USD | 8 | 2% | 376 | 6% | 26 | 10% |
| Non-US | 148 | 39% | 2,146 | 34% | 41 | 16% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 106 | 28% | 2,007 | 32% | 81 | 31% |
| Black NH | 151 | 40% | 2,353 | 37% | 129 | 50% |
| Hispanic/Latinx | 102 | 27% | 1,702 | 27% | 46 | 18% |
| API | 12 | 3% | 154 | 2% | 1 | <1% |
| Other/Unknown | 4 | 1% | 91 | 1% | 3 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 135 | 36% | 2,999 | 48% | 83 | 32% |
| IDU | 91 | 24% | 782 | 12% | 74 | 28% |
| MSM/IDU | 12 | 3% | 268 | 4% | 12 | 5% |
| HTSX | 24 | 6% | 672 | 11% | 32 | 12% |
| Other | 0 | 0% | 89 | 1% | 2 | 1% |
| Presumed HTSX | 30 | 8% | 508 | 8% | 11 | 4% |
| NIR | 83 | 22% | 989 | 16% | 46 | 18% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 7 | 2% | 7 | <1% | 0 | 0% |
| 20–29 | 93 | 25% | 268 | 4% | 6 | 2% |
| 30–39 | 152 | 41% | 957 | 15% | 14 | 5% |
| 40–49 | 61 | 16% | 1,080 | 17% | 24 | 9% |
| 50–59 | 41 | 11% | 1,887 | 30% | 71 | 27% |
| 60–69 | 17 | 5% | 1,569 | 25% | 99 | 38% |
| 70+ | 4 | 1% | 535 | 8% | 46 | 18% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY COUNTY OF RESIDENCE: WORCESTER COUNTY** |

**TABLE 8.12** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Worcester County, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **122** | **100%** | **2,314** | **100%** | **123** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 79 | 65% | 1,493 | 65% | 82 | 67% |
| AFAB | 43 | 35% | 821 | 35% | 41 | 33% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 122 | 100% | 2,303 | 100% | 123 | 100% |
| Transgender | 0 | 0% | 11 | <1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 73 | 60% | 1,249 | 54% | 86 | 70% |
| PR/USD | 6 | 5% | 361 | 16% | 25 | 20% |
| Non-US | 43 | 35% | 704 | 30% | 12 | 10% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 52 | 43% | 834 | 36% | 57 | 46% |
| Black NH | 32 | 26% | 658 | 28% | 28 | 23% |
| Hispanic/Latinx | 35 | 29% | 747 | 32% | 36 | 29% |
| API | <5 | N/A | 47 | 2% | 0 | 0% |
| Other/Unknown | <5 | N/A | 28 | 1% | 2 | 2% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 44 | 36% | 708 | 31% | 27 | 22% |
| IDU | 22 | 18% | 463 | 20% | 50 | 41% |
| MSM/IDU | <5 | N/A | 91 | 4% | 10 | 8% |
| HTSX | 15 | 12% | 409 | 18% | 15 | 12% |
| Other | <5 | N/A | 59 | 3% | 3 | 2% |
| Presumed HTSX | 17 | 14% | 261 | 11% | 7 | 6% |
| NIR | 20 | 16% | 323 | 14% | 11 | 9% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 2 | <1% | 0 | 0% |
| 13–19 | 2 | 2% | 9 | <1% | 0 | 0% |
| 20–29 | 29 | 24% | 121 | 5% | 3 | 2% |
| 30–39 | 35 | 29% | 311 | 13% | 10 | 8% |
| 40–49 | 23 | 19% | 454 | 20% | 18 | 15% |
| 50–59 | 23 | 19% | 660 | 29% | 39 | 32% |
| 60–69 | 10 | 8% | 578 | 25% | 42 | 34% |
| 70+ | 0 | 0% | 179 | 8% | 11 | 9% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: BOSTON** |

**TABLE 9.1** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: City of Boston, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **335** | **100%** | **5,631** | **100%** | **239** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 242 | 72% | 4,308 | 77% | 180 | 75% |
| AFAB | 93 | 28% | 1,323 | 23% | 59 | 25% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 5,588 | 99% | ≥5 | N/A |
| Transgender | <5 | N/A | 43 | 1% | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 206 | 61% | 3,490 | 62% | 176 | 74% |
| PR/USD | 7 | 2% | 329 | 6% | 24 | 10% |
| Non-US | 122 | 36% | 1,812 | 32% | 39 | 16% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 96 | 29% | 1,805 | 32% | 67 | 28% |
| Black NH | 147 | 44% | 2,241 | 40% | 127 | 53% |
| Hispanic/Latinx | 79 | 24% | 1,354 | 24% | 41 | 17% |
| API | 10 | 3% | 146 | 3% | 1 | <1% |
| Other/Unknown | 3 | 1% | 85 | 2% | 3 | 1% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 115 | 34% | 2,658 | 47% | 73 | 31% |
| IDU | 87 | 26% | 722 | 13% | 67 | 28% |
| MSM/IDU | 12 | 4% | 247 | 4% | 11 | 5% |
| HTSX | 20 | 6% | 600 | 11% | 30 | 13% |
| Other | 0 | 0% | 81 | 1% | 2 | 1% |
| Presumed HTSX | 29 | 9% | 453 | 8% | 10 | 4% |
| NIR | 72 | 21% | 870 | 15% | 46 | 19% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 4 | <1% | 0 | 0% |
| 13–19 | 7 | 2% | 7 | <1% | 0 | 0% |
| 20–29 | 78 | 23% | 231 | 4% | 5 | 2% |
| 30–39 | 135 | 40% | 817 | 15% | 12 | 5% |
| 40–49 | 56 | 17% | 950 | 17% | 23 | 10% |
| 50–59 | 38 | 11% | 1,679 | 30% | 66 | 28% |
| 60–69 | 17 | 5% | 1,450 | 26% | 88 | 37% |
| 70+ | 4 | 1% | 493 | 9% | 45 | 19% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: BROCKTON** |

**TABLE 9.2** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Brockton, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **66** | **100%** | **711** | **100%** | **33** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 28 | 42% | 355 | 50% | 27 | 82% |
| AFAB | 38 | 58% | 356 | 50% | 6 | 18% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 711 | 100% | 33 | 100% |
| Transgender | <5 | N/A | 0 | 0% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 278 | 39% | 21 | 64% |
| PR/USD | <5 | N/A | 31 | 4% | <5 | N/A |
| Non-US | 41 | 62% | 402 | 57% | ≥5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 12 | 18% | 94 | 13% | 13 | 39% |
| Black NH | 48 | 73% | 514 | 72% | 13 | 39% |
| Hispanic/Latinx | 6 | 9% | 95 | 13% | 7 | 21% |
| API | 0 | 0% | <5 | N/A | 0 | 0% |
| Other/Unknown | 0 | 0% | ≥5 | N/A | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 7 | 11% | 96 | 14% | 8 | 24% |
| IDU | 7 | 11% | 76 | 11% | 8 | 24% |
| MSM/IDU | <5 | N/A | 5 | 1% | 0 | 0% |
| HTSX | 8 | 12% | 161 | 23% | <5 | N/A |
| Other | <5 | N/A | 14 | 2% | 0 | 0% |
| Presumed HTSX | 12 | 18% | 139 | 20% | <5 | N/A |
| NIR | 30 | 45% | 220 | 31% | 13 | 39% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | 0 | 0% | <5 | N/A | 0 | 0% |
| 20–29 | 12 | 18% | 32 | 5% | <5 | N/A |
| 30–39 | 24 | 36% | 89 | 13% | <5 | N/A |
| 40–49 | 10 | 15% | 120 | 17% | <5 | N/A |
| 50–59 | 10 | 15% | 189 | 27% | 13 | 39% |
| 60–69 | 10 | 15% | 212 | 30% | 9 | 27% |
| 70+ | 0 | 0% | 67 | 9% | 5 | 15% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: EVERETT** |

**TABLE 9.3** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Everett, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **21** | **100%** | **313** | **100%** | **15** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 16 | 76% | 225 | 72% | ≥5 | N/A |
| AFAB | 5 | 24% | 88 | 28% | <5 | N/A |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 21 | 100% | ≥5 | N/A | ≥5 | N/A |
| Transgender | 0 | 0% | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |
| US | 7 | 33% | 119 | 38% | 10 | 67% |
| PR/USD | 0 | 0% | 9 | 3% | <5 | N/A |
| Non-US | 14 | 67% | 185 | 59% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 6 | 29% | 103 | 33% | 7 | 47% |
| Black NH | 8 | 38% | 97 | 31% | <5 | N/A |
| Hispanic/Latinx | 5 | 24% | 98 | 31% | <5 | N/A |
| API | 0 | 0% | <5 | N/A | 0 | 0% |
| Other/Unknown | 2 | 10% | ≥5 | N/A | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 13 | 62% | 138 | 44% | 5 | 33% |
| IDU | <5 | N/A | 21 | 7% | 5 | 33% |
| MSM/IDU | 0 | 0% | <5 | N/A | <5 | N/A |
| HTSX | <5 | N/A | 41 | 13% | <5 | N/A |
| Other | 0 | 0% | <5 | N/A | 0 | 0% |
| Presumed HTSX | <5 | N/A | 32 | 10% | <5 | N/A |
| NIR | <5 | N/A | 74 | 24% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 10 | 48% | 23 | 7% | 0 | 0% |
| 30–39 | 5 | 24% | 52 | 17% | 0 | 0% |
| 40–49 | <5 | N/A | 70 | 22% | <5 | N/A |
| 50–59 | <5 | N/A | 87 | 28% | 6 | 40% |
| 60–69 | <5 | N/A | 60 | 19% | <5 | N/A |
| 70+ | 0 | 0% | 20 | 6% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: LAWRENCE** |

**TABLE 9.4** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Lawrence, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **38** | **100%** | **547** | **100%** | **28** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 28 | 74% | 322 | 59% | 17 | 61% |
| AFAB | 10 | 26% | 225 | 41% | 11 | 39% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 38 | 100% | ≥5 | N/A | 28 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 157 | 29% | ≥5 | N/A |
| PR/USD | <5 | N/A | 164 | 30% | 12 | 43% |
| Non-US | 24 | 63% | 226 | 41% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 5 | 13% | 62 | 11% | 9 | 32% |
| Black NH | <5 | N/A | 44 | 8% | <5 | N/A |
| Hispanic/Latinx | 31 | 82% | 437 | 80% | 18 | 64% |
| API | <5 | N/A | <5 | N/A | <5 | N/A |
| Other/Unknown | 0 | 0% | <5 | N/A | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 16 | 42% | 95 | 17% | <5 | N/A |
| IDU | <5 | N/A | 124 | 23% | 18 | 64% |
| MSM/IDU | <5 | N/A | 12 | 2% | <5 | N/A |
| HTSX | 5 | 13% | 119 | 22% | <5 | N/A |
| Other | 0 | 0% | 14 | 3% | 0 | 0% |
| Presumed HTSX | 5 | 13% | 67 | 12% | 2 | 7% |
| NIR | 8 | 21% | 116 | 21% | 0 | 0% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 14 | 37% | 35 | 6% | 0 | 0% |
| 30–39 | 9 | 24% | 87 | 16% | <5 | N/A |
| 40–49 | 7 | 18% | 96 | 18% | 6 | 21% |
| 50–59 | 5 | 13% | 149 | 27% | 11 | 39% |
| 60–69 | <5 | N/A | 129 | 24% | 8 | 29% |
| 70+ | 0 | 0% | 50 | 9% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: LOWELL** |

**TABLE 9.5** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Lowell, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **37** | **100%** | **704** | **100%** | **32** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 26 | 70% | 433 | 62% | 25 | 78% |
| AFAB | 11 | 30% | 271 | 38% | 7 | 22% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 37 | 100% | ≥5 | N/A | 32 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 317 | 45% | 23 | 72% |
| PR/USD | <5 | N/A | 122 | 17% | ≥5 | N/A |
| Non-US | 22 | 59% | 265 | 38% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 12 | 32% | 191 | 27% | 13 | 41% |
| Black NH | 14 | 38% | 206 | 29% | 5 | 16% |
| Hispanic/Latinx | 6 | 16% | 235 | 33% | 14 | 44% |
| API | <5 | N/A | 64 | 9% | 0 | 0% |
| Other/Unknown | <5 | N/A | 8 | 1% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 13 | 35% | 172 | 24% | 9 | 28% |
| IDU | <5 | N/A | 151 | 21% | 12 | 38% |
| MSM/IDU | 0 | 0% | 18 | 3% | <5 | N/A |
| HTSX | <5 | N/A | 106 | 15% | <5 | N/A |
| Other | 0 | 0% | 24 | 3% | 0 | 0% |
| Presumed HTSX | <5 | N/A | 78 | 11% | <5 | N/A |
| NIR | 13 | 35% | 155 | 22% | 7 | 22% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 8 | 22% | 33 | 5% | <5 | N/A |
| 30–39 | 13 | 35% | 127 | 18% | <5 | N/A |
| 40–49 | 9 | 24% | 119 | 17% | 6 | 19% |
| 50–59 | <5 | N/A | 216 | 31% | 12 | 38% |
| 60–69 | <5 | N/A | 148 | 21% | 10 | 31% |
| 70+ | <5 | N/A | 59 | 8% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: LYNN** |

**TABLE 9.6** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Lynn, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **37** | **100%** | **523** | **100%** | **23** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 23 | 62% | 336 | 64% | 20 | 87% |
| AFAB | 14 | 38% | 187 | 36% | 3 | 13% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | ≥5 | N/A | 23 | 100% |
| Transgender | <5 | N/A | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 259 | 50% | 17 | 74% |
| PR/USD | <5 | N/A | 34 | 7% | <5 | N/A |
| Non-US | 18 | 49% | 230 | 44% | ≥5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 8 | 22% | 145 | 28% | 9 | 39% |
| Black NH | 10 | 27% | 178 | 34% | 6 | 26% |
| Hispanic/Latinx | 18 | 49% | 172 | 33% | 7 | 30% |
| API | <5 | N/A | 21 | 4% | <5 | N/A |
| Other/Unknown | <5 | N/A | 7 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 12 | 32% | 174 | 33% | 6 | 26% |
| IDU | 0 | 0% | 56 | 11% | 6 | 26% |
| MSM/IDU | 0 | 0% | 17 | 3% | <5 | N/A |
| HTSX | <5 | N/A | 71 | 14% | <5 | N/A |
| Other | <5 | N/A | 9 | 2% | 0 | 0% |
| Presumed HTSX | 7 | 19% | 79 | 15% | <5 | N/A |
| NIR | 16 | 43% | 117 | 22% | 6 | 26% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | 0 | 0% | <5 | N/A | 0 | 0% |
| 20–29 | 9 | 24% | 20 | 4% | 0 | 0% |
| 30–39 | 12 | 32% | 91 | 17% | <5 | N/A |
| 40–49 | 9 | 24% | 97 | 19% | <5 | N/A |
| 50–59 | <5 | N/A | 160 | 31% | 7 | 30% |
| 60–69 | <5 | N/A | 122 | 23% | 9 | 39% |
| 70+ | 0 | 0% | 31 | 6% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: MALDEN** |

**TABLE 9.7** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Malden, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **31** | **100%** | **396** | **100%** | **12** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 24 | 77% | 278 | 70% | ≥5 | N/A |
| AFAB | 7 | 23% | 118 | 30% | <5 | N/A |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 31 | 100% | ≥5 | N/A | 12 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | <5 | N/A | 165 | 42% | 7 | 58% |
| PR/USD | <5 | N/A | 6 | 2% | <5 | N/A |
| Non-US | 27 | 87% | 225 | 57% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 7 | 23% | 134 | 34% | 6 | 50% |
| Black NH | 10 | 32% | 145 | 37% | <5 | N/A |
| Hispanic/Latinx | 10 | 32% | 80 | 20% | <5 | N/A |
| API | <5 | N/A | 30 | 8% | 0 | 0% |
| Other/Unknown | <5 | N/A | 7 | 2% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 16 | 52% | 181 | 46% | <5 | N/A |
| IDU | 0 | 0% | 24 | 6% | <5 | N/A |
| MSM/IDU | 0 | 0% | 12 | 3% | 0 | 0% |
| HTSX | 0 | 0% | 45 | 11% | <5 | N/A |
| Other | <5 | N/A | 8 | 2% | 0 | 0% |
| Presumed HTSX | <5 | N/A | 49 | 12% | <5 | N/A |
| NIR | 11 | 35% | 77 | 19% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12\* | <5 | N/A | <5 | N/A | 0 | 0% |
| 13–19 | 0 | 0% | <5 | N/A | 0 | 0% |
| 20–29 | 8 | 26% | 27 | 7% | 0 | 0% |
| 30–39 | 11 | 35% | 69 | 17% | <5 | N/A |
| 40–49 | 5 | 16% | 69 | 17% | <5 | N/A |
| 50–59 | <5 | N/A | 108 | 27% | <5 | N/A |
| 60–69 | <5 | N/A | 85 | 21% | <5 | N/A |
| 70+ | <5 | N/A | 37 | 9% | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: NEW BEDFORD** |

**TABLE 9.8** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: New Bedford, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **29** | **100%** | **556** | **100%** | **30** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 15 | 52% | 334 | 60% | 20 | 67% |
| AFAB | 14 | 48% | 222 | 40% | 10 | 33% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 29 | 100% | ≥5 | N/A | 30 | 100% |
| Transgender | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 15 | 52% | 362 | 65% | 23 | 77% |
| PR/USD | <5 | N/A | 102 | 18% | <5 | N/A |
| Non-US | ≥5 | N/A | 92 | 17% | ≥5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 8 | 28% | 238 | 43% | 19 | 63% |
| Black NH | 9 | 31% | 126 | 23% | 6 | 20% |
| Hispanic/Latinx | 11 | 38% | 183 | 33% | 5 | 17% |
| API | 0 | 0% | <5 | N/A | 0 | 0% |
| Other/Unknown | 1 | 3% | ≥5 | N/A | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 8 | 28% | 120 | 22% | 6 | 20% |
| IDU | 7 | 24% | 166 | 30% | 17 | 57% |
| MSM/IDU | <5 | N/A | 26 | 5% | 0 | 0% |
| HTSX | <5 | N/A | 115 | 21% | 6 | 20% |
| Other | 0 | 0% | 14 | 3% | 0 | 0% |
| Presumed HTSX | 7 | 24% | 44 | 8% | <5 | N/A |
| NIR | <5 | N/A | 71 | 13% | <5 | N/A |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 8 | 28% | 18 | 3% | <5 | N/A |
| 30–39 | 9 | 31% | 53 | 10% | 0 | 0% |
| 40–49 | <5 | N/A | 99 | 18% | <5 | N/A |
| 50–59 | 5 | 17% | 180 | 32% | 6 | 20% |
| 60–69 | <5 | N/A | 159 | 29% | 14 | 47% |
| 70+ | 0 | 0% | 43 | 8% | 6 | 20% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: SPRINGFIELD** |

**TABLE 9.9** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Springfield, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **53** | **100%** | **1,298** | **100%** | **80** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 45 | 85% | 824 | 63% | 57 | 71% |
| AFAB | 8 | 15% | 474 | 37% | 23 | 29% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 1,288 | 99% | 80 | 100% |
| Transgender | <5 | N/A | 10 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | 33 | 62% | 752 | 58% | 51 | 64% |
| PR/USD | 7 | 13% | 411 | 32% | ≥5 | N/A |
| Non-US | 13 | 25% | 135 | 10% | <5 | N/A |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 5 | 9% | 167 | 13% | 9 | 11% |
| Black NH | 23 | 43% | 332 | 26% | 23 | 29% |
| Hispanic/Latinx | 25 | 47% | 777 | 60% | 45 | 56% |
| API | 0 | 0% | 13 | 1% | <5 | N/A |
| Other/Unknown | 0 | 0% | 9 | 1% | <5 | N/A |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 28 | 53% | 335 | 26% | 14 | 18% |
| IDU | <5 | N/A | 327 | 25% | 39 | 49% |
| MSM/IDU | 0 | 0% | 50 | 4% | <5 | N/A |
| HTSX | 6 | 11% | 246 | 19% | 14 | 18% |
| Other | 0 | 0% | 33 | 3% | <5 | N/A |
| Presumed HTSX | <5 | N/A | 101 | 8% | 6 | 8% |
| NIR | 15 | 28% | 206 | 16% | 5 | 6% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | <5 | N/A | 0 | 0% |
| 20–29 | 17 | 32% | 62 | 5% | <5 | N/A |
| 30–39 | 14 | 26% | 156 | 12% | <5 | N/A |
| 40–49 | 7 | 13% | 223 | 17% | 5 | 6% |
| 50–59 | 10 | 19% | 407 | 31% | 34 | 43% |
| 60–69 | <5 | N/A | 339 | 26% | 28 | 35% |
| 70+ | 0 | 0% | 109 | 8% | 11 | 14% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **BY CITY OF RESIDENCE: WORCESTER** |

**TABLE 9.10** HIV infection diagnoses (HIV DX) from 2020–2022, persons living with HIV infection (PLWH) on December 31, 2022, and all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, and age: Worcester, Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX (N)**  **2020–2022** | **HIV DX (%)**  **2020–2022** | **PLWH (N)**  **12/31/2022** | **PLWH (%)**  **12/31/2022** | **Deaths (N)**  **2020–2022** | **Deaths (%)**  **2020–2022** |
| **Total** | **65** | **100%** | **1,230** | **100%** | **68** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |
| AMAB | 42 | 65% | 738 | 60% | 45 | 66% |
| AFAB | 23 | 35% | 492 | 40% | 23 | 34% |
| **Current gender** |  |  |  |  |  |  |
| Cisgender | 65 | 100% | 1,223 | 99% | 68 | 100% |
| Transgender | 0 | 0% | 7 | 1% | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |
| US | ≥5 | N/A | 558 | 45% | 42 | 62% |
| PR/USD | <5 | N/A | 236 | 19% | 20 | 29% |
| Non-US | 27 | 42% | 436 | 35% | 6 | 9% |
| **Race/Ethnicity** |  |  |  |  |  |  |
| White NH | 20 | 31% | 286 | 23% | 23 | 34% |
| Black NH | 24 | 37% | 443 | 36% | 18 | 26% |
| Hispanic/Latinx | 20 | 31% | 459 | 37% | 25 | 37% |
| API | 0 | 0% | 29 | 2% | 0 | 0% |
| Other/Unknown | 1 | 2% | 13 | 1% | 2 | 3% |
| **Exposure mode** |  |  |  |  |  |  |
| MSM | 24 | 37% | 314 | 26% | 13 | 19% |
| IDU | 13 | 20% | 284 | 23% | 29 | 43% |
| MSM/IDU | <5 | N/A | 42 | 3% | 6 | 9% |
| HTSX | 9 | 14% | 236 | 19% | 7 | 10% |
| Other | <5 | N/A | 30 | 2% | <5 | N/A |
| Presumed HTSX | 9 | 14% | 150 | 12% | <5 | N/A |
| NIR | 8 | 12% | 174 | 14% | 8 | 12% |
| **Age** |  |  |  |  |  |  |
| 0–12 | 0 | 0% | <5 | N/A | 0 | 0% |
| 13–19 | <5 | N/A | ≥5 | N/A | <5 | N/A |
| 20–29 | 20 | 31% | 64 | 5% | <5 | N/A |
| 30–39 | 18 | 28% | 177 | 14% | 6 | 9% |
| 40–49 | 14 | 22% | 221 | 18% | 10 | 15% |
| 50–59 | 8 | 12% | 345 | 28% | 23 | 34% |
| 60–69 | <5 | N/A | 315 | 26% | 23 | 34% |
| 70+ | 0 | 0% | 101 | 8% | 5 | 7% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN HIV DIAGNOSES: MASSACHUSETTS OVERALL** |

**TABLE 10.1** HIV infection diagnoses by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age at HIV infection diagnosis, and health service region (HSR): Massachusetts, 2013–2022

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013N** | **2013%** | **2014N** | **2014%** | **2015N** | **2015%** | **2016N** | **2016%** | **2017N** | **2017%** | **2018N** | **2018%** | **2019N** | **2019%** | **2020N** | **2020%** | **2021N** | **2021%** | **2022N** | **2022%** |
| **Total** | **690** | **100%** | **651** | **100%** | **611** | **100%** | **649** | **100%** | **616** | **100%** | **656** | **100%** | **533** | **100%** | **435** | **100%** | **448** | **100%** | **446** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| AMAB | 515 | 75% | 486 | 75% | 451 | 74% | 479 | 74% | 457 | 74% | 470 | 72% | 393 | 74% | 314 | 72% | 312 | 70% | 326 | 73% |
| AFAB | 175 | 25% | 165 | 25% | 160 | 26% | 170 | 26% | 159 | 26% | 186 | 28% | 140 | 26% | 121 | 28% | 136 | 30% | 120 | 27% |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | ≥5 | N/A | 605 | 99% | 642 | 99% | ≥5 | N/A | 650 | 99% | ≥5 | N/A | 430 | 99% | ≥5 | N/A | 440 | 99% |
| Transgender | <5 | N/A | <5 | N/A | 6 | 1% | 7 | 1% | <5 | N/A | 6 | 1% | <5 | N/A | 5 | 1% | <5 | N/A | 6 | 1% |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| US | 418 | 61% | 375 | 58% | 348 | 57% | 391 | 60% | 345 | 56% | 418 | 64% | 280 | 53% | 255 | 59% | 257 | 57% | 223 | 50% |
| PR/USD | 34 | 5% | 35 | 5% | 37 | 6% | 25 | 4% | 41 | 7% | 21 | 3% | 17 | 3% | 18 | 4% | 10 | 2% | 16 | 4% |
| Non-US | 238 | 34% | 241 | 37% | 226 | 37% | 233 | 36% | 230 | 37% | 217 | 33% | 236 | 44% | 162 | 37% | 181 | 40% | 207 | 46% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| White NH | 275 | 40% | 225 | 35% | 233 | 38% | 255 | 39% | 231 | 38% | 236 | 36% | 170 | 32% | 167 | 38% | 160 | 36% | 132 | 30% |
| Black NH | 186 | 27% | 212 | 33% | 179 | 29% | 200 | 31% | 165 | 27% | 209 | 32% | 170 | 32% | 137 | 31% | 150 | 33% | 153 | 34% |
| Hispanic/Latinx | 200 | 29% | 177 | 27% | 168 | 27% | 161 | 25% | 190 | 31% | 173 | 26% | 151 | 28% | 115 | 26% | 121 | 27% | 140 | 31% |
| API | 20 | 3% | 30 | 5% | 22 | 4% | 24 | 4% | 20 | 3% | 29 | 4% | 16 | 3% | 6 | 1% | 13 | 3% | 13 | 3% |
| Other/Unknown | 9 | 1% | 7 | 1% | 9 | 1% | 9 | 1% | 10 | 2% | 9 | 1% | 26 | 5% | 10 | 2% | 4 | 1% | 8 | 2% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MSM | 323 | 47% | 320 | 49% | 269 | 44% | 279 | 43% | 242 | 39% | 253 | 39% | 226 | 42% | 164 | 38% | 162 | 36% | 167 | 37% |
| IDU | 38 | 6% | 31 | 5% | 50 | 8% | 71 | 11% | 116 | 19% | 92 | 14% | 59 | 11% | 78 | 18% | 81 | 18% | 43 | 10% |
| MSM/IDU | 15 | 2% | 17 | 3% | 20 | 3% | 17 | 3% | 26 | 4% | 20 | 3% | 18 | 3% | 22 | 5% | 12 | 3% | 17 | 4% |
| HTSX | 57 | 8% | 38 | 6% | 37 | 6% | 50 | 8% | 49 | 8% | 57 | 9% | 37 | 7% | 48 | 11% | 33 | 7% | 23 | 5% |
| Other | 5 | 1% | 4 | 1% | 5 | 1% | 1 | <1% | 1 | <1% | 2 | <1% | 0 | 0% | 0 | 0% | 1 | <1% | 1 | <1% |
| Presumed HTSX | 94 | 14% | 86 | 13% | 64 | 10% | 63 | 10% | 41 | 7% | 39 | 6% | 37 | 7% | 30 | 7% | 47 | 10% | 61 | 14% |
| NIR | 158 | 23% | 155 | 24% | 166 | 27% | 168 | 26% | 141 | 23% | 193 | 29% | 156 | 29% | 93 | 21% | 112 | 25% | 134 | 30% |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0–12\* | 4 | 1% | 3 | <1% | 4 | 1% | 1 | <1% | 1 | <1% | 2 | <1% | 0 | 0% | 0 | 0% | 1 | <1% | 1 | <1% |
| 13–19 | 16 | 2% | 16 | 2% | 23 | 4% | 18 | 3% | 17 | 3% | 8 | 1% | 12 | 2% | 10 | 2% | 7 | 2% | 5 | 1% |
| 20–29 | 180 | 26% | 181 | 28% | 172 | 28% | 192 | 30% | 189 | 31% | 177 | 27% | 154 | 29% | 115 | 26% | 95 | 21% | 116 | 26% |
| 30–39 | 140 | 20% | 158 | 24% | 147 | 24% | 184 | 28% | 189 | 31% | 201 | 31% | 152 | 29% | 156 | 36% | 154 | 34% | 158 | 35% |
| 40–49 | 182 | 26% | 154 | 24% | 126 | 21% | 126 | 19% | 115 | 19% | 125 | 19% | 87 | 16% | 57 | 13% | 98 | 22% | 75 | 17% |
| 50–59 | 130 | 19% | 94 | 14% | 106 | 17% | 86 | 13% | 72 | 12% | 98 | 15% | 75 | 14% | 57 | 13% | 58 | 13% | 55 | 12% |
| 60–69 | 29 | 4% | 35 | 5% | 27 | 4% | 36 | 6% | 27 | 4% | 39 | 6% | 41 | 8% | 38 | 9% | 32 | 7% | 25 | 6% |
| 70+ | 9 | 1% | 10 | 2% | 6 | 1% | 6 | 1% | 6 | 1% | 6 | 1% | 12 | 2% | 2 | <1% | 3 | 1% | 11 | 2% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Boston | 207 | 30% | 204 | 31% | 153 | 25% | 163 | 25% | 161 | 26% | 154 | 23% | 131 | 25% | 129 | 30% | 128 | 29% | 118 | 26% |
| Central | 46 | 7% | 45 | 7% | 49 | 8% | 70 | 11% | 58 | 9% | 52 | 8% | 62 | 12% | 40 | 9% | 43 | 10% | 33 | 7% |
| Metro West | 106 | 15% | 108 | 17% | 113 | 18% | 90 | 14% | 88 | 14% | 98 | 15% | 86 | 16% | 52 | 12% | 79 | 18% | 66 | 15% |
| Northeast | 126 | 18% | 119 | 18% | 131 | 21% | 138 | 21% | 137 | 22% | 150 | 23% | 110 | 21% | 91 | 21% | 89 | 20% | 84 | 19% |
| Southeast | 116 | 17% | 96 | 15% | 98 | 16% | 105 | 16% | 90 | 15% | 120 | 18% | 91 | 17% | 80 | 18% | 62 | 14% | 88 | 20% |
| Western | 80 | 12% | 66 | 10% | 57 | 9% | 67 | 10% | 52 | 8% | 69 | 11% | 45 | 8% | 35 | 8% | 37 | 8% | 44 | 10% |
| Prison | 9 | 1% | 12 | 2% | 9 | 1% | 16 | 2% | 30 | 5% | 12 | 2% | 8 | 2% | 8 | 2% | 9 | 2% | 13 | 3% |
| Unknown | 0 | 0% | 1 | <1% | 1 | <1% | 0 | 0% | 0 | 0% | 1 | <1% | 0 | 0% | 0 | 0% | 1 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN HIV DIAGNOSES: INDIVIDUALS ASSIGNED MALE AT BIRTH** |

**TABLE 10.2** HIV infection diagnoses among individuals assigned male at birth by current gender, place of birth, race/ethnicity, primary exposure mode, age at HIV infection diagnosis, and health service region (HSR): Massachusetts, 2013–2022

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013N** | **2013%** | **2014N** | **2014%** | **2015N** | **2015%** | **2016N** | **2016%** | **2017N** | **2017%** | **2018N** | **2018%** | **2019N** | **2019%** | **2020N** | **2020%** | **2021N** | **2021%** | **2022N** | **2022%** |
| **Total** | **515** | **100%** | **486** | **100%** | **451** | **100%** | **479** | **100%** | **457** | **100%** | **470** | **100%** | **393** | **100%** | **314** | **100%** | **312** | **100%** | **326** | **100%** |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | ≥5 | N/A | 446 | 99% | 472 | 99% | ≥5 | N/A | 464 | 99% | ≥5 | N/A | 309 | 98% | ≥5 | N/A | 320 | 98% |
| Transgender | <5 | N/A | <5 | N/A | 5 | 1% | 7 | 1% | <5 | N/A | 6 | 1% | <5 | N/A | 5 | 2% | <5 | N/A | 6 | 2% |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| US | 338 | 66% | 306 | 63% | 280 | 62% | 308 | 64% | 268 | 59% | 318 | 68% | 224 | 57% | 201 | 64% | 198 | 63% | 178 | 55% |
| PR/USD | 22 | 4% | 24 | 5% | 28 | 6% | 18 | 4% | 33 | 7% | 16 | 3% | 16 | 4% | 15 | 5% | 5 | 2% | 14 | 4% |
| Non-US | 155 | 30% | 156 | 32% | 143 | 32% | 153 | 32% | 156 | 34% | 136 | 29% | 153 | 39% | 98 | 31% | 109 | 35% | 134 | 41% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| White NH | 240 | 47% | 189 | 39% | 192 | 43% | 208 | 43% | 179 | 39% | 189 | 40% | 135 | 34% | 125 | 40% | 125 | 40% | 108 | 33% |
| Black NH | 103 | 20% | 122 | 25% | 97 | 22% | 123 | 26% | 95 | 21% | 119 | 25% | 105 | 27% | 78 | 25% | 76 | 24% | 85 | 26% |
| Hispanic/Latinx | 149 | 29% | 142 | 29% | 135 | 30% | 121 | 25% | 159 | 35% | 133 | 28% | 123 | 31% | 97 | 31% | 95 | 30% | 114 | 35% |
| API | 16 | 3% | 26 | 5% | 18 | 4% | 20 | 4% | 17 | 4% | 22 | 5% | 14 | 4% | 6 | 2% | 13 | 4% | 11 | 3% |
| Other/Unknown | 7 | 1% | 7 | 1% | 9 | 2% | 7 | 1% | 7 | 2% | 7 | 1% | 16 | 4% | 8 | 3% | 3 | 1% | 8 | 2% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MSM | 323 | 63% | 320 | 66% | 269 | 60% | 279 | 58% | 242 | 53% | 253 | 54% | 226 | 58% | 164 | 52% | 162 | 52% | 167 | 51% |
| IDU | 24 | 5% | 19 | 4% | 33 | 7% | 42 | 9% | 76 | 17% | 54 | 11% | 34 | 9% | 51 | 16% | 54 | 17% | 31 | 10% |
| MSM/IDU | 15 | 3% | 17 | 3% | 20 | 4% | 17 | 4% | 26 | 6% | 20 | 4% | 18 | 5% | 22 | 7% | 12 | 4% | 17 | 5% |
| HTSX | 24 | 5% | 12 | 2% | 12 | 3% | 22 | 5% | 13 | 3% | 18 | 4% | 14 | 4% | 14 | 4% | 10 | 3% | 12 | 4% |
| Other | 3 | 1% | 3 | 1% | 3 | 1% | 1 | <1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | <1% |
| NIR | 126 | 24% | 115 | 24% | 114 | 25% | 118 | 25% | 100 | 22% | 125 | 27% | 101 | 26% | 63 | 20% | 74 | 24% | 98 | 30% |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0–12\* | 2 | <1% | 2 | <1% | 3 | 1% | 1 | <1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | <1% |
| 13–19 | 7 | 1% | 11 | 2% | 14 | 3% | 12 | 3% | 14 | 3% | 7 | 1% | 10 | 3% | 10 | 3% | 5 | 2% | 4 | 1% |
| 20–29 | 144 | 28% | 149 | 31% | 134 | 30% | 151 | 32% | 158 | 35% | 149 | 32% | 124 | 32% | 93 | 30% | 81 | 26% | 95 | 29% |
| 30–39 | 102 | 20% | 113 | 23% | 108 | 24% | 130 | 27% | 136 | 30% | 144 | 31% | 117 | 30% | 118 | 38% | 110 | 35% | 119 | 37% |
| 40–49 | 139 | 27% | 115 | 24% | 94 | 21% | 93 | 19% | 81 | 18% | 80 | 17% | 66 | 17% | 34 | 11% | 61 | 20% | 57 | 17% |
| 50–59 | 93 | 18% | 64 | 13% | 80 | 18% | 68 | 14% | 51 | 11% | 57 | 12% | 49 | 12% | 35 | 11% | 37 | 12% | 32 | 10% |
| 60–69 | 21 | 4% | 23 | 5% | 16 | 4% | 18 | 4% | 15 | 3% | 32 | 7% | 22 | 6% | 22 | 7% | 16 | 5% | 13 | 4% |
| 70+ | 7 | 1% | 9 | 2% | 2 | <1% | 6 | 1% | 2 | <1% | 1 | <1% | 5 | 1% | 2 | 1% | 2 | 1% | 5 | 2% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Boston | 161 | 31% | 156 | 32% | 113 | 25% | 125 | 26% | 125 | 27% | 117 | 25% | 102 | 26% | 99 | 32% | 90 | 29% | 85 | 26% |
| Central | 31 | 6% | 32 | 7% | 37 | 8% | 47 | 10% | 48 | 11% | 33 | 7% | 46 | 12% | 27 | 9% | 27 | 9% | 22 | 7% |
| Metro West | 81 | 16% | 84 | 17% | 88 | 20% | 68 | 14% | 63 | 14% | 73 | 16% | 64 | 16% | 36 | 11% | 54 | 17% | 52 | 16% |
| Northeast | 86 | 17% | 79 | 16% | 100 | 22% | 94 | 20% | 97 | 21% | 98 | 21% | 78 | 20% | 66 | 21% | 63 | 20% | 63 | 19% |
| Southeast | 95 | 18% | 74 | 15% | 63 | 14% | 76 | 16% | 58 | 13% | 85 | 18% | 61 | 16% | 54 | 17% | 38 | 12% | 56 | 17% |
| Western | 54 | 10% | 50 | 10% | 43 | 10% | 56 | 12% | 44 | 10% | 53 | 11% | 37 | 9% | 25 | 8% | 31 | 10% | 36 | 11% |
| Prison | 7 | 1% | 10 | 2% | 6 | 1% | 13 | 3% | 22 | 5% | 10 | 2% | 5 | 1% | 7 | 2% | 8 | 3% | 12 | 4% |
| Unknown | 0 | 0% | 1 | <1% | 1 | <1% | 0 | 0% | 0 | 0% | 1 | <1% | 0 | 0% | 0 | 0% | 1 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN HIV DIAGNOSES: INDIVIDUALS ASSIGNED FEMALE AT BIRTH** |

**TABLE 10.3** HIV infection diagnoses among individuals assigned female at birth by current gender, place of birth, race/ethnicity, primary exposure mode, age at HIV infection diagnosis, and health service region (HSR): Massachusetts, 2013–2022

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013N** | **2013%** | **2014N** | **2014%** | **2015N** | **2015%** | **2016N** | **2016%** | **2017N** | **2017%** | **2018N** | **2018%** | **2019N** | **2019%** | **2020N** | **2020%** | **2021N** | **2021%** | **2022N** | **2022%** |
| **Total** | **175** | **100%** | **165** | **100%** | **160** | **100%** | **170** | **100%** | **159** | **100%** | **186** | **100%** | **140** | **100%** | **121** | **100%** | **136** | **100%** | **120** | **100%** |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 165 | 100% | ≥5 | N/A | 170 | 100% | 159 | 100% | 186 | 100% | 140 | 100% | 121 | 100% | ≥5 | N/A | 120 | 100% |
| Transgender | <5 | N/A | 0 | 0% | <5 | N/A | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | <5 | N/A | 0 | 0% |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| US | 80 | 46% | 69 | 42% | 68 | 43% | 83 | 49% | 77 | 48% | 100 | 54% | ≥5 | N/A | ≥5 | N/A | 59 | 43% | ≥5 | N/A |
| PR/USD | 12 | 7% | 11 | 7% | 9 | 6% | 7 | 4% | 8 | 5% | 5 | 3% | <5 | N/A | <5 | N/A | 5 | 4% | <5 | N/A |
| Non-US | 83 | 47% | 85 | 52% | 83 | 52% | 80 | 47% | 74 | 47% | 81 | 44% | 83 | 59% | 64 | 53% | 72 | 53% | 73 | 61% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| White NH | 35 | 20% | 36 | 22% | 41 | 26% | 47 | 28% | 52 | 33% | 47 | 25% | 35 | 25% | 42 | 35% | 35 | 26% | 24 | 20% |
| Black NH | 83 | 47% | 90 | 55% | 82 | 51% | 77 | 45% | 70 | 44% | 90 | 48% | 65 | 46% | 59 | 49% | 74 | 54% | 68 | 57% |
| Hispanic/Latinx | 51 | 29% | 35 | 21% | 33 | 21% | 40 | 24% | 31 | 19% | 40 | 22% | 28 | 20% | 18 | 15% | 26 | 19% | 26 | 22% |
| API | 4 | 2% | 4 | 2% | 4 | 3% | 4 | 2% | 3 | 2% | 7 | 4% | 2 | 1% | 0 | 0% | 0 | 0% | 2 | 2% |
| Other/Unknown | 2 | 1% | 0 | 0% | 0 | 0% | 2 | 1% | 3 | 2% | 2 | 1% | 10 | 7% | 2 | 2% | 1 | 1% | 0 | 0% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| IDU | 14 | 8% | 12 | 7% | 17 | 11% | 29 | 17% | 40 | 25% | 38 | 20% | 25 | 18% | 27 | 22% | 27 | 20% | 12 | 10% |
| HTSX | 33 | 19% | 26 | 16% | 25 | 16% | 28 | 16% | 36 | 23% | 39 | 21% | 23 | 16% | 34 | 28% | 23 | 17% | 11 | 9% |
| Other | 2 | 1% | 1 | 1% | 2 | 1% | 0 | 0% | 1 | 1% | 2 | 1% | 0 | 0% | 0 | 0% | 1 | 1% | 0 | 0% |
| Presumed HTSX | 94 | 54% | 86 | 52% | 64 | 40% | 63 | 37% | 41 | 26% | 39 | 21% | 37 | 26% | 30 | 25% | 47 | 35% | 61 | 51% |
| NIR | 32 | 18% | 40 | 24% | 52 | 33% | 50 | 29% | 41 | 26% | 68 | 37% | 55 | 39% | 30 | 25% | 38 | 28% | 36 | 30% |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0–12\* | 2 | 1% | 1 | 1% | 1 | 1% | 0 | 0% | 1 | 1% | 2 | 1% | 0 | 0% | 0 | 0% | 1 | 1% | 0 | 0% |
| 13–19 | 9 | 5% | 5 | 3% | 9 | 6% | 6 | 4% | 3 | 2% | 1 | 1% | 2 | 1% | 0 | 0% | 2 | 1% | 1 | 1% |
| 20–29 | 36 | 21% | 32 | 19% | 38 | 24% | 41 | 24% | 31 | 19% | 28 | 15% | 30 | 21% | 22 | 18% | 14 | 10% | 21 | 18% |
| 30–39 | 38 | 22% | 45 | 27% | 39 | 24% | 54 | 32% | 53 | 33% | 57 | 31% | 35 | 25% | 38 | 31% | 44 | 32% | 39 | 33% |
| 40–49 | 43 | 25% | 39 | 24% | 32 | 20% | 33 | 19% | 34 | 21% | 45 | 24% | 21 | 15% | 23 | 19% | 37 | 27% | 18 | 15% |
| 50–59 | 37 | 21% | 30 | 18% | 26 | 16% | 18 | 11% | 21 | 13% | 41 | 22% | 26 | 19% | 22 | 18% | 21 | 15% | 23 | 19% |
| 60–69 | 8 | 5% | 12 | 7% | 11 | 7% | 18 | 11% | 12 | 8% | 7 | 4% | 19 | 14% | 16 | 13% | 16 | 12% | 12 | 10% |
| 70+ | 2 | 1% | 1 | 1% | 4 | 3% | 0 | 0% | 4 | 3% | 5 | 3% | 7 | 5% | 0 | 0% | 1 | 1% | 6 | 5% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Boston | 46 | 26% | 48 | 29% | 40 | 25% | 38 | 22% | 36 | 23% | 37 | 20% | 29 | 21% | 30 | 25% | 38 | 28% | 33 | 28% |
| Central | 15 | 9% | 13 | 8% | 12 | 8% | 23 | 14% | 10 | 6% | 19 | 10% | 16 | 11% | 13 | 11% | 16 | 12% | 11 | 9% |
| Metro West | 25 | 14% | 24 | 15% | 25 | 16% | 22 | 13% | 25 | 16% | 25 | 13% | 22 | 16% | 16 | 13% | 25 | 18% | 14 | 12% |
| Northeast | 40 | 23% | 40 | 24% | 31 | 19% | 44 | 26% | 40 | 25% | 52 | 28% | 32 | 23% | 25 | 21% | 26 | 19% | 21 | 18% |
| Southeast | 21 | 12% | 22 | 13% | 35 | 22% | 29 | 17% | 32 | 20% | 35 | 19% | 30 | 21% | 26 | 21% | 24 | 18% | 32 | 27% |
| Western | 26 | 15% | 16 | 10% | 14 | 9% | 11 | 6% | 8 | 5% | 16 | 9% | 8 | 6% | 10 | 8% | 6 | 4% | 8 | 7% |
| Prison | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | 8 | 5% | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A |
| Unknown | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | 0 | 0% | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN AIDS DIAGNOSES** |

**TABLE 10.4a** AIDS diagnoses by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age at AIDS diagnosis, and health service region (HSR): Massachusetts, 2013–2022

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013N** | **2013%** | **2014N** | **2014%** | **2015N** | **2015%** | **2016N** | **2016%** | **2017N** | **2017%** | **2018N** | **2018%** | **2019N** | **2019%** | **2020N** | **2020%** | **2021N** | **2021%** | **2022N** | **2022%** |
| **Total** | **383** | **100%** | **309** | **100%** | **271** | **100%** | **272** | **100%** | **268** | **100%** | **286** | **100%** | **244** | **100%** | **188** | **100%** | **210** | **100%** | **195** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| AMAB | 268 | 70% | 227 | 73% | 193 | 71% | 183 | 67% | 178 | 66% | 189 | 66% | 165 | 68% | 120 | 64% | 141 | 67% | 131 | 67% |
| AFAB | 115 | 30% | 82 | 27% | 78 | 29% | 89 | 33% | 90 | 34% | 97 | 34% | 79 | 32% | 68 | 36% | 69 | 33% | 64 | 33% |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | ≥5 | N/A | 271 | 100% | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A |
| Transgender | <5 | N/A | <5 | N/A | 0 | 0% | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| US | 221 | 58% | 183 | 59% | 164 | 61% | 148 | 54% | 144 | 54% | 165 | 58% | 128 | 52% | 97 | 52% | 110 | 52% | 99 | 51% |
| PR/USD | 35 | 9% | 30 | 10% | 22 | 8% | 25 | 9% | 18 | 7% | 14 | 5% | 14 | 6% | 12 | 6% | 11 | 5% | 10 | 5% |
| Non-US | 127 | 33% | 96 | 31% | 85 | 31% | 99 | 36% | 106 | 40% | 107 | 37% | 102 | 42% | 79 | 42% | 89 | 42% | 86 | 44% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| White NH | 127 | 33% | 101 | 33% | 98 | 36% | 91 | 33% | 79 | 29% | 92 | 32% | 83 | 34% | 67 | 36% | 59 | 28% | 60 | 31% |
| Black NH | 132 | 34% | 104 | 34% | 88 | 32% | 94 | 35% | 109 | 41% | 103 | 36% | 94 | 39% | 66 | 35% | 85 | 40% | 81 | 42% |
| Hispanic/Latinx | 111 | 29% | 90 | 29% | 71 | 26% | 73 | 27% | 69 | 26% | 74 | 26% | 51 | 21% | 49 | 26% | 56 | 27% | 48 | 25% |
| API | 8 | 2% | 12 | 4% | 9 | 3% | 9 | 3% | 8 | 3% | 12 | 4% | 7 | 3% | 3 | 2% | 6 | 3% | 2 | 1% |
| Other/Unknown | 5 | 1% | 2 | 1% | 5 | 2% | 5 | 2% | 3 | 1% | 5 | 2% | 9 | 4% | 3 | 2% | 4 | 2% | 4 | 2% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MSM | 129 | 34% | 104 | 34% | 79 | 29% | 91 | 33% | 66 | 25% | 88 | 31% | 74 | 30% | 50 | 27% | 62 | 30% | 62 | 32% |
| IDU | 60 | 16% | 39 | 13% | 43 | 16% | 37 | 14% | 40 | 15% | 35 | 12% | 34 | 14% | 25 | 13% | 25 | 12% | 19 | 10% |
| MSM/IDU | 9 | 2% | 13 | 4% | 8 | 3% | <5 | N/A | 6 | 2% | 8 | 3% | 7 | 3% | <5 | N/A | 8 | 4% | 5 | 3% |
| HTSX | 48 | 13% | 36 | 12% | 22 | 8% | 32 | 12% | 40 | 15% | 28 | 10% | 28 | 11% | 25 | 13% | 25 | 12% | 21 | 11% |
| Other | 7 | 2% | 8 | 3% | 8 | 3% | ≥5 | N/A | 7 | 3% | 7 | 2% | 3 | 1% | <5 | N/A | 4 | 2% | 3 | 2% |
| Presumed HTSX | 50 | 13% | 37 | 12% | 30 | 11% | 35 | 13% | 20 | 7% | 26 | 9% | 24 | 10% | 23 | 12% | 22 | 10% | 25 | 13% |
| NIR | 80 | 21% | 72 | 23% | 81 | 30% | 68 | 25% | 89 | 33% | 94 | 33% | 74 | 30% | 62 | 33% | 64 | 30% | 60 | 31% |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0–12\* | 1 | <1% | 1 | <1% | 2 | 1% | 0 | 0% | 1 | <1% | 3 | 1% | 0 | 0% | 0 | 0% | 1 | <1% | 1 | 1% |
| 13–19 | 5 | 1% | 3 | 1% | 4 | 1% | 3 | 1% | 4 | 1% | 0 | 0% | 2 | 1% | 0 | 0% | 0 | 0% | 1 | 1% |
| 20–29 | 53 | 14% | 40 | 13% | 34 | 13% | 43 | 16% | 30 | 11% | 45 | 16% | 33 | 14% | 20 | 11% | 18 | 9% | 20 | 10% |
| 30–39 | 68 | 18% | 62 | 20% | 51 | 19% | 68 | 25% | 62 | 23% | 72 | 25% | 55 | 23% | 49 | 26% | 54 | 26% | 55 | 28% |
| 40–49 | 133 | 35% | 93 | 30% | 75 | 28% | 77 | 28% | 67 | 25% | 58 | 20% | 55 | 23% | 36 | 19% | 60 | 29% | 42 | 22% |
| 50–59 | 82 | 21% | 83 | 27% | 71 | 26% | 51 | 19% | 65 | 24% | 73 | 26% | 56 | 23% | 45 | 24% | 41 | 20% | 44 | 23% |
| 60–69 | 35 | 9% | 18 | 6% | 31 | 11% | 25 | 9% | 31 | 12% | 30 | 10% | 33 | 14% | 31 | 16% | 31 | 15% | 25 | 13% |
| 70+ | 6 | 2% | 9 | 3% | 3 | 1% | 5 | 2% | 8 | 3% | 5 | 2% | 10 | 4% | 7 | 4% | 5 | 2% | 7 | 4% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Boston | 102 | 27% | 78 | 25% | 63 | 23% | 73 | 27% | 67 | 25% | 71 | 25% | 55 | 23% | 42 | 22% | 54 | 26% | 47 | 24% |
| Central | 36 | 9% | 30 | 10% | 36 | 13% | 24 | 9% | 28 | 10% | 30 | 10% | 35 | 14% | 22 | 12% | 23 | 11% | 18 | 9% |
| Metro West | 52 | 14% | 50 | 16% | 38 | 14% | 44 | 16% | 42 | 16% | 46 | 16% | 32 | 13% | 26 | 14% | 39 | 19% | 32 | 16% |
| Northeast | 65 | 17% | 51 | 17% | 50 | 18% | 58 | 21% | 49 | 18% | 59 | 21% | 45 | 18% | 36 | 19% | 41 | 20% | 33 | 17% |
| Southeast | 75 | 20% | 47 | 15% | 50 | 18% | 44 | 16% | 50 | 19% | 54 | 19% | 48 | 20% | 33 | 18% | 32 | 15% | 42 | 22% |
| Western | 53 | 14% | 52 | 17% | 34 | 13% | 29 | 11% | 32 | 12% | 26 | 9% | 29 | 12% | 29 | 15% | 21 | 10% | 23 | 12% |
| Unknown | 0 | 0% | 1 | <1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### \* AIDS diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN PROGRESSION TO AIDS** |

**TABLE 10.4b** Progression to AIDS among people diagnosed with both HIV and AIDS (people diagnosed with AIDS within two months of HIV diagnosis are excluded) by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age at AIDS diagnosis, and health service region (HSR): Massachusetts, 2013–2022

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013N** | **2013%** | **2014N** | **2014%** | **2015N** | **2015%** | **2016N** | **2016%** | **2017N** | **2017%** | **2018N** | **2018%** | **2019N** | **2019%** | **2020N** | **2020%** | **2021N** | **2021%** | **2022N** | **2022%** |
| **Total** | **144** | **100%** | **128** | **100%** | **104** | **100%** | **101** | **100%** | **109** | **100%** | **96** | **100%** | **116** | **100%** | **68** | **100%** | **83** | **100%** | **70** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| AMAB | 89 | 62% | 88 | 69% | 67 | 64% | 64 | 63% | 70 | 64% | 63 | 66% | 73 | 63% | 42 | 62% | 55 | 66% | 47 | 67% |
| AFAB | 55 | 38% | 40 | 31% | 37 | 36% | 37 | 37% | 39 | 36% | 33 | 34% | 43 | 37% | 26 | 38% | 28 | 34% | 23 | 33% |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 128 | 100% | 104 | 100% | 101 | 100% | ≥5 | N/A | 96 | 100% | ≥5 | N/A | 68 | 100% | ≥5 | N/A | ≥5 | N/A |
| Transgender | <5 | N/A | 0 | 0% | 0 | 0% | 0 | 0% | <5 | N/A | 0 | 0% | <5 | N/A | 0 | 0% | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| US | 96 | 67% | 84 | 66% | 75 | 72% | 69 | 68% | 67 | 61% | 65 | 68% | 76 | 66% | 41 | 60% | 50 | 60% | 49 | 70% |
| PR/USD | 22 | 15% | 21 | 16% | 9 | 9% | 12 | 12% | 13 | 12% | 8 | 8% | 9 | 8% | 7 | 10% | 9 | 11% | 4 | 6% |
| Non-US | 26 | 18% | 23 | 18% | 20 | 19% | 20 | 20% | 29 | 27% | 23 | 24% | 31 | 27% | 20 | 29% | 24 | 29% | 17 | 24% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| White NH | 44 | 31% | 44 | 34% | 38 | 37% | 39 | 39% | 35 | 32% | 39 | 41% | 51 | 44% | 25 | 37% | 25 | 30% | 28 | 40% |
| Black NH | 52 | 36% | 40 | 31% | 33 | 32% | 35 | 35% | 38 | 35% | 31 | 32% | 41 | 35% | 21 | 31% | 28 | 34% | 25 | 36% |
| Hispanic/Latinx | 45 | 31% | 41 | 32% | 27 | 26% | 24 | 24% | 32 | 29% | 23 | 24% | 20 | 17% | 20 | 29% | 26 | 31% | 16 | 23% |
| API | 1 | 1% | 2 | 2% | 3 | 3% | 2 | 2% | 4 | 4% | 2 | 2% | 2 | 2% | 1 | 1% | 1 | 1% | 0 | 0% |
| Other/Unknown | 2 | 1% | 1 | 1% | 3 | 3% | 1 | 1% | 0 | 0% | 1 | 1% | 2 | 2% | 1 | 1% | 3 | 4% | 1 | 1% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MSM | 40 | 28% | 35 | 27% | 24 | 23% | 30 | 30% | 25 | 23% | 31 | 32% | 31 | 27% | 17 | 25% | 20 | 24% | 30 | 43% |
| IDU | 36 | 25% | 29 | 23% | 26 | 25% | 26 | 26% | 28 | 26% | 24 | 25% | 29 | 25% | 15 | 22% | 18 | 22% | 14 | 20% |
| MSM/IDU | 5 | 3% | 7 | 5% | 7 | 7% | 0 | 0% | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | 5 | 6% | <5 | N/A |
| HTSX | 28 | 19% | 21 | 16% | 13 | 13% | 15 | 15% | 17 | 16% | 9 | 9% | 15 | 13% | <5 | N/A | 12 | 14% | 9 | 13% |
| Other | 5 | 3% | 7 | 5% | 5 | 5% | 5 | 5% | ≥5 | N/A | ≥5 | N/A | <5 | N/A | 0 | 0% | 1 | 1% | <5 | N/A |
| Presumed HTSX | 14 | 10% | 12 | 9% | 12 | 12% | 10 | 10% | 9 | 8% | 7 | 7% | 14 | 12% | 9 | 13% | 7 | 8% | 5 | 7% |
| NIR | 16 | 11% | 17 | 13% | 17 | 16% | 15 | 15% | 22 | 20% | 18 | 19% | 21 | 18% | 20 | 29% | 20 | 24% | 8 | 11% |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0–12\* | 0 | 0% | 1 | 1% | 0 | 0% | 0 | 0% | 1 | 1% | 2 | 2% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| 13–19 | 2 | 1% | 1 | 1% | 1 | 1% | 2 | 2% | 1 | 1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 1% |
| 20–29 | 17 | 12% | 13 | 10% | 10 | 10% | 15 | 15% | 11 | 10% | 13 | 14% | 13 | 11% | 5 | 7% | 2 | 2% | 7 | 10% |
| 30–39 | 27 | 19% | 21 | 16% | 17 | 16% | 19 | 19% | 23 | 21% | 18 | 19% | 24 | 21% | 15 | 22% | 21 | 25% | 16 | 23% |
| 40–49 | 50 | 35% | 36 | 28% | 30 | 29% | 27 | 27% | 21 | 19% | 14 | 15% | 26 | 22% | 13 | 19% | 24 | 29% | 14 | 20% |
| 50–59 | 30 | 21% | 47 | 37% | 27 | 26% | 27 | 27% | 27 | 25% | 34 | 35% | 32 | 28% | 18 | 26% | 19 | 23% | 17 | 24% |
| 60–69 | 16 | 11% | 6 | 5% | 17 | 16% | 10 | 10% | 21 | 19% | 13 | 14% | 19 | 16% | 12 | 18% | 13 | 16% | 13 | 19% |
| 70+ | 2 | 1% | 3 | 2% | 2 | 2% | 1 | 1% | 4 | 4% | 2 | 2% | 2 | 2% | 5 | 7% | 4 | 5% | 2 | 3% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Boston | 39 | 27% | 32 | 25% | 30 | 29% | 32 | 32% | 29 | 27% | 25 | 26% | 30 | 26% | 15 | 22% | 27 | 33% | 18 | 26% |
| Central | 13 | 9% | 12 | 9% | 14 | 13% | 3 | 3% | 5 | 5% | 8 | 8% | 14 | 12% | 8 | 12% | 7 | 8% | 7 | 10% |
| Metro West | 13 | 9% | 22 | 17% | 12 | 12% | 15 | 15% | 16 | 15% | 16 | 17% | 20 | 17% | 12 | 18% | 13 | 16% | 10 | 14% |
| Northeast | 26 | 18% | 17 | 13% | 13 | 13% | 19 | 19% | 23 | 21% | 24 | 25% | 19 | 16% | 12 | 18% | 14 | 17% | 9 | 13% |
| Southeast | 24 | 17% | 19 | 15% | 20 | 19% | 17 | 17% | 19 | 17% | 15 | 16% | 18 | 16% | 7 | 10% | 10 | 12% | 17 | 24% |
| Western | 29 | 20% | 26 | 20% | 15 | 14% | 15 | 15% | 17 | 16% | 8 | 8% | 15 | 13% | 14 | 21% | 12 | 14% | 9 | 13% |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### See [*Technical Note XXII*](#technical_note_xxii) for definition of AIDS progression.

###### \* AIDS diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN PERSONS LIVING WITH HIV INFECTION** |

**TABLE 10.5a** Persons living with HIV infection by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, current age, and health service region (HSR): Massachusetts, 2013–2017

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013**  **N** | **2013**  **%** | **2014**  **N** | **2014**  **%** | **2015**  **N** | **2015**  **%** | **2016**  **N** | **2016**  **%** | **2017**  **N** | **2017**  **%** |
| **Total** | **21,346** | **100%** | **21,788** | **100%** | **22,060** | **100%** | **22,520** | **100%** | **22,947** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |  |  |
| AMAB | 15,308 | 72% | 15,619 | 72% | 15,798 | 72% | 16,124 | 72% | 16,411 | 72% |
| AFAB | 6,038 | 28% | 6,169 | 28% | 6,262 | 28% | 6,396 | 28% | 6,536 | 28% |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |
| Cisgender | 21,266 | 100% | 21,704 | 100% | 21,971 | 100% | 22,426 | 100% | 22,847 | 100% |
| Transgender | 80 | <1% | 84 | <1% | 89 | <1% | 94 | <1% | 100 | <1% |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |
| US | 13,803 | 65% | 14,008 | 64% | 14,066 | 64% | 14,231 | 63% | 14,326 | 62% |
| PR/USD | 2,372 | 11% | 2,375 | 11% | 2,383 | 11% | 2,389 | 11% | 2,385 | 10% |
| Non-US | 5,171 | 24% | 5,405 | 25% | 5,611 | 25% | 5,900 | 26% | 6,236 | 27% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |
| White NH | 9,069 | 42% | 9,167 | 42% | 9,211 | 42% | 9,289 | 41% | 9,376 | 41% |
| Black NH | 6,181 | 29% | 6,335 | 29% | 6,420 | 29% | 6,589 | 29% | 6,749 | 29% |
| Hispanic/Latinx | 5,484 | 26% | 5,640 | 26% | 5,755 | 26% | 5,932 | 26% | 6,064 | 26% |
| API | 382 | 2% | 412 | 2% | 432 | 2% | 460 | 2% | 500 | 2% |
| Other/Unknown | 230 | 1% | 234 | 1% | 242 | 1% | 250 | 1% | 258 | 1% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |
| MSM | 8,227 | 39% | 8,484 | 39% | 8,650 | 39% | 8,896 | 40% | 9,097 | 40% |
| IDU | 4,010 | 19% | 3,941 | 18% | 3,849 | 17% | 3,796 | 17% | 3,801 | 17% |
| MSM/IDU | 928 | 4% | 930 | 4% | 925 | 4% | 924 | 4% | 933 | 4% |
| HTSX | 3,140 | 15% | 3,171 | 15% | 3,176 | 14% | 3,223 | 14% | 3,258 | 14% |
| Other | 455 | 2% | 460 | 2% | 463 | 2% | 464 | 2% | 470 | 2% |
| Presumed HTSX | 1,760 | 8% | 1,839 | 8% | 1,893 | 9% | 1,967 | 9% | 2,017 | 9% |
| NIR | 2,826 | 13% | 2,963 | 14% | 3,104 | 14% | 3,250 | 14% | 3,371 | 15% |
| **Age** |  |  |  |  |  |  |  |  |  |  |
| 0–12 | 36 | <1% | 37 | <1% | 35 | <1% | 33 | <1% | 28 | <1% |
| 13–19 | 146 | 1% | 118 | 1% | 105 | <1% | 99 | <1% | 97 | <1% |
| 20–29 | 1,233 | 6% | 1,307 | 6% | 1,319 | 6% | 1,402 | 6% | 1,421 | 6% |
| 30–39 | 2,848 | 13% | 2,812 | 13% | 2,824 | 13% | 2,899 | 13% | 3,015 | 13% |
| 40–49 | 6,692 | 31% | 6,205 | 28% | 5,779 | 26% | 5,406 | 24% | 5,072 | 22% |
| 50–59 | 7,427 | 35% | 7,893 | 36% | 8,119 | 37% | 8,257 | 37% | 8,312 | 36% |
| 60–69 | 2,476 | 12% | 2,836 | 13% | 3,195 | 14% | 3,626 | 16% | 4,054 | 18% |
| 70+ | 488 | 2% | 580 | 3% | 684 | 3% | 798 | 4% | 948 | 4% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |
| Boston | 6,390 | 30% | 6,467 | 30% | 6,431 | 29% | 6,467 | 29% | 6,507 | 28% |
| Central | 2,117 | 10% | 2,142 | 10% | 2,142 | 10% | 2,228 | 10% | 2,275 | 10% |
| Metro West | 3,309 | 16% | 3,393 | 16% | 3,466 | 16% | 3,531 | 16% | 3,622 | 16% |
| Northeast | 3,544 | 17% | 3,669 | 17% | 3,793 | 17% | 3,961 | 18% | 4,093 | 18% |
| Southeast | 3,347 | 16% | 3,424 | 16% | 3,489 | 16% | 3,582 | 16% | 3,678 | 16% |
| Western | 2,638 | 12% | 2,692 | 12% | 2,738 | 12% | 2,750 | 12% | 2,771 | 12% |
| Unknown | 1 | <1% | 1 | <1% | 1 | <1% | 1 | <1% | 1 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN PERSONS LIVING WITH HIV INFECTION, CONTINUED** |

**TABLE 10.5b** Persons living with HIV infection by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, current age, and health service region (HSR): Massachusetts, 2018–2022

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2018**  **N** | **2018**  **%** | **2019**  **N** | **2019**  **%** | **2020**  **N** | **2020**  **%** | **2021**  **N** | **2021**  **%** | **2022**  **N** | **2022**  **%** |
| **Total** | **23,209** | **100%** | **23,375** | **100%** | **23,441** | **100%** | **23,481** | **100%** | **23,643** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |  |  |
| AMAB | 16,564 | 71% | 16,683 | 71% | 16,708 | 71% | 16,693 | 71% | 16,791 | 71% |
| AFAB | 6,645 | 29% | 6,692 | 29% | 6,733 | 29% | 6,788 | 29% | 6,852 | 29% |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |
| Cisgender | 23,104 | 100% | 23,270 | 100% | 23,327 | 100% | 23,364 | 100% | 23,521 | 99% |
| Transgender | 105 | <1% | 105 | <1% | 114 | <1% | 117 | <1% | 122 | 1% |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |
| US | 14,397 | 62% | 14,343 | 61% | 14,281 | 61% | 14,142 | 60% | 14,007 | 59% |
| PR/USD | 2,356 | 10% | 2,320 | 10% | 2,281 | 10% | 2,237 | 10% | 2,189 | 9% |
| Non-US | 6,456 | 28% | 6,712 | 29% | 6,879 | 29% | 7,102 | 30% | 7,447 | 31% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |
| White NH | 9,346 | 40% | 9,297 | 40% | 9,260 | 40% | 9,169 | 39% | 9,066 | 38% |
| Black NH | 6,887 | 30% | 6,981 | 30% | 7,030 | 30% | 7,057 | 30% | 7,172 | 30% |
| Hispanic/Latinx | 6,173 | 27% | 6,255 | 27% | 6,304 | 27% | 6,381 | 27% | 6,507 | 28% |
| API | 531 | 2% | 545 | 2% | 546 | 2% | 560 | 2% | 572 | 2% |
| Other/Unknown | 272 | 1% | 297 | 1% | 301 | 1% | 314 | 1% | 326 | 1% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |
| MSM | 9,212 | 40% | 9,315 | 40% | 9,356 | 40% | 9,358 | 40% | 9,436 | 40% |
| IDU | 3,740 | 16% | 3,664 | 16% | 3,612 | 15% | 3,553 | 15% | 3,448 | 15% |
| MSM/IDU | 938 | 4% | 926 | 4% | 927 | 4% | 914 | 4% | 902 | 4% |
| HTSX | 3,271 | 14% | 3,255 | 14% | 3,268 | 14% | 3,255 | 14% | 3,229 | 14% |
| Other | 466 | 2% | 469 | 2% | 460 | 2% | 467 | 2% | 471 | 2% |
| Presumed HTSX | 2,035 | 9% | 2,051 | 9% | 2,066 | 9% | 2,088 | 9% | 2,158 | 9% |
| NIR | 3,547 | 15% | 3,695 | 16% | 3,752 | 16% | 3,846 | 16% | 3,999 | 17% |
| **Age** |  |  |  |  |  |  |  |  |  |  |
| 0–12 | 24 | <1% | 25 | <1% | 22 | <1% | 23 | <1% | 23 | <1% |
| 13–19 | 86 | <1% | 71 | <1% | 54 | <1% | 51 | <1% | 45 | <1% |
| 20–29 | 1,437 | 6% | 1,367 | 6% | 1,230 | 5% | 1,111 | 5% | 1,041 | 4% |
| 30–39 | 3,070 | 13% | 3,130 | 13% | 3,197 | 14% | 3,244 | 14% | 3,328 | 14% |
| 40–49 | 4,738 | 20% | 4,485 | 19% | 4,265 | 18% | 4,109 | 17% | 4,051 | 17% |
| 50–59 | 8,292 | 36% | 8,112 | 35% | 7,875 | 34% | 7,523 | 32% | 7,135 | 30% |
| 60–69 | 4,472 | 19% | 4,891 | 21% | 5,301 | 23% | 5,701 | 24% | 6,020 | 25% |
| 70+ | 1,090 | 5% | 1,294 | 6% | 1,497 | 6% | 1,719 | 7% | 2,000 | 8% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |
| Boston | 6,459 | 28% | 6,445 | 28% | 6,413 | 27% | 6,329 | 27% | 6,299 | 27% |
| Central | 2,340 | 10% | 2,388 | 10% | 2,430 | 10% | 2,412 | 10% | 2,446 | 10% |
| Metro West | 3,699 | 16% | 3,763 | 16% | 3,736 | 16% | 3,805 | 16% | 3,791 | 16% |
| Northeast | 4,159 | 18% | 4,171 | 18% | 4,214 | 18% | 4,255 | 18% | 4,330 | 18% |
| Southeast | 3,759 | 16% | 3,793 | 16% | 3,836 | 16% | 3,889 | 17% | 3,975 | 17% |
| Western | 2,791 | 12% | 2,811 | 12% | 2,808 | 12% | 2,789 | 12% | 2,799 | 12% |
| Unknown | 2 | <1% | 4 | <1% | 4 | <1% | 2 | <1% | 3 | <1% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **TRENDS IN DEATHS AMONG INDIVIDUALS REPORTED WITH HIV** |

**TABLE 10.6** Deaths among individuals reported with HIV by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age at death, and health service region (HSR): Massachusetts, 2013–2022

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2013N** | **2013%** | **2014N** | **2014%** | **2015N** | **2015%** | **2016N** | **2016%** | **2017N** | **2017%** | **2018N** | **2018%** | **2019N** | **2019%** | **2020N** | **2020%** | **2021N** | **2021%** | **2022N** | **2022%** |
| **Total** | **276** | **100%** | **279** | **100%** | **325** | **100%** | **315** | **100%** | **303** | **100%** | **302** | **100%** | **301** | **100%** | **317** | **100%** | **349** | **100%** | **358** | **100%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| AMAB | 208 | 75% | 214 | 77% | 243 | 75% | 236 | 75% | 222 | 73% | 217 | 72% | 213 | 71% | 226 | 71% | 264 | 76% | 266 | 74% |
| AFAB | 68 | 25% | 65 | 23% | 82 | 25% | 79 | 25% | 81 | 27% | 85 | 28% | 88 | 29% | 91 | 29% | 85 | 24% | 92 | 26% |
| **Current gender** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender | ≥5 | N/A | 279 | 100% | ≥5 | N/A | ≥5 | N/A | 303 | 100% | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A |
| Transgender | <5 | N/A | 0 | 0% | <5 | N/A | <5 | N/A | 0 | 0% | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| US | 206 | 75% | 206 | 74% | 257 | 79% | 240 | 76% | 217 | 72% | 223 | 74% | 224 | 74% | 234 | 74% | 265 | 76% | 270 | 75% |
| PR/USD | 46 | 17% | 47 | 17% | 38 | 12% | 35 | 11% | 57 | 19% | 37 | 12% | 42 | 14% | 38 | 12% | 50 | 14% | 45 | 13% |
| Non-US | 24 | 9% | 26 | 9% | 30 | 9% | 40 | 13% | 29 | 10% | 42 | 14% | 35 | 12% | 45 | 14% | 34 | 10% | 43 | 12% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| White NH | 130 | 47% | 133 | 48% | 151 | 46% | 171 | 54% | 146 | 48% | 154 | 51% | 132 | 44% | 146 | 46% | 156 | 45% | 166 | 46% |
| Black NH | 70 | 25% | 73 | 26% | 96 | 30% | 83 | 26% | 65 | 21% | 74 | 25% | 86 | 29% | 93 | 29% | 106 | 30% | 98 | 27% |
| Hispanic/Latinx | 73 | 26% | 69 | 25% | 73 | 22% | 57 | 18% | 85 | 28% | 72 | 24% | 77 | 26% | 70 | 22% | 83 | 24% | 87 | 24% |
| API | 2 | 1% | 1 | <1% | 1 | <1% | 2 | 1% | 2 | 1% | 0 | 0% | 2 | 1% | 1 | <1% | 2 | 1% | 2 | 1% |
| Other/Unknown | 1 | <1% | 3 | 1% | 4 | 1% | 2 | 1% | 5 | 2% | 2 | 1% | 4 | 1% | 7 | 2% | 2 | 1% | 5 | 1% |
| **Exposure mode** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MSM | 66 | 24% | 81 | 29% | 86 | 26% | 84 | 27% | 69 | 23% | 68 | 23% | 86 | 29% | 85 | 27% | 103 | 30% | 110 | 31% |
| IDU | 117 | 42% | 116 | 42% | 138 | 42% | 125 | 40% | 118 | 39% | 116 | 38% | 105 | 35% | 101 | 32% | 120 | 34% | 127 | 35% |
| MSM/IDU | 15 | 5% | 15 | 5% | 14 | 4% | 18 | 6% | 20 | 7% | 20 | 7% | 17 | 6% | 18 | 6% | 19 | 5% | 17 | 5% |
| HTSX | 24 | 9% | 20 | 7% | 23 | 7% | 28 | 9% | 31 | 10% | 39 | 13% | 45 | 15% | 34 | 11% | 42 | 12% | 44 | 12% |
| Other | 4 | 1% | 4 | 1% | 4 | 1% | 2 | 1% | 4 | 1% | 2 | 1% | 7 | 2% | 6 | 2% | 1 | <1% | 0 | 0% |
| Presumed HTSX | 11 | 4% | 15 | 5% | 22 | 7% | 10 | 3% | 18 | 6% | 12 | 4% | 15 | 5% | 16 | 5% | 20 | 6% | 13 | 4% |
| NIR | 39 | 14% | 28 | 10% | 38 | 12% | 48 | 15% | 43 | 14% | 45 | 15% | 26 | 9% | 57 | 18% | 44 | 13% | 47 | 13% |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0–12 | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | <1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| 13–19 | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| 20–29 | 5 | 2% | 8 | 3% | 7 | 2% | 0 | 0% | 8 | 3% | 3 | 1% | 12 | 4% | 8 | 3% | 6 | 2% | 4 | 1% |
| 30–39 | 10 | 4% | 18 | 6% | 16 | 5% | 12 | 4% | 8 | 3% | 16 | 5% | 16 | 5% | 20 | 6% | 20 | 6% | 22 | 6% |
| 40–49 | 63 | 23% | 60 | 22% | 48 | 15% | 50 | 16% | 38 | 13% | 45 | 15% | 32 | 11% | 29 | 9% | 44 | 13% | 38 | 11% |
| 50–59 | 121 | 44% | 122 | 44% | 131 | 40% | 135 | 43% | 123 | 41% | 112 | 37% | 119 | 40% | 110 | 35% | 104 | 30% | 104 | 29% |
| 60–69 | 70 | 25% | 54 | 19% | 90 | 28% | 84 | 27% | 87 | 29% | 86 | 28% | 90 | 30% | 97 | 31% | 130 | 37% | 122 | 34% |
| 70+ | 7 | 3% | 17 | 6% | 33 | 10% | 34 | 11% | 39 | 13% | 39 | 13% | 32 | 11% | 53 | 17% | 45 | 13% | 68 | 19% |
| **HSR** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Boston | 78 | 28% | 64 | 23% | 87 | 27% | 92 | 29% | 65 | 21% | 76 | 25% | 68 | 23% | 78 | 25% | 91 | 26% | 91 | 25% |
| Central | 35 | 13% | 27 | 10% | 43 | 13% | 29 | 9% | 36 | 12% | 34 | 11% | 27 | 9% | 31 | 10% | 46 | 13% | 51 | 14% |
| Metro West | 46 | 17% | 32 | 11% | 37 | 11% | 46 | 15% | 34 | 11% | 43 | 14% | 41 | 14% | 40 | 13% | 44 | 13% | 50 | 14% |
| Northeast | 33 | 12% | 47 | 17% | 53 | 16% | 47 | 15% | 56 | 18% | 59 | 20% | 54 | 18% | 63 | 20% | 55 | 16% | 62 | 17% |
| Southeast | 45 | 16% | 54 | 19% | 49 | 15% | 57 | 18% | 56 | 18% | 50 | 17% | 63 | 21% | 54 | 17% | 52 | 15% | 55 | 15% |
| Western | 39 | 14% | 55 | 20% | 56 | 17% | 44 | 14% | 56 | 18% | 40 | 13% | 48 | 16% | 51 | 16% | 60 | 17% | 49 | 14% |
| Unknown | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | <1% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **CRUDE AND AGE-ADJUSTED RATES PER 100,000 BY DEMOGRAPHIC CHARACTERISTICS** |

**TABLE 11.1** Crude and age-adjusted average rate per 100,000 population of HIV infection diagnosis (HIV DX) from 2020–2022, crude and age-adjusted average rate per 100,000 population of AIDS diagnosis (AIDS DX) from 2020–2022, crude and age-adjusted rate per 100,000 population of HIV prevalence (persons living with HIV infection, PLWH) on December 31, 2022, and crude and age-adjusted average rate per 100,000 population of all-cause deaths from 2020–2022 among individuals reported with HIV by sex assigned at birth, race/ethnicity, and age: Massachusetts

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX**  **2020–2022**  **Crude Rate** | **HIV DX**  **2020–2022**  **Adjusted Rate** | **AIDS DX**  **2020–2022**  **Crude Rate** | **AIDS DX**  **2020–2022**  **Adjusted**  **Rate** | **PLWH**  **12/31/21**  **Crude Rate** | **PLWH**  **12/31/21**  **Adjusted Rate** | **Deaths**  **2020–2022**  **Crude Rate** | **Deaths**  **2020–2022**  **Adjusted**  **Rate** |
| **Total** | **6.3** | **6.4** | **2.8** | **2.8** | **336.3** | **295.6** | **4.9** | **3.9** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |  |
| AMAB | 9.3 | 9.3 | 3.8 | 3.7 | 492.3 | 433.1 | 7.4 | 6.0 |
| AFAB | 3.5 | 3.5 | 1.9 | 1.8 | 189.3 | 167.6 | 2.5 | 2.0 |
| **Race/Ethnicity** |  |  |  |  |  |  |  |  |
| White NH | 3.2 | 3.4 | 1.3 | 1.3 | 187.6 | 149.0 | 3.2 | 2.4 |
| Black NH | 30.7 | 29.6 | 16.2 | 15.7 | 1,503.5 | 1,433.1 | 20.8 | 19.6 |
| Hispanic/Latinx | 14.3 | 13.4 | 5.8 | 6.2 | 744.2 | 903.9 | 9.2 | 12.3 |
| API | 2.1 | 1.8 | 0.7\* | 0.6\* | 111.8 | 105.3 | 0.3\* | 0.3\* |
| **Age** |  |  |  |  |  |  |  |  |
| 0–12\*\* | 0.1\* | N/A | 0.1\* | N/A | 2.4 | N/A | 0.0 | N/A |
| 13–19 | 1.2 | N/A | 0.1\* | N/A | 7.4 | N/A | 0.0 | N/A |
| 20–29 | 10.8 | N/A | 1.9 | N/A | 103.0 | N/A | 0.6 | N/A |
| 30–39 | 16.3 | N/A | 5.5 | N/A | 348.4 | N/A | 2.2 | N/A |
| 40–49 | 9.0 | N/A | 5.4 | N/A | 474.9 | N/A | 4.3 | N/A |
| 50–59 | 5.8 | N/A | 4.4 | N/A | 727.9 | N/A | 10.8 | N/A |
| 60–69 | 3.7 | N/A | 3.4 | N/A | 709.6 | N/A | 13.7 | N/A |
| 70+ | 0.7 | N/A | 0.8 | N/A | 244.8 | N/A | 6.8 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

**\*** Rates based on numerators <12 are marked with an asterisk (\*) and should be interpreted with caution.

###### \*\* HIV and AIDS diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change.

|  |
| --- |
| **CRUDE AND AGE-ADJUSTED RATES PER 100,000 BY HSR, COUNTY, AND SELECT CITIES** |

**TABLE 11.2** Crude and age-adjusted average rate per 100,000 population of HIV infection diagnosis (HIV DX) from 2020–2022, crude and age-adjusted average rate per 100,000 population of AIDS diagnosis (AIDS DX) from 2020–2022, crude and age-adjusted rate per 100,000 population of HIV prevalence (persons living with HIV infection, PLWH) on December 31, 2022, and crude and age-adjusted average rate per 100,000 population of all-cause deaths from 2020–2022 among individuals reported with HIV by health service region (HSR), county, and select cites

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HIV DX**  **2020–2022**  **Crude Rate** | **HIV DX**  **2020–2022**  **Adjusted Rate** | **AIDS DX**  **2020–2022**  **Crude Rate** | **AIDS DX**  **2020–2022**  **Adjusted**  **Rate** | **PLWH**  **12/31/21**  **Crude Rate** | **PLWH**  **12/31/21**  **Adjusted Rate** | **Deaths**  **2020–2022**  **Crude Rate** | **Deaths**  **2020–2022**  **Adjusted**  **Rate** |
| **Total** | **6.3** | **6.4** | **2.8** | **2.8** | **336.3** | **295.6** | **4.9** | **3.9** |
| **HSR of Residence** |  |  |  |  |  |  |  |  |
| Boston | 15.7 | 14.3 | 6.0 | 6.0 | 789.4 | 778.9 | 10.9 | 10.5 |
| Central | 4.2 | 4.3 | 2.3 | 2.3 | 265.6 | 233.7 | 4.6 | 3.8 |
| Metro West | 3.8 | 3.8 | 1.9 | 1.8 | 220.9 | 195.3 | 2.6 | 2.1 |
| Northeast | 6.3 | 6.4 | 2.6 | 2.6 | 308.3 | 272.8 | 4.3 | 3.4 |
| Southeast | 5.7 | 6.2 | 2.6 | 2.6 | 293.5 | 244.2 | 4.0 | 3.0 |
| Western | 4.6 | 4.8 | 2.9 | 2.8 | 334.7 | 298.3 | 6.4 | 4.9 |
| **County of Residence** |  |  |  |  |  |  |  |  |
| Barnstable/Dukes/  Nantucket | 3.9 | 5.3 | 1.8 | 2.0 | 401.7 | 319.8 | 3.3 | 2.4 |
| Berkshire | 2.3\* | 2.6\* | 1.6\* | 1.6\* | 184.5 | 164.1 | 3.1 | 1.8 |
| Bristol | 4.9 | 5.2 | 2.4 | 2.3 | 268.0 | 228.5 | 4.5 | 3.4 |
| Essex | 5.6 | 5.9 | 2.5 | 2.6 | 276.0 | 244.7 | 4.1 | 3.3 |
| Franklin | 1.9\* | 2.1\* | 0.9\* | 0.8\* | 153.5 | 114.0 | 2.3\* | 1.9\* |
| Hampden | 6.4 | 6.6 | 4.2 | 3.9 | 470.6 | 419.1 | 9.4 | 7.6 |
| Hampshire | 2.1\* | 1.8\* | 1.2\* | 1.3\* | 154.0 | 148.5 | 2.7 | 2.2 |
| Middlesex | 4.9 | 4.8 | 2.0 | 1.9 | 277.2 | 247.7 | 3.1 | 2.6 |
| Norfolk | 4.3 | 4.4 | 2.2 | 2.2 | 215.0 | 183.5 | 3.2 | 2.5 |
| Plymouth | 6.4 | 6.9 | 2.9 | 2.9 | 243.2 | 206.4 | 3.5 | 2.8 |
| Suffolk | 15.7 | 14.3 | 6.0 | 6.0 | 790.4 | 779.9 | 10.9 | 10.5 |
| Worcester | 4.7 | 4.8 | 2.7 | 2.7 | 268.4 | 237.8 | 4.8 | 3.8 |
| **City of Residence** |  |  |  |  |  |  |  |  |
| Boston | 16.5 | 15.4 | 6.5 | 6.7 | 833.4 | 841.5 | 11.8 | 11.8 |
| Brockton | 20.8 | 20.6 | 8.5 | 8.1 | 673.0 | 612.1 | 10.4 | 9.4 |
| Everett | 14.3 | 12.3 | 4.8\* | 4.2\* | 637.8 | 605.4 | 10.2 | 9.6 |
| Lawrence | 14.2 | 14.0 | 4.5 | 4.9 | 613.6 | 619.2 | 10.5 | 10.7 |
| Lowell | 10.7 | 10.6 | 4.0 | 4.2 | 609.2 | 593.6 | 9.2 | 8.8 |
| Lynn | 12.2 | 11.9 | 4.6 | 4.8 | 516.5 | 500.0 | 7.6 | 6.9 |
| Malden | 15.6 | 13.6 | 6.0 | 5.3 | 597.6 | 528.1 | 6.0 | 5.9 |
| New Bedford | 9.6 | 9.9 | 5.6 | 5.3 | 550.1 | 491.3 | 9.9 | 7.9 |
| Springfield | 11.3 | 10.9 | 7.9 | 7.6 | 832.4 | 817.8 | 17.1 | 16.1 |
| Worcester | 10.5 | 10.1 | 5.3 | 5.3 | 595.6 | 573.5 | 11.0 | 10.4 |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

\*Rates based on numerators <12 are marked with an asterisk (\*) and should be interpreted with caution.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change.

|  |
| --- |
| **CARE CONTINUUM NEW HIV DIAGNOSES** |

**TABLE 12.1** Stages of HIV care among individuals newly diagnosed with HIV infection in 2021 (and alive through 2022) by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR): Massachusetts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Total (N)** | **Linked to Care (N)** | **Linked to Care (%)** | **Retained in Care (N)** | **Retained in Care (%)** | **Virally Suppressed (N)** | **Virally Suppressed (%)** |
| **Total** | **418** | **381** | **91%** | **343** | **82%** | **354** | **85%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |
| AMAB | 290 | 268 | 92% | 232 | 80% | 247 | 85% |
| AFAB | 128 | 113 | 88% | 111 | 87% | 107 | 84% |
| **Current gender** |  |  |  |  |  |  |  |
| Cisgender | ≥5 | ≥5 | N/A | ≥5 | N/A | ≥5 | N/A |
| Transgender | <5 | <5 | N/A | <5 | N/A | <5 | N/A |
| **Place of birth** |  |  |  |  |  |  |  |
| US | 238 | 215 | 90% | 191 | 80% | 194 | 82% |
| PR/USD | 8 | 7 | 88% | 5 | 63% | 5 | 63% |
| Non-US | 172 | 159 | 92% | 147 | 85% | 155 | 90% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |
| White NH | 150 | 135 | 90% | 124 | 83% | 122 | 81% |
| Black NH | 140 | 126 | 90% | 115 | 82% | 123 | 88% |
| Hispanic/Latinx | 111 | 104 | 94% | 89 | 80% | 93 | 84% |
| API | 13 | 12 | 92% | 11 | 85% | 12 | 92% |
| Other/Unknown | 4 | 4 | 100% | 4 | 100% | 4 | 100% |
| **Exposure mode** |  |  |  |  |  |  |  |
| MSM | 150 | 143 | 95% | 118 | 79% | 132 | 88% |
| IDU | 75 | 67 | 89% | 65 | 87% | 59 | 79% |
| MSM/IDU | 12 | 10 | 83% | 10 | 83% | 9 | 75% |
| HTSX | 30 | 28 | 93% | 24 | 80% | 25 | 83% |
| Other | 1 | 1 | 100% | 1 | 100% | 1 | 100% |
| Presumed HTSX | 45 | 41 | 91% | 37 | 82% | 40 | 89% |
| NIR | 105 | 91 | 87% | 88 | 84% | 88 | 84% |
| **Age** |  |  |  |  |  |  |  |
| 0–12\* | 1 | 1 | 100% | 1 | 100% | 1 | 100% |
| 13–19 | 7 | 6 | 86% | 7 | 100% | 5 | 71% |
| 20–29 | 88 | 81 | 92% | 73 | 83% | 72 | 82% |
| 30–39 | 149 | 133 | 89% | 123 | 83% | 127 | 85% |
| 40–49 | 91 | 85 | 93% | 70 | 77% | 78 | 86% |
| 50–59 | 52 | 49 | 94% | 48 | 92% | 48 | 92% |
| 60–69 | 27 | 23 | 85% | 18 | 67% | 20 | 74% |
| 70+ | 3 | 3 | 100% | 3 | 100% | 3 | 100% |
| **Health Service Region** |  |  |  |  |  |  |  |
| Boston HSR | 121 | 113 | 93% | 101 | 83% | 104 | 86% |
| Central HSR | 37 | 34 | 92% | 34 | 92% | 30 | 81% |
| Metro West HSR | 75 | 72 | 96% | 65 | 87% | 65 | 87% |
| Northeast HSR | 80 | 73 | 91% | 64 | 80% | 69 | 86% |
| Southeast HSR | 59 | 50 | 85% | 48 | 81% | 48 | 81% |
| Western HSR | 36 | 32 | 89% | 24 | 67% | 30 | 83% |
| Prison | 9 | 7 | 78% | 6 | 67% | 7 | 78% |
| Unknown | 1 | 0 | 0% | 1 | 100% | 1 | 100% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### See [*Technical Note XXI*](#technical_note_xxi) for HIV care continuum indicator definitions.

###### \* HIV diagnoses in this age group could include individuals who were born outside the US but diagnosed in Massachusetts.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **CARE CONTINUUM NEW HIV DIAGNOSES** |

**TABLE 12.2** Viral suppression among all individuals newly diagnosed with HIV infection in 2021 (and alive through 2022) and by stage of HIV care: Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total (N)** | **Total (%)** | **Linked to Care (N)** | **Linked to Care (%)** | **Retained in Care (N)** | **Retained in Care (%)** |
| **Total** | **418** | **100%** | **381** | **100%** | **343** | **100%** |
| **Viral Suppression** |  |  |  |  |  |  |
| Virally Suppressed | 354 | 85% | 334 | 88% | 317 | 92% |
| Not Virally Suppressed | 56 | 13% | 47 | 12% | 26 | 8% |
| Viral Suppression Unknown | 8 | 2% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### See [*Technical Note XXI*](#technical_note_xxi) for HIV care continuum indicator definitions.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **CARE CONTINUUM PERSONS LIVING WITH HIV INFECTION** |

**TABLE 12.3** Stages of HIV care among persons living with HIV infection in 2022 (and diagnosed through 2021) by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR): Massachusetts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Total (N)\*** | **Engaged in Care (N)** | **Engaged in Care (%)** | **Retained in Care (N)** | **Retained in Care (%)** | **Virally Suppressed (N)** | **Virally Suppressed (%)** |
| **Total** | **22,455** | **15,849** | **71%** | **9,677** | **43%** | **14,238** | **63%** |
| **Sex assigned at birth** |  |  |  |  |  |  |  |
| AMAB | 15,960 | 11,086 | 69% | 6,673 | 42% | 10,021 | 63% |
| AFAB | 6,495 | 4,763 | 73% | 3,004 | 46% | 4,217 | 65% |
| **Current gender** |  |  |  |  |  |  |  |
| Cisgender | 22,339 | 15,771 | 71% | 9,639 | 43% | 14,172 | 63% |
| Transgender | 116 | 78 | 67% | 38 | 33% | 66 | 57% |
| **Place of birth** |  |  |  |  |  |  |  |
| US | 13,332 | 9,642 | 72% | 5,665 | 42% | 8,678 | 65% |
| PR/USD | 2,095 | 1,466 | 70% | 964 | 46% | 1,332 | 64% |
| Non-US | 7,028 | 4,741 | 67% | 3,048 | 43% | 4,228 | 60% |
| **Race/Ethnicity** |  |  |  |  |  |  |  |
| White NH | 8,669 | 6,220 | 72% | 3,616 | 42% | 5,641 | 65% |
| Black NH | 6,765 | 4,804 | 71% | 3,004 | 44% | 4,209 | 62% |
| Hispanic/Latinx | 6,167 | 4,245 | 69% | 2,712 | 44% | 3,875 | 63% |
| API | 549 | 371 | 68% | 219 | 40% | 335 | 61% |
| Other/Unknown | 305 | 209 | 69% | 126 | 41% | 178 | 58% |
| **Exposure mode** |  |  |  |  |  |  |  |
| MSM | 9,047 | 6,404 | 71% | 3,653 | 40% | 5,846 | 65% |
| IDU | 3,242 | 2,224 | 69% | 1,457 | 45% | 1,951 | 60% |
| MSM/IDU | 871 | 604 | 69% | 365 | 42% | 543 | 62% |
| HTSX | 3,130 | 2,256 | 72% | 1,418 | 45% | 2,042 | 65% |
| Other | 459 | 344 | 75% | 219 | 48% | 278 | 61% |
| Presumed HTSX | 2,014 | 1,479 | 73% | 945 | 47% | 1,318 | 65% |
| NIR | 3,692 | 2,538 | 69% | 1,620 | 44% | 2,260 | 61% |
| **Age** |  |  |  |  |  |  |  |
| 0–12 | 22 | 17 | 77% | 15 | 68% | 16 | 73% |
| 13–19 | 41 | 32 | 78% | 23 | 56% | 28 | 68% |
| 20–29 | 923 | 711 | 77% | 440 | 48% | 603 | 65% |
| 30–39 | 3,136 | 2,230 | 71% | 1,270 | 40% | 1,919 | 61% |
| 40–49 | 3,868 | 2,639 | 68% | 1,545 | 40% | 2,350 | 61% |
| 50–59 | 6,818 | 4,845 | 71% | 2,915 | 43% | 4,398 | 65% |
| 60–69 | 5,764 | 4,135 | 72% | 2,666 | 46% | 3,789 | 66% |
| 70+ | 1,883 | 1,240 | 66% | 803 | 43% | 1,135 | 60% |
| **Health Service Region** |  |  |  |  |  |  |  |
| Boston HSR | 5,980 | 4,055 | 68% | 2,466 | 41% | 3,628 | 61% |
| Central HSR | 2,324 | 1,683 | 72% | 1,180 | 51% | 1,572 | 68% |
| Metro West HSR | 3,617 | 2,471 | 68% | 1,387 | 38% | 2,206 | 61% |
| Northeast HSR | 4,120 | 2,894 | 70% | 1,727 | 42% | 2,392 | 58% |
| Southeast HSR | 3,784 | 2,793 | 74% | 1,758 | 46% | 2,626 | 69% |
| Western HSR | 2,627 | 1,953 | 74% | 1,159 | 44% | 1,814 | 69% |
| Prison | 0 | 0 | N/A | 0 | N/A | 0 | N/A |
| Unknown | 3 | 0 | 0% | 0 | 0% | 0 | 0% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### See [*Technical Note XXI*](#technical_note_xxi) for HIV care continuum indicator definitions.

###### \* Total N includes all PLWH who have ever been diagnosed with HIV infection in Massachusetts (through 2021) with no evidence of death or having moved out of the state or country and differs from the total number of PLWH presented elsewhere in the report. Routine quality assurance and follow up are conducted to update mortality status and the current residence of PLWH and to update the number of PLWH used for this analysis.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **CARE CONTINUUM PERSONS LIVING WITH HIV INFECTION** |

**TABLE 12.4** Viral suppression among all persons living with HIV infection in 2022 (and diagnosed in 2021) and by stage of HIV care: Massachusetts

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total (N)** | **Total (%)** | **Engaged in Care (N)** | **Engaged in Care (%)** | **Retained in Care (N)** | **Retained in Care (%)** |
| **Total** | **22,455** | **100%** | **15,849** | **100%** | **9,677** | **100%** |
| **Viral Suppression** |  |  |  |  |  |  |
| Virally Suppressed | 14,238 | 63% | 14,238 | 90% | 9,093 | 94% |
| Not Virally Suppressed | 886 | 4% | 886 | 6% | 435 | 4% |
| Viral Suppression Status Unknown | 7,331 | 33% | 725 | 5% | 149 | 2% |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### See [*Technical Note XXI*](#technical_note_xxi) for HIV care continuum indicator definitions.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

|  |
| --- |
| **CARE CONTINUUM PERSONS LIVING WITH HIV INFECTION** |

**TABLE 12.5** Viral suppression among persons living with HIV infection in 2022 (and diagnosed in 2021) and engaged in care: by sex assigned at birth, current gender, place of birth, race/ethnicity, primary exposure mode, age, and Health Service Region (HSR): Massachusetts

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Engaged in Care (Total N)** | **Virally Suppressed (N)** | **Virally Suppressed (%)** |
| **Total** | **15,849** | **14,238** | **90%** |
| **Sex assigned at birth** |  |  |  |
| AMAB | 11,086 | 10,021 | 90% |
| AFAB | 4,763 | 4,217 | 89% |
| **Current gender** |  |  |  |
| Cisgender | 15,771 | 14,172 | 90% |
| Transgender | 78 | 66 | 85% |
| **Place of birth** |  |  |  |
| US | 9,642 | 8,678 | 90% |
| PR/USD | 1,466 | 1,332 | 91% |
| Non-US | 4,741 | 4,228 | 89% |
| **Race/Ethnicity** |  |  |  |
| White NH | 6,220 | 5,641 | 91% |
| Black NH | 4,804 | 4,209 | 88% |
| Hispanic/Latinx | 4,245 | 3,875 | 91% |
| API | 371 | 335 | 90% |
| Other/Unknown | 209 | 178 | 85% |
| **Exposure mode** |  |  |  |
| MSM | 6,404 | 5,846 | 91% |
| IDU | 2,224 | 1,951 | 88% |
| MSM/IDU | 604 | 543 | 90% |
| HTSX | 2,256 | 2,042 | 91% |
| Other | 344 | 278 | 81% |
| Presumed HTSX | 1,479 | 1,318 | 89% |
| NIR | 2,538 | 2,260 | 89% |
| **Age** |  |  |  |
| 0–12 | 17 | 16 | 94% |
| 13–19 | 32 | 28 | 88% |
| 20–29 | 711 | 603 | 85% |
| 30–39 | 2,230 | 1,919 | 86% |
| 40–49 | 2,639 | 2,350 | 89% |
| 50–59 | 4,845 | 4,398 | 91% |
| 60–69 | 4,135 | 3,789 | 92% |
| 70+ | 1,240 | 1,135 | 92% |
| **Health Service Region** |  |  |  |
| Boston HSR | 4,055 | 3,628 | 89% |
| Central HSR | 1,683 | 1,572 | 93% |
| Metro West HSR | 2,471 | 2,206 | 89% |
| Northeast HSR | 2,894 | 2,392 | 83% |
| Southeast HSR | 2,793 | 2,626 | 94% |
| Western HSR | 1,953 | 1,814 | 93% |
| Prison | 0 | 0 | N/A |
| Unknown | 0 | 0 | N/A |

**Table Notes:**

See [***Technical Notes***](#technical_notes) and [***List of Commonly Used Acronyms***](#list_acronyms) for more information.

###### See [*Technical Note XXI*](#technical_note_xxi) for HIV care continuum indicator definitions.

###### Please consider the impact of the COVID-19 pandemic on infectious disease screening, treatment, and surveillance in the interpretation of 2020–2022 data.

###### Data Source: MDPH Bureau of Infectious Disease and Laboratory Sciences.

###### Data are current as of 1/1/2024 and may be subject to change. Percentages may not add up to 100% due to rounding.

**TECHNICAL NOTES**

1. **Data source for all HIV case data:**

Massachusetts Department of Public Health (MDPH) Bureau of Infectious Disease and Laboratory Sciences (BIDLS) HIV Surveillance Program, data are current as of 1/1/2024 and may be subject to change.

## **Individuals diagnosed with HIV infection:**

New HIV diagnoses include only individuals who were first diagnosed in Massachusetts. HIV diagnoses data reflect the year of HIV infection diagnosis among all individuals reported with HIV infection, with or without an AIDS diagnosis, for the most recently available three-year (2020–2022) or ten-year (2013–2022) period.

1. **Individuals living with HIV infection by current residence:**

## As of January 1, 2018, the Massachusetts Department of Public Health (MDPH) Bureau of Infectious Disease and Laboratory Sciences (BIDLS) HIV fact sheets, epidemiologic reports, and other HIV data presentations include all individuals living with HIV infection who are currently residing in Massachusetts. These prevalent cases include those who may have been first diagnosed in another state. Reports of incidence or new diagnoses will continue to include only individuals who are first diagnosed in Massachusetts. Please note that HIV fact sheets, data reports, and presentations published from 2011 to 2017 include only cases that were first diagnosed in Massachusetts. BIDLS service planning continues to ensure responsive services to the entire population living with HIV infection in Massachusetts, regardless of place of diagnosis.

## **Individuals diagnosed with AIDS:**

## AIDS diagnoses include only individuals who were first diagnosed in Massachusetts for the most recently available three-year (2020–2022) or ten-year (2013–2022) period.

## **Deaths among individuals with HIV:**

## All-cause death data include only individuals who were first diagnosed with HIV in Massachusetts for the most recently available three-year (2020–2022) or ten-year (2013–2022) period.

## **Individuals born in Puerto Rico or other US Dependencies (American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands)**

95.5% of individuals diagnosed with HIV infection (HIV DX) from 2020–2022, 99.2% of individuals diagnosed with HIV infection from 2013–2022, 97.9% of persons living with HIV infection on 12/31/2022, 99.5% of individuals diagnosed with AIDS from 2013–2022, 99.3% of individuals who died from 2020–2022, and 99.1% of individuals who died from 2013–2022 who were born in a US dependency were born in Puerto Rico.

## **Individuals born outside the US (non-US born)**

## Individuals born outside the US (non-US born) excludes individuals born in the United States, Puerto Rico, American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands.

## **Gender**

Current gender data present number and percentage distributions of HIV surveillance data for cisgender (persons whose current gender identity corresponds with their sex assigned at birth) and transgender individuals. Please note that reported numbers among transgender individuals are likely to be underestimates due to underreporting of current gender.

## **Configuration of Health Service Regions (HSR)**

For HIV and AIDS diagnoses, residence is at diagnosis. For individuals living with HIV infection and deaths, residence is based on the most recent record available. Definitions of Health Service Regions can be found at: [Health Services Regions.](https://www.mass.gov/info-details/massgis-data-ma-executive-office-of-health-human-services-regions#:~:text=The%20regions%20%2D%20Western%2C%20Central%2C,and%20towns%20(see%20map))


## The figure is a map of Massachusetts displaying the location of each of the six health service regions: Boston, Central, Metrowest, Northeast, Southeast, and Western.

## **Prisons**

HSRs are regions defined geographically to facilitate targeted health service planning. While prisons are not an HSR, the prison population is presented separately because of its unique service planning needs. The prisons category represents persons who were diagnosed with HIV infection while in a correctional facility. As these data do not reflect current incarceration status, the category is not included for individuals living with HIV infection or deaths among individuals with HIV.

## **Configuration of Massachusetts cities/towns and counties**

For HIV and AIDS diagnoses, residence is at diagnosis. For individuals living with HIV infection and deaths, residence is based on the most recent record available.



1. **Age**

Age in years is at HIV diagnosis for individuals diagnosed with HIV infection, age on 12/31/2022 for individuals living with HIV infection, and age at death for individuals reported with HIV who died. Please note, pediatric HIV infections diagnosed under age 13 are reported by year of diagnosis; therefore, the annual number of pediatric diagnoses differs from the annual number of perinatal infections (among infants) that are reported by year of birth.

## **Background on HIV reporting system**

## Massachusetts Department of Public Health (MDPH) regulations started requiring healthcare providers to submit case report forms, with demographic and risk information, on individuals diagnosed with AIDS in 1983, and with HIV infection in 1999. Existing cases of HIV infection diagnosed through 1998 were also to be reported by the end of 1999. When comparing HIV infection diagnosed before 1999 to HIV infection diagnosed after 1999, users should consider the differences in HIV reporting requirements for these two time periods. Since HIV was not reported at diagnosis prior to 1999 and clinical providers were given a relatively short time frame within which to report all prevalent HIV cases, the pre-1999 data may be less complete than data reported after 1999. Additionally, pre-1999 HIV infection diagnoses do not include individuals who were diagnosed with HIV infection and who died before 1999 without being reported with AIDS, nor do they include individuals who were no longer receiving HIV-related health care in Massachusetts at the point when HIV (non-AIDS) reporting became mandatory.

Beginning in 2019, all new diagnoses of HIV infection were assigned to field epidemiologists for partner services, to ensure disease education/comprehension, and assist with linkage to HIV care. As a part of this process, field epidemiologists helped to collect pertinent epidemiological, demographic, and risk information of the individual.

1. **Data limitations**

While trends in new HIV diagnoses are the best indicator of those who are most at risk of HIV infection, HIV surveillance reflects only incident diagnoses among individuals who are in care and not the actual incidence of new infections. Individuals may be living with HIV infection for many years prior to being tested and seeking care, at which point the case is considered a “diagnosis” and reported to the MDPH Bureau of Infectious Disease and Laboratory Sciences. In the most recent years of data presented, delays may occur in the reporting of a case to MDPH after it is diagnosed. Although Massachusetts regulations require providers to submit HIV case reports in a timely fashion, some 2022 HIV infection diagnoses will be reported to the surveillance program after the release of this report. Thus, the 2022 data presented in this report may change slightly. Previous analyses of Massachusetts HIV case data have suggested that the distribution of HIV infection diagnoses by race/ethnicity, sex assigned at birth and exposure mode for cases reported more than 6 months after diagnosis was not substantially different than the distribution of HIV cases reported within 6 months. Caution should be exercised when considering changes in HIV diagnosis trends for 2022.

1. **Deaths among people reported with HIV**

The death data presented in this report include all deaths among people diagnosed and reported with HIV in Massachusetts to present a full description of trends in mortality among this population. This includes deaths from non-HIV related causes such as drug overdoses, suicides, motor vehicle accidents and other causes. Therefore, the total number of annual deaths reported here will vary from the number of HIV-related deaths reported in *Massachusetts Deaths* by the Massachusetts Department of Public Health, Office of Population Health (available at <https://www.mass.gov/lists/death-data>). The death data reported here are considered complete through 2022. Data on deaths occurring in Massachusetts are from matches with the Massachusetts Registry of Vital Records and Statistics and from provider reports. Data on deaths occurring outside of Massachusetts are from matches with the Social Security Death Master File.

1. **HIV primary exposure mode definitions**

The HIV primary exposure mode indicates the most probable risk behavior associated with HIV infection. Assignment of primary exposure mode is done in accordance with Centers for Disease Control and Prevention (CDC) guidelines when multiple exposure modes are reported. Although the reported primary exposure mode is the most likely mode of transmission, there is always the possibility that it is not the actual mode of transmission. Following is a description of the exposure mode categories:

* **MSM (Male-to-Male Sex):** Includes all individuals assigned male at birth who report any sexual contact with other individuals that identify as male. Please note that in accordance with CDC guidelines, this category is defined by an individual’s assigned sex at birth and not an individual’s current gender identity.
  + **Sex with Men:** This exposure mode category is used by the Bureau of Infectious Disease and Laboratory Sciences (BIDLS) to categorize sexual risk in transgender women reporting sex with men only. For the purposes of official reporting in the MA HIV Surveillance System and to CDC, exposure mode for transgender women is based on sex assigned at birth, and therefore would be reported as male-to-male sex.
* **IDU (Injection Drug Use):** Cases among persons who report injection drug use.
* **MSM/IDU:** Includes all individuals assigned male at birth who report both sexual contact with other individuals that identify as male and injection drug use.
  + **Sex with Men/IDU:** This exposure mode category is used by BIDLS to categorize sexual risk in transgender women reporting both sex with men and injection drug use. For the purposes of official reporting in the MA HIV Surveillance System and to CDC, exposure mode for transgender women is based on sex assigned at birth, and therefore would be reported as MSM/IDU.
* **Heterosexual Sex:** Cases among persons who report heterosexual sex with a person with, or at increased risk for, HIV infection (e.g., a person who injects drugs (PWID)). The sub-categories for this mode of transmission are listed below.

Heterosexual Sex w/ a person who injects drugs

Heterosexual Sex w/ a person w/ HIV infection or AIDS

Heterosexual Sex w/ bisexual male

Other Heterosexual Sex: includes all other sub-categories of heterosexual risk, such as heterosexual contact with a person infected through a blood transfusion.

* + - * + **Other:** Cases among persons with other known exposure modes, including receipt of clotting factor, receipt of transfusion or transplant, and mother-to-child transmission through pregnancy, childbirth, or breastfeeding (perinatal transmission).
        + **Presumed Heterosexual:** The presumed heterosexual risk category is used by BIDLS exclusively for individuals assigned female at birth to identify HIV exposure mode when sex with individuals that identify as male was the only reported risk factor, there was no evidence of current or past IDU, and behavioral risk and HIV status information about sexual partners that identify as male was unknown. The rationale for the application of the presumed heterosexual risk category to individuals assigned female at birth only has been addressed in the MDPH Office of HIV report “Intersecting Risks: HIV Infection among Heterosexual Women and Men in Massachusetts” (2010).
* **NIR (No Identified Risk):** Cases among persons with no reported history of exposure to HIV through any of the listed exposure categories. Follow-up is conducted to determine risk for those cases that are initially reported without a risk identified. Includes cases among individuals assigned male at birth who were previously categorized in Massachusetts as Presumed Heterosexual.

1. **Cell suppression methodology:**

Values one through four are suppressed for denominator populations less than 50,000 or for unknown population sizes. Additional values of zero and greater than or equal to five may be suppressed to prevent back calculation. Values less than five are not suppressed for unknown health service region or for compound categories (categories containing two or more subcategories, such as ‘other/undetermined’ race/ethnicity or ‘other’ exposure modes, which includes pediatric, blood, and blood product exposure modes), because the exact count of each subcategory cannot be determined.

1. **Population estimates used for rate calculations**

As of 1/1/2020, BIDLS calculates rates per 100,000 population using denominators estimated by the University of Massachusetts Donahue Institute using a modified Hamilton-Perry model. 2020 population estimates were used for single-year rates; for pooled year rates (i.e., 2019-2021), the 2020 population estimates were multiplied by three. For more information, see: Strate S, et al. Small Area Population Estimates for 2011 through 2020, report published Oct 2016, and <http://www.donahue.umassp.edu/business-groups/economic-public-policy-research/massachusetts-population-estimates-program>. Note that rates and trends calculated using previous methods cannot be compared to these.

1. **Rates based on numerators <12**

Rates based on numerators <12 are marked with an asterisk (\*) and should be interpreted with caution.

1. **Explanation of age-adjusted rates**

A rate of a disease per 100,000 population is a useful way to compare groups with substantially different population sizes rather than relying on the raw number of cases. For example, the number of individuals living with HIV infection (PLWH) on December 31, 2023 who are Hispanic/Latinx is 6,507, whereas the number of individuals living with HIV infection who are white (non-Hispanic) is 9,066. Although the *number* of individuals living with HIV infection who are Hispanic/Latinx in Massachusetts is smaller than the number of individuals living with HIV infection who are white (non-Hispanic), we also need to consider that there are far fewer individuals of Hispanic/Latinx heritage living in Massachusetts than white (non-Hispanic) individuals. Hispanic/Latinx individuals represent 12% of the Massachusetts population compared to white (non-Hispanic) individuals who represent 71% of the population. If HIV had the same impact on the Hispanic/Latinx population of the state as on the white (non-Hispanic) population, then there should be six times as many cases in white (non-Hispanic) individuals, but there are less than twice as many. By calculating a rate which takes into consideration the differences in the population size, it is evident that the number of individuals living with HIV infection for every 100,000 Hispanic/Latinx individuals in Massachusetts is much higher than the rate for every 100,000 white (non-Hispanic) individuals. This is called a "crude rate" and is calculated by dividing the number of individuals living with HIV infection by the population of interest (the total number of Hispanic/Latinx individuals in Massachusetts, for example) and multiplying by 100,000. (See example below.)

## Example: Calculation of crude HIV prevalence rate for white (non-Hispanic) individuals, Massachusetts (187.6 per 100,000)

|  |  |
| --- | --- |
| Crude HIV prevalence rate for white (non-Hispanic) individuals | = [number of white (non-Hispanic) individuals living with HIV infection ÷ population size of white (non-Hispanic) individuals] ×100,000 |
|  | = (9,066/4,832,394.52) ×100,000 |
|  | = (0.001876) ×100,000 |
|  | = 187.6 |

However, sometimes, in addition to the population size being different, the age composition of the populations is different. In Massachusetts, the black (non-Hispanic) and Hispanic/Latinx populations are on average younger than white (non-Hispanic) population (medians: 29.7 years and 24.5 years vs. 38.8 years, respectively). Therefore, it is necessary to age-adjust the HIV prevalence rate to get a true comparison of the impact of the disease across racial/ethnic groups without an effect from the differences in age composition. Age-adjustment of rates minimizes the distortion created by differences in age composition. Age-adjusted rates are calculated by weighting the age-specific rates for a given population by the age distribution of a standard population. The weighted age-specific rates are then summed to produce the adjusted rate for all ages combined.

1. **HIV Care Continuum Indicator Definitions:**

* HIV care continuum among individuals newly diagnosed with HIV infection in Massachusetts: “Newly Diagnosed” includes individuals diagnosed in 2021, alive through 12/31/2022, and living in Massachusetts based on last known address. “Linked to Care” is defined as having ≥1 viral load (VL) or CD4 test result within 3 months of diagnosis. “Retained in Care” is defined as having ≥2 VL or CD4 test results at least 3 months apart during the 12-month period after diagnosis. “Virally Suppressed” is defined as having a VL <200 copies/mL for the most recent VL test drawn during the 12-month period after diagnosis.
* HIV care continuum among persons living with HIV infection (PLWH) in Massachusetts: “PLWH” refers to individuals diagnosed through 2021, alive through 12/31/2022, and living in Massachusetts based on last known address. “Engaged in Care” is defined as having ≥1 VL or CD4 test result in 2022. “Retained in Care” is defined as having ≥2 VL or CD4 test results at least 3 months apart in 2022. “Virally Suppressed” is defined as having a VL <200 copies/mL for the most recent VL test drawn in 2022.

1. **AIDS Progression**

Progression to AIDS refers to individuals diagnosed with HIV while living in Massachusetts who were later diagnosed with AIDS while living in Massachusetts. Individuals diagnosed with HIV or AIDS outside of Massachusetts are excluded. Individuals diagnosed with HIV and AIDS concurrently (AIDS diagnosis within 2 months of HIV diagnosis) are also excluded. Year refers to year of AIDS diagnosis.

1. Providers may use this number to report individuals newly diagnosed with a notifiable sexually transmitted infection, including HIV, or request partner services. Partner services is a free and confidential service for individuals recently diagnosed with a priority infection. The client-centered program offers counseling, linkage to other health and social services, anonymous notification of partners who were exposed and assistance with getting testing and treatment. For more information, see: <https://www.mass.gov/service-details/partner-services-program-information-for-healthcare-providers>) [↑](#footnote-ref-1)
2. Please see “Massachusetts HIV Epidemiologic Profile – Statewide Report” for a description of data highlights, available at: <https://www.mass.gov/lists/hivaids-epidemiologic-profiles> [↑](#footnote-ref-2)